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Abstract 
Noscapine is a major alkaloid that is found, along with the more commonly known 
drugs morphine and codeine, in the latex of opium poppy (Papaver somniferum). 
Noscapine has classically been used as a cough suppressant, but also has emerging 
antitumor properties. Unlike morphine and codeine, noscapine has no addictive 
properties. Recently, a 10-gene cluster for the synthesis of noscapine was discovered. 
The first distinct step in this pathway is an O-methylation of scoulerine to 
tetrahydrocolumbamine by a class I S-adenosylmethionine (SAM) dependent 
methyltransferase, referred to as Papaver somniferum O-methyltransferase 1 
(PSMT1). PSMT1 is therefore an interesting target for detailed structural and 
functional analysis. PSMT1 has been expressed as a fusion protein, tagged to improve 
solubility, and purified for X-ray diffraction studies. Here we present the structures 
of an “apo” enzyme and an enzyme complex with SAM, bound in “open” enzyme 
conformations. A surface entropy reduction mutant enzyme allowed access to a 
closed conformation high-resolution structure in complex with 
S-adenosylhomocysteine (SAH) and the product tetrahydrocolumbamine. 
These X-ray structures provide deep insight into the structure function relationships 
of PSMT1. PSMT1 is a homodimer with distinct dimerisation, SAM binding and 
substrate binding domains. PSMT1 undergoes an inward rotation of approximately 
10 degrees of the SAM binding domain upon substrate binding. This results in an 8 Å 
closure of the active site cleft. The acceptor substrate binds in a hydrophobic cleft, 
held in place by two hydrogen bonds via the hydroxyl groups at positions 2 and 9 of 
scoulerine.  
Further analysis of the plant O-methyltransferase catalytic dyad has been carried out 
by site-directed mutagenesis and X-ray diffraction studies. Subunit cooperativity has 
also been investigated with the proposal of two regulatory features. Here I present 
one of the highest resolution closed conformation structure of a plant 
O-methyltransferase to date. This provides the template for our understanding of, 
and future engineering substrate specificity in plant methyltransferases; an 
important class of enzymes in secondary metabolism.  
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1. Introduction 
 Papaver somniferum 
Papaver somniferum more commonly known as opium poppy is an annual herb which 
grows to around 1.5 m tall and has a single flower that can be white, red or blue-
purple in colour. After flowering the fruit or seed pod grows to around 5 cm in 
diameter. Opium poppy produces a substance called latex which contains a variety 
of alkaloids such as codeine, morphine, noscapine, papaverine, laudanosine and 
sanguinarine. Latex is the cytoplasm of specialised laticifer cells which are associated 
with the phloem. The latex of opium poppy was historically extracted by scoring the 
unripe seed pod allowing the latex to seep out and dry. The dry latex is known as 
opium and is black in colour and typically contains around 10 % morphine, depending 
on the strain cultivated. 
 A Brief History of Opium Poppy 
Opium poppy has been exploited by humans for thousands of years due to its unique 
medicinal properties. It has been proposed that opium poppy was first cultivated 
around 3000-5000 BC in ancient Mesopotamia, which is modern day Iraq and 
Kuwait.1,2 
Philippus Aureolus Theophrastus Bombastus von Hohenheim known as Paracelsus, 
was a 16th century alchemist whom is credited as the founding father of toxicology.3 
He popularised Paracelsus’ laudanum which is a tincture (an alcohol preparation of a 
drug) form of opium prepared with other substances. It was described as sleep 
inducing and possessed analgesic properties.4 The name laudanum comes from the 
Latin laudare which means to praise. In the early 17th century Thomas Sydenham 
standardised the use of opium in what was known as Sydenham’s laudanum. It was 
a tincture containing about 10 % opium, resulting in around 1 % morphine content, 
along with clove, saffron and cinnamon.1,4,5 It was portrayed as a cure for all. The 
National Institute for Health and Care Excellence (NICE) ‘Guidelines for palliative care 
for adults: strong opioids for pain relief’ recommends a typical daily dose of between 
20-30 mg of oral morphine, this would have corresponded to approximately 2-3 mL 
17 
of Sydenham’s laudanum.6 Thomas Dover, an apprentice of Sydenham produced a 
powdered form of opium called Dover’s powder.5 These two preparations were 
common place for centuries as an analgesic medicine, used to treat pain and disease. 
Despite the attempts to standardise the preparations, they could vary in potency due 
to natural differences or adultery of the material. Standardisation would only be 
possible once the active compound for pain relief had been identified, isolated and 
characterised. 
It was not until 1806 that Friedrich Sertürner first reported the isolation of morphine 
from opium.1,4,7 He initially named it ‘principium somniferum’ but later renamed to 
morphium after Morpheus the Greek God of dreams due to its sleep inducing effect 
when administered to animals.5 Nowadays, the term morphine is used instead of 
morphium. The discovery of morphine is a milestone in the history of modern 
pharmacology: For the first time it had become possible to observe and measure the 
relationship between a precise dose of an active compound and its pharmaceutical 
effect. The discovery ushered in an intense era of discovery of pharmaceutically 
active molecules from plants that is still continuing today. Soon after the isolation of 
morphine in 1817 Pierre Jean Robiquet isolated noscapine from Derosne’s salt.8,9 
Derosne’s salt was a salt extracted from opium in 1803 by Jean-François Derosne, 
which contained noscapine and other alkaloids.9,10 Pierre Jean Robiquet also isolated 
codeine in 1832.9,11 Thebaine was discovered in 1832 by Thibouméry and papaverine 
was discovered by Georg Merck in 1849.12,13  
In modern medicine the use of morphine has been reduced nearly exclusively to 
intravenous injection in hospital settings.14 Codeine is widely used and is available as 
over the counter oral medication with paracetamol.15 Codeine is preferred for oral 
consumption due to its longer acting analgesic effects. Noscapine is also still utilised 
as a cough suppressant in many countries.16 
18 
 
Figure 1.1: Timeline of opium poppy major discoveries in relation to noscapine 
 Alkaloids 
Alkaloids are nitrogen containing secondary metabolites which are structurally very 
heterogeneous compounds most of which possess basic properties, hence the name 
alkaloids. Secondary metabolites are not just produced by plants, they are also 
synthesised in bacteria, algae, corals, sponges and lower animals.17 Alkaloids are not 
essential for plant growth but are thought to play a role in plant defence against 
herbivores and pathogens.18 Commonly known alkaloids are cocaine, nicotine, 
caffeine, atropine, morphine, codeine and noscapine, Figure 1.2. A large range of 
alkaloids have been exploited by humans, such as those named above. Cocaine, 
nicotine and caffeine are stimulants which are commonly abused. Atropine is a 
central and peripheral nervous system blocker used in several medical settings, such 
as bradycardia (slow heart rate) and as a treatment for poisoning by nerve agents 
and pesticides. Morphine and codeine are analgesics used to treat moderate to 
severe pain. Morphine can be chemically acetylated producing heroin which has been 
abused for many years generating a plethora of socio-economic problems. Noscapine 
has classically been utilised as an antitussive but also possesses weak antitumor 
properties.19 Noscapine has no analgesic properties. 
18
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Figure 1.2: Structures of common alkaloids 
1.3.1. Benzylisoquinoline Alkaloids 
Alkaloids derived from opium poppy belong to the benzylisoquinoline class, Figure 
1.4. The biosynthesis of benzylisoquinoline alkaloids (BIA) start with shikimic acid, 
produced in the shikimate biosynthetic pathway, which is subsequently converted to 
chorismic acid by sequential phosphorylation, alkylation, dephosphorylation and 
dehydration, Figure 1.3.20 Chorismate mutase converts chorismic acid to prephenic 
acid which is then decarboxylated to phenylpyruvate.21 L-phenylalanine is generated 
by transamination of phenylpyruvate by prealinine aminotransferase, which is 
subsequently hydroxylated at C4 to generate L-tyrosine by biopterin-dependent 
phenylalanine hydroxylase (PAH).  
L-Tyrosine is the precursor of 4-hydroxyphenylacetaldehyde (4-HPAA) and dopamine 
(3,4-dihydroxyphenylethylamine) which are generally cited as the essential starting 
building blocks for BIAs. 4-Hydroxyphenylacetaldehyde is produced by deamination 
of L-tyrosine by the 2-oxoglutarate dependent tyrosine transaminase or by L-amino 
acid oxidase and subsequent decarboxylation of 4-hydroxyphenylpyruvate by 
4-hydroxyphenylpyruvate decarboxylase.22,23 Dopamine is produced by the 
hydroxylation of L-tyrosine followed by decarboxylation by tyrosine hydroxylase and 
aromatic amino acid decarboxylase, respectively.23 
Cocaine Nicotine Caffeine Atropine
Morphine Codeine Noscapine
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Figure 1.3: Biosynthesis of dopamine and 4-hydroxyphenylacetaldehyde from Shikimic Acid 
The first committed biosynthetic step to BIAs is a condensation reaction between the 
tyrosine derivatives dopamine (red) and 4-hydroxyphenyacetaldehyde (blue) to 
produce (S)-norcoclaurine by norcoclaurine synthase (NCS), Figure 1.5.24,25 Dopamine 
forms the tetrahydroisoquinoline moiety, whereas 4-HPAA forms the C1 linked 
benzyl component, together they form the 1-benzylisoquinoline core of all 
benzylisoquinoline alkaloids, Figure 1.4. Papaverine is the simplest BIA produced by 
opium poppy and is chemically synthesised for industrial use, whereas all other BIAs 
are extracted from plants.26–28 
 
Figure 1.4: Common benzylisoquinoline structural subgroups in opium poppy  
Phthalideisoquinoline
1-Benzylisoquinoline
Protoberberine
MorphinanPromorphinan
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Several enzymatic reactions comprising of O-methylation, N-methylation and 
aromatic ring hydroxylation generates (S)-reticuline from (S)-norcoclaurine. 
(S)-reticuline, is regarded as the central intermediate from which the majority of the 
benzylisoquinoline alkaloids are derived, Figure 1.5.18,28 From (S)-reticuline there are 
four main branch pathways in opium poppy, benzylisoquinoline alkaloid biosynthesis 
leading to the benzophenanthridine sanguinarine in roots, the morphinan and the 
phthalideisoquinoline noscapine branch pathways which are mostly found in aerial 
parts of the plants.28,29 The enzymatic steps to noscapine are discussed in detail in 
Section 1.4.1, pg. 24. 
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Figure 1.5: Overview of alkaloid biosynthesis in opium poppy. 4-hydroxyphenyacetaldehyde and dopamine 
coloured to illustrate the formation of the tetrahydroisoquinoline moiety in (S)-norcoclaurine. Solid arrows 
represent a single enzymatic step while dashed arrows represent multiple enzymatic steps 
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 Noscapine 
Noscapine is a phthalideisoquinoline alkaloid derived from opium poppy (Papaver 
somniferum) and was one of the first alkaloids to be isolated.8,9 It has classically been 
utilised as a cough suppressant due to its antitussive activity, reported to be 
discovered in 1930 by review articles,10,30 but the earliest scientific paper describing 
this activity is from 1954.31 Unlike other alkaloids from opium poppy such as codeine 
and morphine, noscapine does not possess analgesic or sedative properties and is 
nonaddictive. It has been utilised as tablets and syrups to be taken orally and is still 
available to purchase over the counter in many countries.16 Although the mode of 
action of noscapine’s antitussive properties is not known, it has been shown to 
interact with the central nervous system of guinea pig by binding to the brain stereo-
specifically with high affinity in a saturatable manner.32 
Interest in noscapine as a drug has increased over the last 10-20 years due to its 
antitumor properties. In 1998 it was reported that noscapine arrests cells in 
metaphase and induces apoptosis in dividing cells.19 It is postulated that noscapine 
binds to tubulin subunits, promoting tubulin assembly, which ultimately leads to cell 
death in several tumour cell lines and tumours in mice.19,33 Noscapine is effective at 
treating a range of various cancers such as T-cell lymphoma, breast cancer, 
melanoma, ovarian carcinoma, glioblastoma, colon cancer and non-small cell lung 
cancer.33–39  
Noscapine has been the subject of a variety of phase I and phase II clinical trials.40,41 
To increase the therapeutic properties of noscapine several derivatives have been 
synthesised, Figure 1.6. Several modifications have been tested for increased 
therapeutic properties including H9’, N6’ and O6 substitution along with O1 carbonyl 
reduction in conjunction with H9’ substitution.37,42–47 
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Figure 1.6: Noscapine derivatives. Adapted from Chen et al. (2015)10 
1.4.1. Noscapine Biosynthesis 
The current proposed biosynthetic pathway to noscapine is shown in Figure 1.7.48 
The first committed step to generate BIAs is the stereospecific condensation reaction 
of dopamine and 4-hydroxyphenyacetaldehyde (4-HPAA) by norcoclaurine synthase 
(NCS) generating (S)-norcoclaurine by a Pictet-Spengler-type reaction.24,49–51 NCS has 
been proposed to have evolved from a Bet v 1 or PR10 ancestor. Bet v 1 is a major 
allergen protein family which has 28-38 % sequence identity and PR10 is a 
pathogenesis-related (PR) 10 protein family with 50-60 % sequence identity to NSC.24 
The Pictet-Spengler-type reaction mechanism based on the crystal structure involves 
the formation of an iminium ion by a nucleophilic attack of the dopamine amine 
group to the aldehyde carbonyl of 4-HPAA followed by release of water. The C5 of 
Noscapine
H substitution
N substitution
O substitution
Carbonyl 
Reduction
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the catechol moiety of dopamine undergoes electrophilic attack by the imine-carbon, 
resulting in ring closure followed by the deprotonation to form the product, 
(S)-norcoclaurine.50,52 (S)-norcoclaurine contains the core 1-benzylisoquinoline 
structure that all BIAs possess. 
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Figure 1.7: Current proposed biosynthetic pathway to noscapine 
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(S)-Norcoclaurine is then methylated at the C6 hydroxyl position to produce 
(S)-coclaurine by the dimeric class I S-adenosylmethionine (SAM) dependent 
O-methyltransferase norcoclaurine 6-O-methyltransferase (6OMT).53,54 Methylation 
is proposed to occur by histidine acting as a catalytic base, deprotonating the 
hydroxyl group at position C6 of (S)-norcoclaurine followed by the phenolate anion 
performing a nucleophilic attack on the methyl-sulphonium moiety of SAM, 
generating (S)-coclaurine.55 (S)-Coclaurine is the first branchpoint intermediate with 
the biosynthetic pathway to laudanosine branching off here, whereas the rest of the 
benzylisoquinoline alkaloids continue along the common pathway to (S)-reticuline. 
(S)-Coclaurine is then N-methylated by the SAM dependent N-methyltransferase 
coclaurine N-methyltransferase (CNMT) generating (S)-N-methylcoclaurine.56 This is 
one of two N-methylations involved in the biosynthesis of noscapine and is an 
essential modification for the cyclisation of the 1-benzylisoquinoline sub-structure to 
that of the protoberberines. N-methylation reaction mechanism is proposed to be 
similar to that of 6OMT as they both belong to the class I methyltransferase family 
where a catalytic base deprotonates the secondary amine followed by nucleophilic 
attack on the methyl-sulphonium ion.57 
(S)-N-Methylcoclaurine is then hydroxylated at the C3’ position by 
N-methylcoclaurine 3'-hydroxylase (NMCH), a cytochrome P450 dependent 
monooxygenase generating 3'-hydroxy-N-methyl-(S)-coclaurine.58 NMCH was first 
discovered in California poppy (Eschscholzia californica) and classified as CYP80B1. A 
putative ortholog was subsequently discovered in opium poppy and classified as 
CYP80B3.58,59 Cytochrome P450 dependent monooxygenases require heme, iron and 
molecular oxygen as cofactors for catalysis. The consensus reaction mechanism is 
that the substrate binds and a cytochrome P450 reductase reduces iron(III) to iron(II) 
allowing molecular oxygen to bind. A second electron transfer occurs, reducing the 
Fe(II)-superoxide adduct generating a peroxide intermediate. Water is then released 
by the double protonation of the peroxide intermediate forming a highly reactive iron 
(V) oxo species, known as Compound 1, which reacts with the substrate to produce 
the hydroxylated product.60 
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3'-Hydroxy-N-methyl-(S)-coclaurine undergoes O-methylation of the hydroxyl group 
at the C4’ position by the SAM dependent 3'-hydroxy-N-methylcoclaurine 
4'-O-methyltransferase (4’OMT), to generate the central branch metabolite 
(S)-reticuline.54,61 
(S)-Reticuline is the precursor to several different branch pathways in opium poppy, 
as outlined in Figure 1.5. From (S)-reticuline the laudanosine, sanguinarine and 
noscapine branch pathway emerge, along with the morphinan branch pathway which 
produces morphine and codeine via thebaine.62 The first committed step to 
morphine is the isomerisation of (S)-reticuline to (R)-reticuline by STORR ((S)- to 
(R)-reticuline), a cytochrome P450 and oxidoreductase fusion protein.63,64 Morphine 
and codeine are potent narcotics with analgesic effects, whereas thebaine is 
poisonous to humans. Although thebaine is not utilised as a drug, it is the starting 
chemical for several semi-synthetic drugs such as oxycodone and oxymorphone.65,66 
Production of sanguinarine and noscapine involves conversion of (S)-reticuline to 
(S)-scoulerine by the flavin adenine dinucleotide (FAD)-linked oxidoreductase 
berberine bridge enzyme (BBE), also known as (S)-scoulerine oxidase.67,68 BBE is 
responsible for the cyclisation reaction between the N2 methyl group of the 
tetrahydroisoquinoline moiety of (S)-reticuline and the C2 of its C1 linked benzyl 
moiety forming the C ring of the protoberberine sub-structure, Figure 1.4.  
BBE catalyses a unique reaction that has so far remained elusive to organic chemists 
due to its challenging mechanism. The proposed reaction mechanism is the proton 
abstraction of the C3’ hydroxyl group by a conserved base, resulting in an SN2-type 
nucleophilic attack on the N-methyl group by C2’. This results in formation of the 
berberine bridge covalent bond and the expulsion of a hydride from the N-methyl 
group to the FAD cofactor. Rearomatisation of the protoberberine D ring occurs by a 
secondary base deprotonation at C8a resulting in the formation of (S)-scoulerine and 
the protoberberine sub-structure.69 The FAD cofactor is ultimately regenerated by 
reoxidation utilising molecular oxygen to generate hydrogen peroxide. 
(S)-Scoulerine is O-methylated at the C9 hydroxyl position producing 
(S)-tetrahydrocolumbamine by the class I SAM dependent O-methyltransferase 
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called Papaver somniferum O-methyltransferase 1 (PSMT1) also known as scoulerine 
O-methyltransferase (SOMT).48,70,71  
(S)-Tetrahydrocolumbamine is converted to (S)-canadine by canadine synthase 
(CAS/CanSyn), also known as the cytochrome P450 CYP719A21.72,73 CanSyn is 
responsible for the methylenedioxy bridge formation on the A ring of 
(S)-tetrahydrocolumbamine. The proposed reaction mechanism proceeds by the 
formation of Compound 1, as previously described, which abstracts a proton from 
the C3 methoxy group on the A ring of (S)-tetrahydrocolumbamine, forming an 
Fe(IV)-hydroxyl species and a reactive radical carbon intermediate. The reactive 
radical carbon intermediate is involved in a hydroxyl rebound mechanism, where the 
Fe(IV)-OH hydroxyl is inserted into the reactive carbon intermediate forming a 
hemiacetal group. Subsequent dehydration of the hemiacetal group leads to the 
formation of an oxonium ion. Base assisted proton abstraction on the C2 hydroxyl 
group leads to a nucleophilic attack on the oxonium ion resulting in the formation of 
the methylenedioxy bridge.74 
(S)-Canadine is N-methylated by the SAM dependent tetrahydroprotoberberine 
cis-N-methyltransferase (TNMT) to generate N-methylcanadine.75 N-methylcanadine 
is hydroxylated sequentially at the C1 position and then C13 by N-methylcanadine 
1-hydroxylase (CYP82Y1) and 1-hydroxy-N-methylcanadine 13-O-hydroxylase 
(CYP82X2), respectively, to make 1-hydroxy-N-methylcanadine and then (13S, 
14R)-1,13-dihydroxy-N-methylcanadine.48,76,77 The hydroxyl group at C13 opens up 
(13S, 14R)-1,13-dihydroxy-N-methylcanadine to be acetylated by 1,13-dihydroxy-N-
methylcandine 13-O-acetyltransferase (PSAT1).77 Acetylation acts as a protecting 
group, such as those used in organic synthesis, postponing the formation of the 
hemiacetal ring leading to the phthalideisoquinoline sub-structure, but may also play 
a role in the transport of pathway intermediates.77 
The resulting compound, (13S, 14R)-1-hydroxy-13-O-acetyl-N-methylcanadine, is 
hydroxylated at the C8 position by 1-hydroxy-13-O-acetyl-N-methylcanadine 
8-hydroxylase (CYP82X1) producing (13S, 14R)-1,8-dihydroxy-13-O-acetyl-
N-methylcanadine.48,77 (13S, 14R)-1,8-dihydroxy-13-O-acetyl-N-methylcanadine 
30 
spontaneously converts to 4'-O-desmethyl-3-O-acetylpapaveroxine with the 
cleavage of the N7-C8 bond. 
4'-O-Desmethyl-3-O-acetylpapaveroxine is subsequently O-methylated by the unique 
heterodimer Papaver somniferum O-methyltransferase 2 (PSMT2)/ Papaver 
somniferum O-methyltransferase 3 (PSMT3) producing 
3-O-acetylpapaveroxine.48,71,78 Interestingly a heterodimer of PSMT2/6OMT can also 
catalyse the 4’-O methylation of 4'-O-desmethyl-3-O-acetylpapaveroxine, which 
explains why virus induced gene silencing (VIGS) of PSMT2 resulted in the 
accumulation of narcotoline (4’-O-desmetylnoscapine) but VIGS of PSMT3 had no 
altered phenotype.48,78 
3-O-Acetylpapaveroxine is converted to papaveroxine by carboxylesterase 1 (CXE1) 
which removed the O3-acetate group.48,77,78 This leads to the spontaneous 
rearrangement to narcotine hemiacetal, where the C3 hydroxyl acts as a nucleophile 
to attack the C4 aldehyde group to form the phthalideisoquinoline sub-group 
hemiacetal moiety. The final biosynthetic step to noscapine is the reduction of the 
C1 hydroxyl group of narcotine hemiacetal to a carbonyl group by Papaver 
somniferum short-chain dehydrogenase/reductase (PSSDR1).48,79 
The noscapine branch pathway as outlined in Figure 1.5 and described above is 
largely encoded for by the noscapine gene cluster, Figure 1.8.48 The noscapine gene 
cluster contains 10 genes responsible for all the enzyme catalysed biosynthetic steps 
from (S)-scoulerine to noscapine, except for that of tetrahydroprotoberberine cis-N-
methyltransferase (TNMT). TNMT is also involved in the sanguinarine biosynthetic 
pathway. Six out of the ten enzymes were characterised by virus induced gene 
silencing and heterologous expression in yeast.48 Subsequent research characterised 
the remaining four enzymes, leading to the elucidation of PSMT2/PSMT3 
heterodimer.76–78 The identification of the gene cluster is an excellent example of 
gene duplication, neofunctionalisation and genome reorganisation. The clustering of 
genes is assumed to offer an evolutionary advantage as the gene cluster is likely to 
be inherited in its entirety, ensuring all the catalytic machinery is present for the 
biosynthesis of noscapine. 
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Figure 1.8: The noscapine gene cluster in opium poppy. The intron exon structure and the positions of the ten 
noscapine specific genes are shown above the black line which represents 401 Kb of genomic sequence. Exons are 
represented by grey boxes and introns by black lines. The arrows represent the 5’ to 3’ orientation of each gene, 
adapted from Winzer et al., 201248 
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 Methyltransferases 
There are several distinct methods nature has implemented to methylate substrates, 
all utilising a co-substrate with a labile methyl group. The most common of 
methyltransferase are that of the S-adenosylmethionine (SAM) dependent 
methyltransferase class.80 This is not surprising as SAM has the most favourable 
energetics due to the charged methyl-sulphonium centre and is said to be the second 
most commonly used co-substrate by enzymes, with the first being ATP.80,81 Less 
common but arguably just as important are the 5-methyltetrahydrofolate and the 
betaine dependent methyltransferases. All three types of enzyme consume the 
co-substrate/methyl donor to methylate a substrate, Figure 1.9. Methyltransferases 
methylate a wide variety of substrates from small molecules in primary and 
secondary metabolism to DNA and proteins, and methylation can be on carbon, 
oxygen, nitrogen, sulphur and halides.71,80,82–86  
 
Figure 1.9: Natural methyl donors. Labile methyl groups are coloured red 
This thesis will focus on the SAM dependent methyltransferase and only briefly 
mention the other types due to their role in SAM regeneration.  
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 S-Adenosylmethionine Dependent Methyltransferases 
The first SAM dependent methyltransferase to have its structure solved by X-ray 
crystallography was that of DNA C5-cytosine methyltransferase M.HhaI complexed 
with SAM to 2.5 Å in 1993 (PDB:1HMY).86 There are five classes of SAM dependent 
methyltransferases which are all structurally diverse which have been numbered I-V 
based on the chronological order of discovery. This is a great example of functional 
convergence. Enzymes which catalyse the same reaction but from distinct structural 
families have been noted before and have been named analogous enzymes, Figure 
1.10.80,82,87 
Typically, enzymes that catalyse the same reaction have the same structural protein 
fold and evolutionarily related but can vary substantially in amino acid sequence, 
these are termed homologues. Homologous enzymes have a common ancestor and 
by analysing their protein sequences conserved residues can be identified. The core 
catalytic residues of proteins are generally highly conserved, along with residues 
involved in stabilisation of core folds. Homologous enzymes can be catalytically 
promiscuous accepting different substrates due to gene duplication and 
neofunctionalisation.88–90 This can lead to new catalytic properties arising within the 
same structural fold.91 In contrast, for the case of the SAM dependent 
methyltransferases convergent evolution has taken place where at least five distinct 
structural folds have evolved to catalyse the same type of reaction utilising the same 
co-substrate, SAM.80 
Class I methyltransferases contain a Rossmann-like fold which consists of a seven 
stranded β-sheet typically with the topology 6↑7↓5↑4↑1↑2↑3↑, with 1 being 
the N-terminus.80 In between β-strand 1 and 2 is an α-helix which is classed as the 
core β-α-β sandwich fold, this is the most conserved motif within the class I 
methyltansferases.92 Typically, there is a Gly-X-Gly-X-Gly motif in the tight loop 
between the first β-strand and the α-helix. The final conserved feature of the 
superfold is an acidic residue at the end of β-strand 2 which forms hydrogen bonds 
with the hydroxyl groups of the ribose ring of the nucleotide. The class I 
methyltransferase family contains mostly monomeric enzymes made up solely of the 
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Rossmann-like fold domain but homodimeric, heterodimeric and tetrameric forms 
have also been reported with additional domains.93 
Class II methyltransferases, also known as MetH reactivation domain, reactivate the 
vitamin B12 cofactor in E. coli cobalamin (vitamin B12)-dependent methionine 
synthase (MetH) by reductive methylation of the oxidised cobalt (Co2+ (inactive)à 
Co+(active)).94 Class II methyltransferases consist of a central anti-parallel β-sheet 
surrounded by α-helices in a C-like shape, where SAM binds in an extended 
conformation along the concaved region in the centre of the C-like shape forming 
hydrogen bond interactions with the conserved RxxxGY motif. 
Class III methyltransferase structure was discovered in a homodimerc protein called 
cobalt-precorrin-4 methyltransferase (CbiF) from Bacillus megaterium.95 This 
structural family consists of two α-β-α domains each containing five β-strands and 
four α-helices, with SAM binding within a cleft between the two domains. 
Class IV methyltransferases contain the SPOUT family of RNA methytransferases.96 
This structural family consists of a knot-like structure containing a β-sheet made up 
of six parallel β-strands in order 321546 surrounded by seven α-helices, in an α-β-α 
fold.97 The N-terminal domain is representative of half a Rossman-like fold, such as 
in the class I methyltransferases, but differ at the C-terminal domain with a α-helix 
looping back into the active site, generating a rare deep trefoil knot.98 SAM has been 
shown to bind to β-strands 4-6 in a bent conformation with the conserved NxGxxxR 
and SxN motifs. This class of enzyme has been shown to be a dimer in solution.97 
Class V methyltransferases are the SET domain proteins that have been shown to 
methylate lysines in the N-terminus of histones and ribulose-1,5-bisphosphate 
carboxylase/oxygenase (RuBisCO).99,100 This structural family consists of three curved 
β-sheets made up from eight β-strands with a C-terminal α-helix knot-like structure. 
The binding site for SAM is located in a cleft within the SET domain. Surrounding the 
SET domain are pre-SET and post-SET regions that are thought to play a role in 
substrate specificity.  
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Figure 1.10: The tertiary structure of S-adenosylmethionine dependent methyltransferase classes I-V, left, along 
with their corresponding topology diagrams, right. a-class I, b-class II, c-class III, d-class IV, d-class V. Figure taken 
from Schubert et al. 200380 
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1.6.1. S-Adenosylmethionine Metabolism 
The consumption of SAM by SAM dependent methyltransferases generates 
S-adenosylhomocysteine (SAH), Figure 1.11.101 SAH is a potent inhibitor of SAM 
dependent methyltransferases, therefore it is quickly hydrolysed by 
adenosylhomocysteine hydrolase to adenosine and homocysteine. To regenerate 
SAM, homocysteine is methylated by methionine synthase which utilises 
5-methyltetrahydofolate as a methyl donor or betaine homocysteine 
methyltransferase which utilises betaine as the methyl donor to generate 
methionine. The final step to regenerate SAM is the adenylation of methionine by 
methionine adenosyltransferase utilising ATP.102,103 The synthesis of SAM from 
methionine is responsible for around 80 % of methionine metabolism, whereas the 
remaining 20 % is utilised for the synthesis of proteins.104 
 
Figure 1.11: S-Adenosylmethionine metabolism. 1-SAM dependent methyltransferase, 2-adenosylhomocysteine 
hydrolase, 3-methionine synthase, 4-betaine homocysteine methyltransferase, 5-methionine adenosyltransferase 
 Plant O-Methyltransferases  
Plant O-methyltransferases are a large enzymatic family, many of which are involved 
in lignin biosynthesis, while others methylate a large range of low molecular weight 
plant secondary metabolites such as alkaloids, flavonoids, phenylpropanoids and 
terpenoids, Figure 1.12. All known plant substrates are phenolic in nature with most 
having adjacent hydroxyl/catecholic groups. 
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Figure 1.12: Plant secondary metabolite chemical structures utilised by O-methyltransferases 
Plant O-methyltransferases are part of the class I methyltransferases family which 
contain the Rossmann-like superfold, Figure 1.10.82 The first plant 
O-methyltransferase to be successfully cloned was that of caffeoyl-CoA 
3-O-methyltransferase from parsley involved in disease resistance response.105 
Recent advantages in large-scale genomic sequencing has resulted in hundreds of 
plant O-methyltransferases available in public databases but relatively little is known 
about their substrate specificity. 
1.7.1. Plant O-Methyltransferase Structure 
The first plant O-methyltransferases to have their structures solved were that of 
chalcone O-methyltransferase and isoflavone O-methyltransferase from Madicago 
sativa by X-ray crystallography in 2001.106 Since then the structure of several other 
homodimeric O-methyltransferases have been solved, including several caffeic acid 
O-methyltransferases, monolignol 4-O-methyltransferase, isoflavanone 
4'-O-methyltransferase, coniferyl alcohol 9-O-methyltransferase and norcoclaurine 
6-O-methyltransferase, Figure 1.13.55,107–112 The majority of characterised plant 
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O-methyltransferases are homodimers but data also shows scope for heterodimeric 
enzymes with altered substrate specificity.59,78,113 
 
Figure 1.13: Crystal structures of several plant O-methyltransferases. Peptides are shown as ribbons, coloured by 
chain. The ligands are shown as cylinders coloured by atom: carbon (green), oxygen (red), nitrogen (blue), sulphur 
(yellow).PDB codes listed where available55,107–112 
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All current available structures are of homodimeric enzymes and have the same 
overall fold with a N-terminal dimerisation/substrate binding domain along with a 
conserved C-terminal SAM binding domain, Figure 1.13. They have been shown to 
have a large conformational change upon binding of the substrates but the causation 
of active site closure is unclear.  
The plant O-methyltransferases which have their structures solved are in either a 
open or a closed conformation. All the “apo” structures are in an open conformation, 
the majority of “holo” (SAH bound) structures are in an open conformation and the 
majority of the complex (SAH and substrate/product bound) structures are in a closed 
conformation but there are exceptions.55,106,112 For example, norcoclaurine 
6-O-methyltransferase with SAH bound is in a closed conformation and chalcone 
O-methyltransferase with SAH and isoliquiritigenin bound is in an open 
conformation.55 Probing causation of conformational changes by X-ray 
crystallography is difficult due to crystal growth selective pressures stabilising 
alternative conformations.  
The dimeric structure opens up the possibility of subunit co-operativity which has 
been reported for Thalictrum tuberosum O-methyltransferases and Sorghum bicolor 
coffeoyl-CaA O-methyltransferase.113,114 Subunit co-operativity can occur when an 
enzyme contains two or more active sites. For positive co-operativity, binding of a 
substrate at one active site increases the affinity at a second site. Whereas, for 
negative co-operativity the opposite is observed, where binding of a substrate at one 
site decreases the affinity at a second site. The most common method to measure 
co-operativity is by fitting the Hill equation to activity assay data to generate a Hill 
coefficient.115 The Hill coefficient is described as ‘an interaction coefficient, reflecting 
the extent of cooperativity among multiple ligand binding sites’. 115 
1.7.2. Reaction Mechanism 
Several reaction mechanisms have been reported in the literature for plant 
O-methyltransferases. Sorghum bicolor caffeic acid O-methyltransferase has been 
reported to proceed in a random order bi-bi mechanism; where the substrates, 
caffeic acid and SAM, bind in a random order, catalysis occurs, and the products are 
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released in a random order.111 Lineweaver-Burk plots were generated comparing 
activity at various concentration of methyl acceptor (caffeic acid) in respect to SAM 
and various concentrations of SAM in respect to methyl acceptor. Both graphs show 
an intercept on the x-axis indicating sequential order reaction kinetics. Product 
inhibition studies showed SAH was a non-competitive inhibitor towards caffeic acid 
but was competitive towards SAM, and the methylated product (ferulic acid) was a 
competitive inhibitor to both SAM and caffeic acid. This data led the authors to 
propose rapid equilibrium random order mechanism where caffeic acid and SAH lead 
to a dead end complex.  
Whereas, for Linum nodiflorum coniferyl alcohol 9-O-methyltransferase it has been 
proposed that the methyl acceptor (coniferyl alcohol) binds first followed by SAM in 
a sequential order mechanism based on dissociation constants (Kd).110 The 
dissociation constants measured by isothermal calorimetry showed that the methyl 
acceptor Kd value lowered by a factor of 1.8 in the presence of SAM compared to 
without SAM present. Whereas the Kd for SAM decreased by a factor of 222 in the 
presence of methyl acceptor compared to without.  
Hydroxy-N-methylcoclaurine 4’-O-methyltransferase from Coptis japonica has been 
reported to proceed by an ordered mechanism based on product inhibition studies.54 
The inhibition studies utilising SAH as the inbibitor showed non-competitive 
inhibition to the methyl acceptor (norlaudanosoline) but showed competitive 
inhibition towards SAM. Whereas, methyl acceptor product (norreticuline) inhibition 
showed non-competitive inhibition in respect to both methyl acceptor and SAM.  
The conflicting reaction mechanisms proposed for this class of enzyme may be due 
to the large conformational change upon binding on the substrates, and is most likely 
a random order mechanism where upon both SAM and the methyl acceptor binding 
the active site closes, resulting in the large decrease in Kd seen by Walters et al.110 
Product inhibition studies to determine the reaction mechanism is a not an 
appropriate technique for this class of enzyme as the methylated product will 
interfere with SAM binding due to steric clashes of the methyl groups causing an 
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artificial competitive result. A better alternative would be to utilise a substrate 
analogue which can bind to the substrate pocket but cannot be methylated. 
1.7.3. S-Adenosylmethionine Binding Site 
Kozbial and Mushegian proposed five conserved motifs involved in SAM binding of 
Rossmann-like fold methyltransferases based on multiple sequence alignment and 
structural data. 116 Motif I consists of the first β-strand, the following loop and the 
first α-helix. β-strand one contains a conserved acidic residue (D or E) in the middle 
of the stand along with one or more positively charged residues at its N-terminus 
which do not interact with the substrate. There is also a conserved GxGxG sequence 
in the loop of motif I which forms a hydrophobic wall that interacts directly with the 
carboxypropyl moiety of SAM. 
Motif II consists of β-strand two and the following loop with a conserved acidic 
residue at the C-terminal end of β-strand 2 which hydrogen bonds to the hydroxyl 
groups on the ribose ring. The loop following interacts with the adenine ring. Motif 
III is β-strand three and the following loop which contains a conserved acidic residue 
at the C-terminus that interacts with adenine. Motif IV is β-strand four and the 
following loops with a conserved D/E/N residue at the N-terminus of the loops which 
is not involved in substrate binding. The variable C-terminal region of motif IV 
interacts with the sulphonium moiety of SAM. Motif V is the α-helix following 
β-strand four and contains hydrophobic or aromatic residues which stabiles the 
adenine moiety of SAM. Motif VI is that of β-strand five and the preceding tight loop 
containing a conserved glycine residue with unknown function. 
These motifs are conserved in plant O-methyltransferases along with several other 
conserved features based on this authors analysis of the crystal structures shown in 
Figure 1.13. SAM is bound by a conserved lysine which interacts extensively with the 
amino acid moiety of SAM, forming hydrogen bonds with the carboxylic acid of SAM 
via its terminal amine group and the amine group of SAM via its backbone carbonyl 
moiety, Figure 1.14. π Orbital hydrogen bond interactions between the aromatic ring 
of adenine and that of the sulphur (Sδ) in methionine and on the opposing face to the 
second carbon (Cγ) of the alkane sidechain of a conserved leucine except for 
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isoflavone O-methyltransferase which has an arginine at this position, but the same 
interaction is maintained. 
 
Figure 1.14: A summary of conserved features involved in SAM binding based on chalcone-,106 isoflavone-,106 
caffeic acid-107 and norcoclaurine 6-55 O-methyltransferases. SAM is shown in black with the labile methyl group 
in green, non-covalent bonding residues are shown in blue, non-covalent bonds are shown in red and hydrophobic 
interactions are shown in pink 
1.7.4. Phenolic Substrate Binding Site 
Only a few plant O-methyltransferases have had their three dimensional structure 
determined, with even less in an closed ternary complex.55,106,110,112 These are Lolium 
perenne caffeic acid O-methyltransferase (COMT) (PDB: 3P9I, 3P9K)112, Clarkia 
breweri monolignol O-methyltransferase (MOMT) (PDB: 5CVJ, 5CVV), Thalictrum 
flavum norcoclaurine 6-O-methyltransferase (N6OMT) (PDB: 5ICE),55 Medicago 
sativa Chalcone O-methyltransferase (ChOMT) (PDB: 1FP1),106 Medicago sativa 
Isoflavone O-methyltransferase (IOMT) (PDB: 1FP2),106 Linum nodiflorum coniferyl 
alcohol 9-O-methyltransferase (Ca9OMT)(PDB: 4EVI, 4E70).110 ChOMT is the only 
structure with its natural methyl acceptor bound in the active site but is in such a 
conformation that catalysis cannot occur; as a water molecule is coordinated to the 
catalytic dyad. These six proteins all possess the characteristic C-terminal Rossman-
like fold SAM binding domain along with the N-terminal dimerisation and substrate 
binding domain. The residues responsible for SAM binding in the C-terminal domain 
are well conserved as highlighted in the multiple sequence alignment, Figure 1.15, 
and discussed in Section 1.7.3, pg. 41. Ca9OMT implements a different catalytic 
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mechanism with a catalytic dyad of cysteine and aspartic acid, as opposed to histidine 
and aspartic acid. This is not surprising as it methylates a hydroxyl group at the end 
of an alkyl chain rather than a phenolic ring as described for the other enzymes. 110 
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Figure 1.15: Multiple sequence alignment of plant O-methyltransferases in a tertiary complex in closed 
conformation submitted to the Protein Database. Ca9OMT employs a different catalytic mechanism. Residues 
highlighted in cyan are the conserved residue involved in SAM binding as outlined in Figure 1.14. Red residues are 
the catalytic dyad and yellow residues are conserved in phenolic substrate binding. Lolium perenne caffeic acid 
O-methyltransferase (COMT), Clarkia breweri monolignol O-methyltransferase (MOMT) Thalictrum flavum 
norcoclaurine 6-O-methyltransferase (N6OMT), Medicago sativa Chalcone O-methyltransferase (ChOMT), 
Medicago sativa Isoflavone O-methyltransferase (IOMT), Linum nodiflorum coniferyl alcohol 
9-O-methyltransferase (Ca9OMT) 
COMT ----------MGSTAA--------DMAASADEDACMF--ALQLASSSVLPMTLKNAIELG 40
MOMT ----------MGSTGNAE--IQI-IPTHSSDEEANLF--AMQLASAAVLPMALKAAIELD 45
N6OMT ---------------MEM------INKENLSSQAKLW----NFIYGFADSLVLKSAVQLD 35
ChOMT ----------MGNSYITKEDNQISATSEQTEDSACLS--AMVLTTNLVYPAVLNAAIDLN 48
IOMT ----------MASSINGR------KPSEIFKAQALLY----KHIYAFIDSMSLKWAVEMN 40
Ca9OMT   --------------MDAA------TAVELLDAQPQVW----HHFLGYINSMTLQCALELD 36
.                     *. *:::.
COMT LLEILVAAG--GKSLTPTEVAAKLPSAA-NPEAPDMVDRILRLLASYNVVTCLVE--EGK 95
MOMT VLEIMAKSVPPSGYISPAEIAAQLPT-T-NPEAPVMLDRVLRLLASYSVVTYTLR--ELP 101
N6OMT LANIIHNHGSP---MTLSELSLHLPSQP---VNQDALYRVLRYLVHMKLFTKSSIDGE-- 87
ChOMT LFEIIAKATPPGAFMSPSEIASKLPASTQHSDLPNRLDRMLRLLASYSVLTSTTR--TIE 106
IOMT IPNIIQNHGKP---ISLSNLVSILQVPS---SKIGNVRRLMRYLAHNGFFEIIT-KEE-- 91
Ca9OMT   IADVIHRHGHP---IPLNQLAAALEIPQ---TKAPFLSRLMRMLVHLGYFTQVITKPEDE 90
: :::         :   ::   :            : *::* *     .          
COMT DGR-----LSRSYGAAP-VCKFLTPNEDGVSMAALALMNQDKVLMESWYYLKDAVLDGGI 149
MOMT SGK-----VERLYGLAP-VCKFLTKNEDGVSLAPFLLTATDKVLLEPWFYLKDAILEGGI 155
N6OMT ----------LRYGLAP-PAKFLVKGWDK-CMLGAILTITDKDFMAPWHYLKEGILNDGS 135
ChOMT DGG-----AERVYGLSM-VGKYLVPDESRGYLASFTTFLCYPALLQVWMNFKEAVVDEDI 160
IOMT ----------ESYALTV-ASELLVRGSDL-CLAPMVECVLDPTLSGSYHELKKWIYEE-- 137
Ca9OMT   NDD-----VLPSYWLAP-LSRLLLKQNPY-NARSLTFCSVHEHLVDPWRQMSAWLRTGKE 143
*  :      :                    .   :  :.  :     
COMT P-------FN-KAYGMSAFEYHGTDPRFNRVFNEGMKNHSIIITKKL-LELYHGFEGLGT 200
MOMT P-------FN-KAYGMNEFDYHGTDHRFNKVFNKGMSSNSTITMKKI-LEMYNGFEGLTT 206
N6OMT TS----TAFE-KALGTNIWDYMAEHPEKNQLFNEGMANDTRLIMSALVKECSSMFDGITT 190
ChOMT DL------FK-NVHGVTKYEFMGKDKKMNQIFNKSMVDVCATEMKRM-LEIYTGFEGIST 212
IOMT DL----TLFG-VTLGSGFWDFLDKNPEYNTSFNDAMASDSKLINL-ALRDCDFVFDGLES 191
Ca9OMT   DGKDTPNAFAFAHEGKKVYEVCSEDANFSQLFSEGMAGDSWLFSRALVSKCRDAFEGLSS 203
*     *   ::    . . .  *...*                  * .:  
COMT LVDVGGGVGATVAAIAAHYPTIKGVNFDLPHVISEAP-QFPGVTHVGGDMFK-EVPSGDT 258
MOMT IVDVGGGTGAVASMIVAKYPSINAINFDLPHVIQDAP-AFSGVEHLGGDMFD-GVPKGDA 264
N6OMT IVDVGGGTGTAVRNIAKAFPHIKCTVYDLPHVIADSP-GYTEINSIQGDMFK-YIPNADA 248
ChOMT LVDVGGGSGRNLELIISKYPLIKGINFDLPQVIENAP-PLSGIEHVGGDMFA-SVPQGDA 270
IOMT IVDVGGGTGTTAKIICETFPKLKCIVFDRPQVVENLS-GSNNLTYVGGDMFT-SIPNADA 249
Ca9OMT   LVDVGGGTGNTSKVIAETFPNIHCTVFDLPHVVSGPKQTHPNLDYESGNMFTDEIPHADA 263
::***** *     *   :* :.   :* *:*:         :    *:**   :* .: 
COMT ILMKWILHDWSDQHCATLLKNCYDALPAH---GKVVLVQCILPVNPEAN-PSSQGVFHVD 314
MOMT IFIKWICHDWSDEHCLKLLKNCYAALPDH---GKVIVAEYILPPSPDPS-IATKVVIHTD 320
N6OMT IMMKCILHDWDDKECIEILKRCKDAVPRDG--GKVIIIDIILDVKSE-H-PYTKMRLTLD 304
ChOMT MILKAVCHNWSDEKCIEFLSNCHKALSPN---GKVIIVEFILPEEPNTS-EESKLVSTLD 326
IOMT VLLKYILHNWTDKDCLRILKKCKEAVTNDGKRGKVTIIDMVIDKKKDEN-QVTQIKLLMD 308
Ca9OMT   VLFKWVLCDWPDEPVLKMLKQCKKALTKNGVKGKLMIADHVLDHESCNDSNSMGTSLILD 323
:::* :  :* *:    :*..*  ::      **: : : ::  .              *
COMT MIMLAHNPGGRERYEREFQALARGAGFTGVKSTYIYANAW-AIEFTK-- 360
MOMT ALMLAYNPGGKERTEKEFQALAMASGFRGFKVASCAFNTY-VMEFLKTA 368
N6OMT LDMML-NTGGKERTEEEWKKLIHDAGYKGYKIT-HISAVQSVIEAYPY- 350
ChOMT NLMFI-TVGGRERTEKQYEKLSKLSGFSKFQVACRAFNSLGVMEFYK-- 372
IOMT VNM-A-CLNGKERNEEEWKKLFIEAGFQHYKIS-PLTGFLSLIEIYP-- 352
Ca9OMT   MLFMS-FLEGSLRTEKQWAKLFAEAGFKDYKIT-PVGGLRVLIEVYP-- 368
:      *  *   ::  *   :*:               :*     
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Phenolic substrate binding has not been studied in great detail, with only five 
conventional plant O-methyltransferases crystallised with the substrate, product or 
an analogue ligand bound. These are listed in Figure 1.15, COMT, MOMT, N6OMT, 
ChOMT and Ca9OMT. Conventional plant O-methyltransferases are those which 
utilise the His/Asp catalytic dyad for catalysis. The conserved residues involved in 
substrate binding are highlighted in yellow in Figure 1.15, along with the catalytic 
dyad in red, which is also involved in substrate binding. Interestingly the residues 
involved in phenolic substrate binding are conserved as shown in, Figure 1.16. The 
catalytic dyad of histidine and aspartic acid hydrogen bond to the methylated oxygen 
via Nε and Oδ, respectively. The phenolic ring is clamped in place between a 
methionine CεH-π bond and phenylalanine on the opposing face via CH-π bonding. 
The thiol group on the methionine and the phenylalanine also interact with the 
transferred methyl group in the product bound structures, which would suggest that 
these residues are crucial in the correct orientation of the sulphonium methyl group 
on SAM and the positioning of the substrate for efficient methylation. 
 
 
Figure 1.16: A summary of conserved features involved in plant O-methyltransferase phenolic substrate binding. 
The phenolic product is shown in black, interacting residues are shown in blue, non-covalent interaction are shown 
in red and the transferred methyl group is shown in green 
1.7.5. Catalytic Mechanism 
O-methyltransferases have a conserved catalytic dyad of histidine and aspartic 
acid.55,106,112 The consensus reaction mechanism is the deprotonation of the hydroxyl 
group on the substrate by the conserved histidine, generating a nucleophile. 
Subsequently, nucleophilic attack upon the sulphonium methyl group by the 
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activated phenolic substrate proceeded by a SN2 reaction, resulting in the formation 
of the methylated substrate, Figure 1.17. Site-directed mutagenesis studies have 
shown that mutations of the catalytic histidine result in inactive protein or protein 
with severely reduced activity, less than 1 %.106,107,117 One mutation study of the 
aspartic acid in wheat flavone O-methyltransferase showed the loss of activity when 
substituted with a hydrophobic side chain and severe loss of activity when mutated 
to glutamic acid, but when mutated to asparagine 84 % of activity was retained.117 
They also reported mutations in the catalytic histidine “resulted in nearly complete 
loss of protein expression”. 117 
 
Figure 1.17: Diagram of the conserved SN2 nucleophilic attack reaction of SAM dependent methyltransferases 
where Nu represents the nucleophile and R1 and R2 represent the adenosyl and aminobutyryl moieties of SAM/SAH. 
The transferred methyl group is shown in green 
 Summary and Aims 
Plant O-methyltransferases substrate specificity has not been studied in detail due to 
a limited number of high resolution structures with the natural substrate or product 
bound in the active site. The conserved features of phenolic substrate binding have 
been analysed and summarised in Figure 1.16. Whereas, the residues involved in SAM 
binding have been studied in great detail with consensus motifs being described in 
the literature and summarised in Figure 1.14. 
The opium poppy O-methyltransferase Papaver somniferum O-methyltransferase 1 
(PSMT1) is responsible for the conversion of scoulerine to tetrahydrocolumbamine in 
the pathway to noscapine. Noscapine has potent antitumor properties due to its 
interaction with tubulin leading to cell arrest in metaphase.19 PSMT1 catalyses the 
first step of the noscapine branch pathway in opium poppy and is encoded in the 
noscapine gene cluster, discovered in the Graham lab, which encodes for all 
enzymatic steps for the conversion of scoulerine to noscapine except for 
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tetrahydroprotoberberine cis-N-methyltransferase (TNMT).48 The noscapine gene 
cluster also encodes for two other methyltransferases Papaver somniferum 
O-methyltransferase 2 (PSMT2) and Papaver somniferum O-methyltransferase 3 
(PSMT3). The substrates for PSMT2 and PSMT3 were recently discovered, by 
heterologous gene expression in yeast, with the two polypeptides working together 
as a heterodimer to methylate the 4’-hydroxyl group on 4’-O-Desmethyl-3-O-
acetylpapaveroxine to produce 3-O-acetylpapaveroxine, Figure 1.7.78 
The major aim of this thesis was to characterise and generate structural information 
for PSMT1. Three-dimensional high resolution structural data provides a wealth of 
information allowing the rationalisation of reaction mechanism and substrate 
specificity. Currently there is little understanding about how the plant 
O-methyltransferase family of enzymes achieves substrate specificity, as only a few 
of them have been structurally elucidated. The work presented in this thesis 
contributes to our understanding through a detailed analysis of high resolution three-
dimensional structures of PSMT1. 
During the course of this PhD programme the author also carried out work over a 12 
month period aimed at determining the crystallographic structure of the Iron (II)/ 
2-oxoglutartae dependent dioxygenases codeine-O-demethylase (CODM) and 
thebaine-6-O-demethylase (T6ODM). CODM and T6ODM are responsible for the final 
demethylation steps on the biosynthetic pathway to morphine, Figure 1.5. 118,119 The 
pathway to morphine can take two routes with a bifurcation at thebaine depending 
on the actions of CODM and T6ODM. The major pathway, from which the enzymes 
are named, is via codeine where T6ODM demethylates thebaine to create neopinone 
which spontaneously rearranges to codeinone. Codeinone is then reduced by 
codeinone reductase (COR) to codeine and subsequently converted to morphine by 
3-O-demethylation by CODM. The secondary route utilised the same enzymes but it 
an alternate order. Thebaine is demethylated by CODM at the O3 position to produce 
oripavine. Oripavine is subsequently demethylated by T6ODM, followed by COR to 
produce morphinone and morphine, respectively. T6ODM and CODM proved 
recalcitrant to crystallisation and this work will not be discussed in this thesis. 
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2. Materials and Methods 
 Molecular and Microbiological Methods 
2.1.1. E. coli Strains 
Expression and cloning hosts are commercially bought E. coli strains listed in Table 
2.1. 
Strain Brand Resistance Use 
BL21(DE3) Agilent - Expression 
XL10 Gold 
Ultracompetent 
Stratagene Tetracycline, 
Chloramphenicol 
Cloning 
Table 2.1: List of commercial E. coli stains with their antibiotic resistance and use 
2.1.2. Plasmids 
The plasmid pETFPP-3-PSMT1 containing a gene encoding a glutathione S-transferase 
(GST)-PSMT1 fusion protein separated by a 3C protease cleavage recognition site 
with a hexa-His N-terminal tag (6xHis-GST-r3CP-PSMT1) was generated from 
previous work undertaken in the Davies/Graham groups in collaboration with the 
Technology Facility at the Department of Biology, University of York. The pETFPP-3-
PSMT1 had been shown to produce sufficient soluble PSMT1 protein for 
crystallisation trials. The plasmid map of pETFPP-3-PSMT1 and the protein sequence 
are shown in Figure 2.1 and Figure 2.2, respectively (full nucleotide sequence shown 
in Appendix 8.1).  
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Figure 2.1: Plasmid map of pETFPP-3-PSMT1. The open reading frame contains a gene under the control of a T7 
promotor encoding for GST-PSMT1 fusion protein separated by a 3C protease cleavage site and a hexa-His affinity 
tag on the N-terminus. Plasmid map generated using SerialCloner 2.6 (Serial Basic) 
MGSSHHHHHH SSMSPILGYW KIKGLVQPTR LLLEYLEEKY EEHLYERDEG 50 
DKWRNKKFEL GLEFPNLPYY IDGDVKLTQS MAIIRYIADK HNMLGGCPKE 100 
RAEISMLEGA VLDIRYGVSR IAYSKDFETL KVDFLSKLPE MLKMFEDRLC 150 
HKTYLNGDHV THPDFMLYDA LDVVLYMDPM CLDAFPKLVC FKKRIEAIPQ 200 
IDKYLKSSKY IAWPLQGWQA TFGGGDHPPK GLEVLFQGPA MATNGEIFNT 250 
YGHNHQSATV TKITASNESS NGVCYLSETA NLGKLICIPM ALRAAMELNV 300 
FQLISKFGTD AKVSASEIAS KMPNAKNNPE AAMYLDRILR LLGASSILSV 350 
STTKKSINRG GDDVVVHEKL YGLTNSSCCL VPRQEDGVSL VEELLFTSDK 400 
VVVDSFFKLK CVVEEKDSVP FEVAHGAKIF EYAATEPRMN QVFNDGMAVF 450 
SIVVFEAVFR VYDGFLDMKE LLDVGGGIGT SVSKIVAKYP LIRGVNFDLP 500 
HVISVAPQYP GVEHVAGDMF EEVPKGQNML LKWVLHDWGD ERCVKLLKNC 550 
WNSLPVGGKV LIIEFVLPNE LGNNAESFNA LIPDLLLMAL NPGGKERTIS 600 
EYDDLGKAAG FIKTIPIPIS NGLHVIEFHK  
Figure 2.2: 6xHis-GST-r3CP-PSMT1 amino acid sequence in pETFFP-3-PSMT1. Green-His-tag, orange- GST, purple-
3CP cleavage recognition site and red-PSMT1 
2.1.3. Bacterial Culture Media 
E. coli was cultured in two different media. Luria-Broth (LB) medium, consisting of 
10 g tryptone, 10 g NaCl, 5 g yeast extract in 1 L of deionised water, sterilised by 
autoclaving at 121 ᵒC for 15 minutes, was used for plasmid preparations, glycerol 
stocks and inoculum for gene expression. Terrific-Broth (TB) medium was used for 
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recombinant gene expression, consisting of 12 g tryptone, 24 g yeast extract, 4 mL 
glycerol in 900 mL deionised water, sterilised by autoclaving at 121 ᵒ C for 15 minutes. 
To the sterile broth 100 mL of filter sterilised TB salts (0.17 M KH2PO4, 0.72 M K2HPO4) 
were added aseptically just before use. 
LB Agar plates were prepared by the addition of 1.6 g of agar per 100 mL of LB media 
before autoclaving. The LB agar was cooled to about 50 ᵒC, the relevant antibiotic 
was added under aseptic techniques and poured into sterile round plastic dishes. The 
plates were stored at 4 ᵒC until needed. 
2.1.4. Antibiotics 
Antibiotics were added to the media and plates to select for E. coli containing a 
plasmid conferring antibiotic resistance. The two antibiotics used during this work 
were kanamycin and ampicillin. Kanamycin and ampicillin are prepared at 1000x 
stocks in distilled water, 50 mg mL-1 and 100 mg mL-1 respectively, and filter sterilised. 
2.1.5. Cultivation of Bacteria 
E. coli was generally cultured at 37 ᵒC, 250 rpm in an orbital shaker. For small scale, 
overnight cultures 10 mL of LB media plus the relevant antibiotic was cultured in a 
50 mL falcon tube. The media was inoculated by either picking a single colony from a 
plate or directly from a glycerol stock with a sterile 200 μL pipette tip, then placed 
directly into the media. The 50 mL flacon tube cap was loosely fitted to allow aeration 
and held in place with tape to stop the cap vibrating off. LB plates were incubated at 
37 ᵒC overnight. 
For recombinant gene expression 500 mL of TB media with the appropriate antibiotic 
in a 2 L baffled shaker flask, was inoculated with 10 % (v/v) overnight culture. Once 
the optical density (OD) measured spectroscopically at 600 nm was 0.6 – 0.8 
expression was induced by adding IPTG at a final concentration of 1 mM, from a 
1000x (1 M) stock solution. The incubation temperature was reduced to 16 ᵒC before 
induction, to aid protein folding. Cells were harvested by centrifugation (5000 rpm, 
4 ᵒC for 30 minutes) and transferred to 50 mL falcon tubes. Recombinant protein was 
then purified from the cells or the cell pellet was stored at -20 ᵒC. 
51 
2.1.6. Preparation of Glycerol Stocks 
Glycerol stocks were prepared for the long-term storage of viable E. coli cells 
at -80 ᵒC. 1 mL of overnight culture was aliquoted into a 2 mL plastic tube containing 
0.5 mL of 50 % glycerol and thoroughly mixed. Glycerol was used as a cryo-protectant 
to stop ice crystal formation. The glycerol stocks were flash frozen with liquid 
nitrogen (-196 ᵒC), and stored at -80 ᵒC. 
2.1.7. Preparation of Chemically Competent E. coli Cells 
Chemically competent E. coli cells are required for the transformation of foreign 
plasmid DNA into the cells. To prepare these, cells were sampled from a glycerol stock 
and spread on an LB plate with no antibiotic. A single colony from this plate was 
cultured overnight in 10 mL LB without antibiotic. 1 mL of overnight culture was used 
to inoculate 100 mL LB. Once OD reached 0.6, the cells were pelleted equally in two 
50 mL falcon tubes by centrifugation at 4,000 rpm at 4 ᵒC for 10 minutes. The 
supernatant was removed and the cells resuspended in 25 mL of cold, filter sterilised 
0.05 M CaCl2, then incubated for 20 minutes on ice. The cells were pelleted in the 
same manner as before, then resuspended in 10 mL of cold filter sterilised 0.1 M 
CaCl2, 14 % (v/v) glycerol. The now chemically competent E. coli cells were aliquoted 
into 1.5 ml tubes, flash frozen with liquid nitrogen and stored at -80 ᵒC. 
2.1.8. DNA Transformation into E. coli 
Plasmid DNA transformation of chemically competent E. coli cells was achieved using 
the heat shock method. 1 μL of purified plasmid DNA was mixed with 50 µL of BL21 
(DE3) cells or 30 µL XL10 gold cells on ice, then incubated for 30 minutes, Table 2.2. 
The cells were then heat shocked by exposing them to 42 ᵒC using a heat block for 45 
seconds before returning to ice for 2 minutes. The heat shock treated cells were then 
mixed with 0.4 mL LB for BL21 (DE3) cells or 0.2 mL of LB for XL10 gold cells without 
antibiotic and incubated at 37 ᵒC, 500 rpm. The culture was then spread onto LB 
plates containing the relevant antibiotic for the plasmid of choice. For site-directed 
mutagenesis (SDM) 5 μL of DpnI treated PCR product was mixed with 50 μL of XL10 
gold cells, heat shock treated then incubated with 0.3 mL of LB.  
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Cell Type Use Volume of cells Volume of LB Media 
BL21(DE3) Expression 50 μL 0.4 mL 
XL10 Gold 
Cloning 30 μL 0.2 mL 
SDM 50 μL 0.3 mL 
Table 2.2: Volume and usage of chemically competent E. coli cells required for transformation 
2.1.9. Isolation of Plasmid DNA from E. coli 
Plasmid DNA was isolated exclusively form E. coli XL10 Gold cells cultured overnight 
using a QIAprep spin miniprep kit (Qiagen) as described in the manufacturer’s 
manual. Plasmids were eluted with 30 μL of water. 
2.1.10. DNA Sequencing 
Plasmid DNA sequencing was carried out by GATC Biotech using their high-
throughput Sanger sequencing service. The samples were prepared to their sample 
requirements: 5 μL isolated plasmid DNA (80-100 ng μl-1) and 5 μL of 5 μM primer in 
a 1.5 mL tube. If plasmid DNA concentration was lower than 80 ng μL-1, 2.5 μL of 
10 μM plasmid plus 7.5 μL plasmid DNA at (50-70 ng μL-1) was used. 
2.1.11. Oligonucleotides 
Oligonucleotides were designed with the aid of the Agilent QuikChange Primer 
Design tool (Agilent). All oligonucleotides were synthesised by Integrated DNA 
Technologies and purified by desalting. Upon receiving the desalted oligonucleotides, 
they were resuspended in molecular biology grade water to 100 μM. 10 μM working 
stock solutions were generated and all stored at -20 ᵒC. 
2.1.12. Site-Directed Mutagenesis 
Site-directed mutagenesis (SDM) of plasmid DNA was carried out using the whole 
plasmid mutagenesis method. Overlapping oligonucleotides (primers) containing the 
desired mutation or mutations, flanked on either side with 15-20 complimentary 
nucleotides were generated with an annealing temperature of 78-79 ᵒC. 10 ng of 
purified plasmid DNA was mixed with forward and reverse primers, water and KOD 
hot start master mix (Novagen), Table 2.3. KOD hot start master mix is a 2x mixture 
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containing KOD hot start polymerase, deoxynucleotides and reaction buffer 
containing MgSO4. The whole plasmid was then amplified by PCR, typically using the 
thermal-cycling conditions outlined in Table 2.4. Extension time is based on KOD 
activity of 1 min 10 seconds per kilo base pairs at 68 ᵒC, where optimal proofreading 
activity is obtained. Following the PCR, 1 μL of DpnI restriction enzyme (20 units μL-
1) was added to the reaction mixture and incubated at 37 ᵒC to digest the methylated 
template DNA. The mutated plasmid DNA then transformed E. coli XL10 Gold cells. 
Three colonies exhibiting antibiotic resistance had their plasmid DNA extracted from 
overnight cultures and sequenced.  
Reagent Volume (μL) [Final] 
Molecular biology grade water 21  
Forward Primer (10 μM) 1.5 0.3 μM 
Reverse Primer (10 μM) 1.5 0.3 μM 
Template DNA (10 ng μL-1) 1 10 ng 
KOD hot start master mix 25 0.02 U mL-1 
Table 2.3: Quick Change site directed mutagenesis reaction constituents 
Step Temperature Time Cycles 
Hot Start 95 ᵒC 1 minute 1 
Denature 95 ᵒC 30 seconds 
20 Anneal 50 ᵒC 1 minute 
Extend 68 ᵒC 8 minute 30 seconds 
Storage 10 ᵒC Hold 1 
Table 2.4: Thermal-cycling conditions for site directed mutagenesis 
2.1.13. Measurement of DNA Concentration 
Nucleic acid concentration was measure using an Epoch microplate 
spectrophotometer (BioTek) equipped with a Take3 micro volume plate. 3 μL of each 
sample were pipetted onto the plate along with blanks and the absorbance at 260 
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nm (A260) measured. Nucleic acid was quantified assuming an A260 of 1 equates to 50 
μg mL-1 dsDNA. 
 Biochemical Methods 
2.2.1. Isolation of Recombinant Protein  
2.2.1.1. Cell Lysis and Protein Extraction 
Cell pellets were resuspended in nickel affinity purification buffer A (50 mM Tris-HCl 
pH 8.0, 500 mM NaCl, 20 mM imidazole pH 8.0, 10 mM β-mercaptoethanol) at a ratio 
of 8 mL of buffer to 1 g of cell pellet. A protease inhibitor cocktail tablet (cOmplete, 
Roshe) was added to reduce protease degradation of the target protein. The 
resuspended cells were lysed using mechanical methods by sonication, 15 seconds 
on/15 seconds off for 5 minutes. DNase I was added to the lysate to cleave the 
bacterial DNA, resulting in reduced viscosity of the solution. All steps were performed 
on ice to reduce the activity of proteases. 
The cell debris was removed by centrifugation, 18,000 rpm for 45 minutes at 4 ᵒC. 
The supernatant, containing all soluble proteins was filtered through a 0.22 μM 
syringe driven filter. 
2.2.1.2. Affinity Chromatography 
The clarified lysate was applied to a 5 mL HisTrap FF crude column (GE healthcare) 
using an ÄKTA purification system (GE healthcare), pre-equilibrated with nickel 
affinity purification buffer A (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole 
pH 8.0, 10 mM β-mercaptoethanol). The column was washed with buffer A to remove 
expression host proteins, leaving only the PSMT1 fusion construct bound. 
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2.2.1.3. On-Column Cleavage 
On-column cleavage was implemented by injecting 5 mL of 0.25 mg mL-1 hexa-
histidine tagged 3C protease fusion protein directly onto the 5 mL HisTrap FF crude 
column, containing bound His-GST-r3CP-PSMT1, using a syringe and incubated 
overnight at 4 ᵒC. The protease cleaved the His-GST-r3CP-PSMT1 at the 3C protease 
cleave recognition site, liberating PSMT1 from its solubility partner, with a small three 
residue N-terminal overhang. The released PSMT1 was then removed from the 
column by washing the column with nickel affinity buffer A and collecting fractions in 
a 2 mL 96 deep-well collection plate. The bound proteins, containing un-cleaved His-
GST-r3CP-PSMT1, cleaved His-GST and 3C protease were eluted with nickel affinity 
purification buffer B (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 0.5 M imidazole pH 8.0, 
10 mM β-mercaptoethanol). Fractions with an A280 response were analysed by SDS-
PAGE and the fractions containing PSMT1 (43 kDa) were pooled. 
2.2.1.4. 1.1.2.1 Desalting 
After on-column cleavage the protein sample was desalted in preparation for ion 
exchange. This was achieved by using a HiPrep 26/60 Desalting column (GE 
Healthcare) according to the manufacturers protocol on an ÄKTA purification system 
(GE healthcare). The protein solution was concentrated to less than 10 mL and 
injected via a 15 mL loop onto the column, pre-equilibrated with 50 mM Tris pH 8.0, 
10 mM β-mercaptoethanol. Multiple HiPrep 26/60 desalting columns were 
connected in series for large purifications. 
2.2.1.5. Ion Exchange Chromatography 
Anion exchange was implemented as a second purification step. Anion exchange 
columns contain a positively charged resin which can bind negatively charged 
molecules/proteins. The theoretical isoelectric point (pI) of PSMT1 is 5.46, generated 
using the ProtParam tool on the ExPASy server.120 This results in PSMT1 having a net 
negative charge in the buffer system used, Tris pH 8.0. Desalted protein was injected 
using a 15 mL loop onto a HiScreen Q HP 4.7 mL (GE Healthcare) anion exchange 
column pre-equilibrated with 50 mM Tris pH 8.0, 10 mM β-mercaptoethanol (ion 
exchange Buffer A). The 15 mL loop was filled with 10 mL of protein solution multiple 
times until all protein solution was loaded onto the column. The column was washed 
56 
with 5 % ion exchange buffer B (50 mM Tris pH 8.0, 1 M NaCl, 10 mM 
β-mercaptoethanol) to remove weakly bound proteins. A 10-50 % buffer B gradient 
was applied over 50 mL to elute PSMT1. A step to 100% buffer B was used to remove 
strongly bound proteins. The eluate was fractionally collected and protein visualised 
by measuring absorbance at 280 nm and SDS-PAGE. Fractions containing PSMT1 (43 
kDa) were pooled.  
2.2.1.6. Size Exclusion Chromatography 
PSMT1 was concentrated in a volume of less than 0.5 mL using a 30 kDa centrifugal 
concentration unit and injected onto a S200 16/600 gel filtration column (GE 
Healthcare) pre-equilibrated with 50 mM Tris pH 8.0, 150 mM NaCl, 10 mM 
β-mercaptoethanol. 1 mL fractions were collected and protein content measured by 
A280. Fractions containing protein were analysed by SDS-PAGE and those containing 
PSMT1 were pooled. 
2.2.1.7. Buffer Exchange 
Purified PSMT1 was buffer exchanged into 10 mM Tris pH 8.0, 5 mM TCEP for 
crystallisation trials. This was achieved by repeated concentration and dilution of the 
protein solution using a 30 kDa centrifugal concentrating unit (Millipore). 
2.2.2. Concentration of Protein Solution 
Protein solutions were concentrated using Millipore centrifugal concentrating units 
according to the manufacturers protocol.  
2.2.3. The Quantification of Protein Concentration 
2.2.3.1. UV spectroscopy 
The protein concentration in an aqueous solution was determined by spectroscopic 
methods. The theoretical molar extinction coefficient (ε) was calculated using Expasy 
ProtParam Server as A = ε c l, where A is the absorbance at 280 nm, ε is the molar 
extinction co-efficient (M-1 cm-1), c is the concentration (M) and l is the path length, 
the concentration of the purified protein solution can be calculated using its 
absorbance at 280 nm.120 
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2.2.3.2. Bradford Protein Assay 
The Bradford protein assay was used to determine protein concentration as an 
alternate method to that of UV spectroscopy. The Bradford protein assay exploits 
brilliant blue G-250 dyes ability to bind to proteins, resulting in the deprotonation of 
the dye. This leads to a colour change, red to blue, which was monitored by 
measuring absorbance at 595 nm (A595). The 1 mL standard assay as described in the 
Quick Start™ Bradford protein assay instruction manual (BioRad) was followed. 
2.2.4. Polyacrylamide Gel Electrophoresis (PAGE) 
2.2.4.1. SDS-Polyacrylamide Gel Electrophoresis 
Denaturing SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was implemented to 
visualise and estimate the molecular weight of purified protein. The protein sample 
was mixed 1:2 with SDS-PAGE sample buffer (50 mM Tris pH 6.8, 10 % (v/v) glycerol, 
2 % SDS, 0.05 % bromophenol blue, 0.7 M β-mercaptoethanol) and heated to 100 °C 
for 5 min. This unfolded the protein allowing the SDS to bind to the protein uniformly, 
giving the protein a net negative charge. The reducing agent β-mercaptoethanol is 
used to break disulphide bonds to reduce the effects of tertiary structure. The 
samples were loaded onto 12 % SDS-PAGE gels along with molecular weight 
standards. Electrophoresis was carried out using a Mini-PROTEAN Tetra Cell (BioRad) 
in running buffer (0.2 M glycine, 25 mM Tris, 0.1 % SDS) and ran at 200 V for 50 
minutes. After electrophoresis, the gels were stained with magic dye and 
photographed using an InGenius LHR Gel Imaging System (Syngene). Molecular 
weight standards were prepared by mixing 25 μL of low range molecular weight 
markers with 375 μL of SDS-PAGE sample buffer. Magic dye is produced in a total 
volume of 2.5 L consisting of 150 mg of brilliant blue G-250 dye and 8.6 mL HCl. SDS-
PAGE gels were produced in-house using the BioRad Mini-PROTEAN Tetra Cell Casting 
Module (BioRad). 12 % gels were made up as in Table 2.5. 
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Component Resolving Gel 12 % Resolving Gel 10 % Stacking Gel 
Deionised Water 3.2 mL 4.0 mL 3.2 mL 
Resolving gel 
buffer 
2.5 mL 2.5 mL - 
Stacking gel buffer - - 1.3 mL 
10 % Acrylamide 4.2 mL 3.3 mL 0.5 mL 
10 % APS 50 μL 50 μL 25 μL 
TEMED 8 μL 8 μL 8 μL 
Table 2.5: SDS-PAGE Gel recipe. Resolving gel buffer- 1.5 M Tris pH 8.8, 0.4 % SDS, stacking gel buffer- 0.5 M pH 
6.8, 0.4 % SDS. APS- ammonium persulphate, TEMED- Tetramethylethylenediamine 
2.2.4.2. Native-PAGE 
Native polyacrylamide gel electrophoresis (Native-PAGE) differs from SDS-PAGE as 
SDS is omitted from all components. This technique separates proteins based on their 
charge and hydrodynamic radius and was utilised to determine if a purified protein 
was homogeneous. Gels and reagents were made up as for SDS-PAGE but SDS is 
omitted and replaced with deionised water, Table 2.5. 10 % gels were used and 
electrophoresis was carried out at 35 V for 1 hour at 4 ᵒC. 
2.2.5. Size Exclusion- Multi Angle Laser Light Scattering (SEC-MALLS) 
Size exclusion multi angle laser light scattering (SEC-MALLS) was utilised to determine 
the molecular weight of proteins in solution. SEC-MALLS was carried out in the 
Technology Facility (TF) at the University of York using a Shimadzu LC-20AD liquid 
chromatography machine linked to a Shimadzu SIL-20A auto-sampler. Purified 
protein samples of 1-2 mg mL-1 were injected onto a Superdex 200 10/300 GL column 
(GE Healthcare). Measurements were taken using a Shimadzu SPD-20A UV detector, 
a Wyatt Optilab rEX refractive index monitor, a Wyatt DAWN HELEOS light scattering 
detector and analysed using Wyatt ASTRA software package. 
2.2.6. Thermal Shift Assay -Thermofluor Assay 
A thermal shift assay is used to determine the temperature at which a protein unfolds 
thus conferring its stability in a given solution. The thermofluor assay utilises the 
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ability of the dye SYPRO™ orange (Life Technologies) to bind to hydrophobic patches. 
In aqueous solution, the dye is quenched but once the dye binds to the exposed 
hydrophobic regions, exposed upon protein unfolding, the dye can be excited at 492 
nm and fluoresces at 610 nm.  
A working stock of SYPRO orange was prepared by making a 5x solution of SYPRO 
orange in 10 mM Tris pH 8.0, 5 mM TCEP with a total volume of 1 mL. Purified protein 
at a concentration of 1 mg mL-1 in 10 mM Tris pH 8.0, 5 mM TCEP, determined by UV 
spectroscopy, was mixed 1:1 with the dye in a total volume of 30 μL in a 96 well plate. 
The plate was heated from 25 ᵒC to 95 ᵒC at 1 ᵒC per 30 seconds. Fluorescence was 
measured every 30 seconds. Melting temperature (Tm) is calculated as the midpoint 
of the unfolding event characterised by an increase in fluorescence.  
2.2.7. Activity Assay 
The enzymatic activity of PSMT1 was determined by a stopped assay and analysed by 
UPLC-MS/MS. Reactions were carried out in 0.1 mM glycine-NaOH pH 9, 25 mM 
sodium ascorbate, 1 mM β-mercaptoethanol, 100 μM SAM and with scoulerine 
concentrations ranging from 0.05-10 μM. Reactions were performed in a total 
volume of 11.5 mL and incubated at 37 ᵒC in a water bath. Reactions were started by 
the addition of 0.5 ml of 1 μg mL-1 enzyme. 1 mL samples were taken between 15 
seconds – 5 minutes and quenched with equal volumes of methanol. The quenched 
samples were dried using a SpeedVac (Genevac), a centrifugal evaporator. The dried 
samples were then resuspended in 100 μL 10 % acetic acid.  
All samples were analysed, alongside standards of scoulerine and 
tetrahydrocolumbamine by UPLC-MS/MS. The reverse-phase UPLC method 
implemented was first introduced by Winzer et al., 2012 (Winzer et al., 2012). A 
Waters Acquity UPLC system (Waters Ltd.) was used quipped with a Acquity UPLC 
BEH C18 1.7 μm 2.1 x 100 mm column (Waters Ltd.) incubated at 60 ᵒC. The mobile 
phases consisted of A: 10 mM ammonium bicarbonate pH 10.2 and B: Methanol. A 
gradient was used as described in Table 2.6, at a flow rate of 0.5 mL minute-1. 2 μL of 
sample was injected and analysed using a Thermo TSQ Endura triple quadrupole in 
ESI positive mode using selective reaction monitoring (SRM). Scoulerine and 
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tetrahydrocolumbamine were detected using the settings in Table 2.7 and Figure 2.3. 
Resolution for Q1 and Q3 was 0.7 FEHM and a collision induced dissociation gas rate 
of 1.5 mTorr. The runs were controlled by Thermo Xcalibur software (Thermo Fisher 
Scientific), and analysed using Thermo Xcalibur software, Microsoft Excel (Microsoft) 
and GraphPad (Prism). 
Min %A %B Flow rate 
0.0 98 2 0.5 
0.2 98 2 0.5 
0.5 60 40 0.5 
4.0 20 80 0.5 
4.5 20 80 0.5 
4.6 98 2 0.5 
5.0 98 2 0.5 
Table 2.6: UPLC gradient profile for analysis of PSMT1 assay. Solvent A: 10 mM ammonium bicarbonate pH 10.2, 
Solvent B: Methanol. Flow rate in ml min-1 
 
Figure 2.3: UPLC gradient profile for analysis of PSMT1 assay. Solvent A: 10 mM ammonium bicarbonate pH 10.2 
(Blue), Solvent B: Methanol (Orange) 
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Table 2.7: Mass spectrometer SRM settings for the analysis of scoulerine and tetrahydrocolumbamine 
2.2.8. Protein Molecular Weight Determination by Mass Spectrometry 
Purified protein at ranges from 1-15 mg mL-1 were submitted to the Technology 
Facility at the University of York for molecular weight determination by electrospray 
ionisation- mass spectrometry (ESI-MS). 
2.2.9. Surface Entropy Reduction 
Surface entropy reduction (SER) was first proposed by Derewenda in 2004121 and is a 
technique that generates low entropy patches on the protein surface by site directed 
mutagenesis. The technique relies on the UCLA MBI surface entropy reduction 
prediction (SERp) server.122 The SERp server carries out a series of processes giving a 
score to each residue for a given protein sequence. The secondary structure is 
predicted by PSIRED, a conformational entropy profile is generated and finally PSI-
BLAST is utilised to predict residue conservation. Lysine and glutamic acid have been 
shown to localise predominantly on the surface and interfere with protein-protein 
interfaces.123,124 A typical high scoring residue will be a glutamic acid or lysine on a 
surface exposed loop which is non-conserved. Finally, the values are plotted along 
the sequence and clusters of up to three high scoring residues surrounded by low 
scoring residues are suggested for mutation. 
 Protein Crystallisation  
2.3.1. Initial Screening 
Initial crystallisation screening experiments were carried out using commercially 
bought sparse matrix screens utilising the sitting drop method in MRC 96 well dual 
drop plates. 46 μL of a crystallisation screen was transferred from a 2 mL 96 deep-
Compound Retention 
Time (min) 
RT 
Window 
(min) 
Precursor 
(m/z) 
Product 
(m/z) 
Collision 
Energy (V) 
RF 
Lens 
(V) 
Scoulerine 2.2 0.7 328.049 178 24.815 139 
Tetrahydrocol-
umbamine 
2.9 0.7 342.08 178 24.815 145 
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well block to a MRC 96 well dual drop crystallisation plate using a HYDRA II 96-channel 
micro-dispenser liquid handling robot (Thermo Scientific). A mosquito liquid handling 
robot (TTP Labtech) was utilised to dispense protein solution, typically at 10-15 mg 
mL-1 and crystallisation condition into the sitting drop wells, typically 150 nl of each. 
The plates were sealed with a UV transparent film and stored in a Rigaku Minstrel HT 
UV (Rigaku) at either 20 ᵒC or 4 ᵒC. Plates were imaged periodically with visible and 
UV light and remotely monitored using Rigaku XtalTrak™ (Rigaku). 
2.3.2. Crystallisation Optimisation 
‘Hits’ from the initial screen are conditions which produced promising results such as 
small crystals, needles or clustered precipitate, these were taken forward for 
optimisation. Optimisation was carried out in 48 well trays by varying the pH, salt 
concentration and precipitant concentration around that of the initial hit. The drop 
volumes used were increased to a total volume of 1 μL, typically, 0.5 μL of buffering 
condition to 0.5 μL of protein solution. The optimisation plates were produced by 
hand using electronic pipettes and incubated under the same conditions as the 
original hit. 
2.3.3. Data Collection 
Crystals were fished/picked using a protein crystal mounting loop (Hampton 
CrystalCap™ Spine HT) from the crystallisation plate. If additional cryo-protectant 
was needed the crystal was exposed to a drop of cryo-protectant solution before 
flash freezing with liquid nitrogen. Initial X-ray diffraction studies were carried out in-
house utilising a Rigaku MicroMax-007 HF X-ray Generator and a Rigaku R-Axis IV++ 
image plate detector. 0 ᵒ and 90 ᵒ images were taken with an oscillation of 0.5 ᵒ and 
5-minute exposures to 2.5 Å. If sufficient X-ray diffraction was observed the crystal 
were sent to Diamond Light Source for collection of a full data set. Data collected at 
Diamond Light Source was auto-processed by XIA2 on the beamline.125 
2.3.4. Phasing 
Molecular replacement was carried out using Molrep.126 
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2.3.5. Model Building and Refinement 
Models were built using the CCP4i2 suite of software including BUCCANEER, REFMAC 
and COOT.127–131 
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3. Structural Characterisation of PSMT1  
 Introduction 
Papaver somniferum O-methyltransferase 1 (PSMT1) is an S-adenosylmethionine 
dependent class I O-methyltransferase found in opium poppy with a molecular 
weight of 42.6 kDa, consisting of 390 amino acids. PSMT1 is responsible for the 
catalytic conversion of scoulerine to tetrahydrocolumbamine, Figure 3.1, by 
methylating the 9-hydroxyl position of the substrate in the biosynthetic pathway to 
noscapine, Figure 1.7. 
 
Figure 3.1: PSMT1 reaction schematic 
PSMT1 was originally discovered and named scoulerine O-methyltransferase 1 
alongside two other O-methyltransferase PSMT2 and PSMT3.71 The first scoulerine 
O-methyltransferase to be discovered and characterised was that from Coptis 
japonica, a putative orthologue of PSMT1.70 All three showed activity towards 
scoulerine as a substrate with PSMT1 having the highest Vmax at 2036 nmol min-1 mg-1 
of protein and the lowest Km of 28.5 μM. PSMT1 was discovered to be part of a gene 
cluster for noscapine biosynthesis along with nine other genes encoding several 
enzyme classes including two O-methyltransferases (PSMT2 and PSMT3), four 
cytochrome P450s (CYP82X1, CYP82X2. CYP82Y1 and CYP71A21), short-chain 
dehydrogenase/reductase (PSSDR1), an acetyltransferase (PSAT1) and a 
carboxylesterase (PSCXE1), Figure 1.8.48 The discovery together with functional 
genomics analysis allowed a biochemical pathway for noscapine to be proposed.48 
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PSMT1 was characterised by virus induced gene silencing and in vitro biochemical 
analysis as catalysing the first committed step in the noscapine branch pathway, 
Figure 1.5 and Figure 1.7.48,71 At the time the function of the two other 
O-methyltransferases, PSMT2 and PSMT3, were not fully elucidated but PSMT2 was 
indicated in methylation at the 4’-OH position of a secoberbine intermediate to 
produce papaveroxine. Subsequent research by Li and Smolke132 which involved the 
heterologous expression of the genes from the noscapine gene cluster in 
Saccharomyces cerevisiae revealed PSMT2 and PSMT3 work as a heterodimer to 
catalyse the 4’-O-methylation of 4’-O-desmethyl-3-O-acetylpapaveroxine to 
3-O-acetylpapaveroxine. Interestingly they also noted that a heterodimer of PSMT2 
and norcoclaurine 6-O-methyltransferase (6OMT) can also catalyse this 
4’-O-methylation reaction. 
This chapter describes the heterologous expression of PSMT1, its purification, 
crystallisation and subsequent structure determination by X-ray crystallography. 
 Materials and Method 
3.2.1. Expression and Purification of PSMT1 
PSMT1 was expressed from pETFPP-3-PSMT1 as an N-terminally hexa-histidine 
tagged GST fusion protein with a 3C-protease cleave site linker (6xHis-GST-r3CP-
PSMT1) in E. coli BL21 (DE3) cells for in vitro characterisation (as described in Section 
2.2.1). The full-length construct has a predicted molecular weight of 70.5 kDa with 
the cleaved components having molecular weights of: 6xHis-GST 27.6 kDa and PSMT1 
42.8 kDa, calculated utilising ProtParam.120  
A single colony from a Luria-Broth (LB) agar plate containing 50 μg mL-1 kanamycin 
was picked and used to inoculate 10 mL of LB medium with 50 μg mL-1 kanamycin. 
This was incubated at 37 ᵒC overnight. 5 mL of the overnight culture was used to 
inoculate 500 mL Terrific Broth (TB) medium with 50 μg mL-1 kanamycin in 2.5 L 
baffled shaker flasks. The 500 mL culture was incubated at 37 ᵒC, 200 rpm until cell 
growth entered the exponential phase indicated by an absorbance at 600 nm (A600nm) 
of 0.6 – 1.0, also known as optical density (OD). Once the desired OD was achieved 
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the cultures were cooled to 16 ᵒC and expression of the gene encoding 6xHis-GST-
r3CP-PSMT1 was induced by addition of isopropyl-β-1-thiogalactopyranoside (IPTG) 
to a final concentration of 1 mM. The culture was incubated at 16 ᵒC, 200 rpm 
overnight, for at least 18 hours, for the overexpression of the fusion protein. Cells 
were harvested by centrifugation at 5000 rpm at 4 ᵒC for 30 minutes in a Beckman 
Avanti J-HC equipped with a JLA 8.1000 rotor. The supernatant was discarded and 
the cells pellet was either resuspended in 50 mM Tris pH 8.0, 500 mM NaCl, 10 mM 
β-mercaptoethanol, 20 mM imidazole with DNaseI and a protease inhibitor cocktail 
tablet (cOmplete™, Roche) for purification or stored at -20 ᵒC. 
The cells were lysed by sonication utilising a large probe with the cells solution on ice 
to reduce protease activity. A programme of short 15 second pulses with 15 seconds 
resting time was used to reduce heat induced protein damage. The cell debris was 
removed by centrifugation at 18,000 rpm for 45 minutes at 4 ᵒC in a Sorvall SS34 
rotor, followed by filtration using a 0.22 μM syringe driven filter.  
PSMT1 was purified using a multi-step purification protocol, utilising nickel affinity 
chromatography on-column cleavage, desalting and ion exchange. Nickel affinity 
chromatography was used to capture the 6xHis-tagged fusion protein, then Human 
rhinovirus-3C protease cleaved the fusion protein releasing PSMT1 from the 6xHis-
GST purification/solubility tag. Desalting removed the low molecular weight solutes 
such as NaCl and imidazole from the protein solution. Finally, anion exchange 
chromatography was used to remove any remaining contaminating proteins.  
The clarified cell lysate was loaded onto a 5 mL HisTrap nickel affinity column (GE 
Healthcare) which was pre-equilibrated with nickel affinity buffer A (50 mM Tris pH 
8.0, 500 mM NaCl, 10 mM β-mercaptoethanol, 20 mM Imidazole). 6xHis-GST-r3CP-
PSMT1 would bind to the Ni2+ via the 6xHis-tag while host proteins will not bind and 
were removed by flowing nickel affinity buffer A across the column until the A280 
response returned to baseline. The column was then treated with 1 column volume 
(CV) of 0.25 mg mL-1 Human rhinovirus-3C protease (3CP) (6xHis-Maltose Binding 
Protein-3CP, 64 kDa) and incubated overnight at 4 ᵒC. The 3CP would cleave 6xHis-
GST-r3CP-PSMT1 into two at the 3CP recognition site (r3CP): the 
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purification/solubility tag (6xHis-GST) and the now free protein of interest, PSMT1 
with a 3 residue N-terminus overhang. The cleaved PSMT1 was washed off the 
column with nickel affinity buffer A. The purification/solubility tag and 3CP stay 
bound to the column which were subsequently eluted with nickel affinity buffer B (50 
mM Tris pH 8.0, 500 mM NaCl, 10 mM β-mercaptoethanol, 0.5 M Imidazole). 
Fractions with a high A280 response were analysed by SDS-PAGE and fractions 
containing bands corresponding to PSMT1 ca. 43 kDa were pooled. The fractions 
containing PSMT1 were pooled then desalted using a HiPrep 26/60 Desalting column 
(GE Healthcare) pre-equilibrated with ion exchange buffer A (50 mM Tris pH 8.0, 
10 mM β-mercaptoethanol). 
Desalted PSMT1 solution was then loaded onto a HiScreen Q HP 4.7 ml (GE 
Healthcare) anion exchange column pre-equilibrated with ion exchange buffer A (50 
mM Tris pH 8.0, 10 mM β-mercaptoethanol). The column was washed with 10 % ion 
exchange buffer B (50 mM Tris pH 8.0, 10 mM β-mercaptoethanol, 1 M NaCl) to 
remove weakly bound proteins. Bound PSMT1 was eluted with a 10-50 % buffer B 
gradient over 10 CVs and a 100 % buffer B step was utilised to elute strongly bound 
proteins and regenerate the column. 
The fractions containing PSMT1, determined by SDS-PAGE analysis, were pooled and 
buffer exchanged into 10 mM Tris pH 8.0, 5 mM TCEP utilising repeated 
concentration and dilution of the protein solution using a 30 kDa centrifugal 
concentrating unit. Finally, the protein was concentrated to 15 mg mL-1 for 
crystallisation trials or stored at -80 ᵒC for future experiments. The concentration of 
PSMT1 was determined using its calculated extinction coefficient of 0.698 M-1 cm-1 at 
280 nm. All steps were analysed by SDS-PAGE for purity. 
3.2.2. Activity Assays 
The activity of PSMT1 was investigated using scoulerine and SAM as substrates, 
Figure 3.1, by UPLC-MS/MS. Enzymatic assays were conducted using scoulerine 
obtained from Prof Peter J. Schammells (Monash University, Australia) and SAM 
(Santa Cruz Biotechnology). The rate of methylation of scoulerine to 
tetrahydrocolumbamine by PSMT1 was determined for both scoulerine and SAM as 
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the substrate. Each reaction was carried out in a total volume of 11.5 mL of 100 mM 
glycine-NaOH pH 9.0, 25 mM sodium ascorbate, 1 mM β-mercaptoethanol with 
either SAM at a constant 100 μM while varying scoulerine from 0.05 μM to 10 μM or 
scoulerine at a constant 5 μM while varying SAM from 0.01 μM to 100 μM. The 
reactions were incubated at 37 ᵒC in a water bath and the reactions were initiated by 
the addition of 0.5 mL of 1 μg mL-1 of purified PSMT1 from on-column cleavage in 
nickel affinity buffer A. Protein concentration of a ca. 1 mg mL-1 was prepared by 
monitoring A280 and diluted to ca. 1 μg mL-1. The actual concentration of the ca. 1 mg 
ml-1 solution was determined using the Bradford protein assay as described in 
(Section 2.2.3.2, pg. 57), this value was used to calculate the reaction rate. 1 mL 
aliquots were taken at intervals over a maximum of 5 minutes and quenched with 1 
mL of methanol. The quenched samples were subsequently dried using a SpeedVac 
centrifugal evaporator (Genevac) and then resuspended in 100 μL of 10 % acetic acid 
to give a 10-fold increase in concentration for quantification by UPLC-MS/MS. 
The enzymatic assay samples were analysed alongside standards of scoulerine and 
tetrahydrocolumbamine (Santa Cruz Biotechnology) utilising a modified method by 
Winzer et al., 2012.48 A Waters Acquity UPLC system (Waters Ltd.) equipped with a 
Acquity UPLC BEH C18 1.7 μm 2.1 x 100 mm column (Waters Ltd.) incubated at 60 ᵒC 
was utilised to separate the alkaloids by reverse phase chromatography. The mobile 
phases consisted of A: 10 mM ammonium bicarbonate pH 10.2 and B: Methanol with 
a flow rate of 0.5 mL minute-1. 2 μL of the sample was injected onto the column and 
the alkaloids eluted with a gradient of solvent B over 5 minutes as shown in Figure 
2.3 and Table 2.6. Scoulerine and tetrahydrocolumbamine were quantified using a 
Thermo TSQ Endura triple quadrupole Mass Spectrometer (MS) in ESI positive mode 
using selective reaction monitoring (SRM), which provided greater sensitivity over 
the orbitrap utilised in the published method.48 SRM is a highly sensitive and selective 
method of detection with a high signal to noise ratio. This is achieved by the first 
quadrupole selecting for the mass to charge for either scoulerine (328 m/z) or 
tetrahydrocolumbamine (342 m/z). The second quadrupole fragments the precursor 
ion by collision induced dissociation before the third, and final quadrupole is set to 
select the fragmentation product which results in 
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cases the fragment product which gave the highest signal intensity had a m/z of 178. 
Compound optimisation was carried out for both scoulerine (Appendix 8.2) and 
tetrahydrocolumbamine (Appendix 8.3), separately, by directly injecting them into 
the MS using a syringe driver. Scoulerine and tetrahydrocolumbamine were detected 
over a time window of 0.7 minutes, 1.85 - 2.55 minute and 2.55 - 3.25 minute, 
respectively. The time windows were selected so only one fragmentation product 
was detected at a time, to give the greatest response possible.  
The concentration of tetrahydrocolumbamine was calculated for each sample based 
on a calibration curve of known concentrations versus response. Concentration 
against time was plotted and an initial rate calculated for each reaction. The specific 
rate of reaction in nmol min-1 mg-1 of protein was plotted against the concentration 
of substrate being varied. Each point represents the mean specific rate of reaction at 
each substrate concentration over three independent replicates with standard error 
of the mean shown as vertical error bars. Km and Vmax were calculated by direct fit of 
the Michaelis-Menten equation in GraphPad software (Prism). 
3.2.3. Size Exclusion-Multi-Angle Laser Light Scattering 
Size Exclusion Multi-Angle Laser Light Scattering (SEC-MALLS) was carried out in the 
Bioscience Technology Facility (TF) at the University of York using a Shimadzu 
LC-20AD liquid chromatography machine linked to a Shimadzu SIL-20A auto-sampler. 
100 μL of purified protein samples of 2 mg mL-1 in 10 mM Tris pH 8.0 were injected 
onto a Superdex 200 10/300 GL column (GE Healthcare) pre-equilibrated with 10 mM 
Tris pH 8.0, 150 mM NaCl. Measurements were taken using a Shimadzu SPD-20A UV 
detector, a Wyatt Optilab rEX refractive index monitor, a Wyatt DAWN HELEOS light 
scattering detector and analysed using Wyatt ASTRA software package. BSA was ran 
as a control. 
3.2.4. Thermal Shift Assay -Thermofluor Assay 
1 mg mL-1 PSMT1 in 10 mM Tris pH 8.0, 5 mM TCEP which was purified by nickel 
affinity on-column cleavage followed by desalting and anion exchange was mixed 
with 5x SYPRO orange dye at a 1:1 ratio, totalling 30 μL in a 96 well plate. 5x SYPRO 
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orange dye was prepared by diluting 5000x SYPRO orange dye in DMSO to 5x in 
10 mM Tris pH 8.0, 5 mM TCEP. Protein sample was analysed alongside that of a 
buffer only sample as a control. The samples were heated at 2 ᵒC minute-1 and 
fluorescence recorded every 30 seconds, excitation 492 nm, emission 610 nm. The 
fluorescence intensity was normalised and plotted against temperature. The melting 
point of the protein was determined at the midpoint of the unfolding event 
characterised by an increase in intensity. 
3.2.5. Protein Molecular Weight Determination by Mass Spectrometry 
The molecular weight of PSMT1 was determined by the Molecular Interactions 
Laboratory at the Bioscience Technology Facility based at the University of York as a 
service. The protein sample was buffer exchanged in to 2 mM Tris pH 8.0 using 
centrifugal concentrator units and submitted at a concentration of 5-10 mg ml-1. The 
calculated molecular weight was corrected in reference to the external standard 
myoglobin. 
3.2.6. Crystallisation of PSMT1  
PSMT1 crystallisation trays were setup using a 1:1 ratio of 15 mg mL-1 PSMT1 in 10 
mM Tris, 5 mM TCEP pH 8.0, utilising the vapour diffusion method in MRC 96 well 
dual sitting drop crystallisation plates, and incubated at 20 °C in a Rigaku Minstrel HT 
UV crystal imager (Rigaku). Drops containing 150 nL of protein solution and 150 nL of 
crystallisation screen condition were dispensed by a mosquito liquid handling robot 
(TTP Labtech). The reservoir contained 46 μL of commercially bought crystallisation 
screen as an initial screen. Co-crystallisation experiments were carried out with 0.7 
mM SAH or 2 mM scoulerine or both. Conditions with ‘hits’ such as small crystals or 
globular precipitate were optimised in 48 well sitting drop plates. Optimisation 
consisted of varying the components within the hit reservoir, such as pH and 
percipient concentrations, to obtain better crystals for X-ray diffraction studies. 48 
well sitting drop trays were set-up by hand using electronic pipettes, the same ratio 
of reservoir solution to protein solution were used with a total volume of 1 μL, against 
100 μL of reservoir solution and stored at the same temperature. Crystals were 
tested in house using a Rigaku MicroMax-007 HF X-ray Generator and Rigaku R-Axis 
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IV++ image plate detector. 0 ᵒ and 90 ᵒ X-ray diffraction images are taken with an 
oscillation of 0.5 ᵒ, 5 minute exposures to 2.5 Å resolution. Crystals which diffracted 
well were sent to Diamond Light Source for collection of a full data set. 
3.2.7. Structure Determination 
Diffraction images for crystals of apoPSMT1 were auto-processed using xia2 to space 
group P 31 2 1 but subsequently changed to P 32 2 1 and solved by molecular 
replacement using a previously obtained structure of apoPSMT1 in the Davies Lab. 
MOLREP was used using default parameters, resulting in 4 molecules per asymmetric 
unit. Iterative rounds of model building in COOT and maximum likelihood-refinement 
utilising REFMAC were carried out to build the model.129–131 
 Results and Discussion 
3.3.1. Expression and Purification of PSMT1 
PSMT1 was successfully expressed as part of a fusion protein, 6xHis-GST-r3CP-PSMT1 
from the plasmid pETFPP-3-PSMT1 in E. coli BL21(DE3) cells. Soluble PSMT1 was 
purified to homogeneity using a multistep process of nickel affinity on-column 
cleavage with 3C protease, Figure 3.2, followed by desalting and anion exchange 
chromatography, Figure 3.3.  
Purification of PSMT1 by nickel affinity on-column cleavage with 3C protease was 
analysed by SDS-PAGE, Figure 3.2. 6xHis-GST-r3CP-PSMT1 (70 kDa) in the cell lysate 
(lane 1) was loaded onto a 5 mL nickel affinity chromatography column. 6xHis-GST-
r3CP-PSMT1 bound to the column while cellular proteins did not bind and flowed 
through the column (lane 2). 5 mL of 0.25 mg mL-1 HRV 3C protease (lane 3) was 
injected onto the column and incubated overnight at 4 ᵒC. The HRV 3C protease 
would cleave the fusion construct at the HRV 3C protease cleavage site (r3CP) 
liberating PSMT1 from its solubility and affinity tag, 6xHis-GST. The now free PSMT1 
was washed off the column with nickel affinity buffer A (lanes 4-12). The fractions 
consisting mostly that of PSMT1, indicated by a stained band of ca. 43 kDa were 
pooled. The pooled fractions also contained some contaminating HRV 3C protease 
ca. 64 kDa and un-cleaved fusion protein ca. 70 kDa. The proteins bound to the 
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column were eluted with nickel affinity buffer B (lanes 13-14). These fractions 
contained the full length PSMT1 fusion protein (70 kDa), HRV 3C protease (64 kDa), 
the cleaved solubility/purification tag (6xHis-GST, 28 kDa) and cleaved PSMT1 (43 
kDa). The presence of free PSMT1 in the elution fractions is most likely due to further 
processing of the fusion protein after elution of the proteins from the column. 
 
Figure 3.2: Purification of PSMT1 by on-column cleavage analysed by SDS-PAGE. 1: Soluble fraction loaded onto 
IMAC column, 2: IMAC flow-through containing proteins which have not bound to the column. 3: 6xHis-MBP-3CP 
utilised for on-column cleavage. 4-12: Fractions collected after on-column cleavage containing cleaved PSMT1. 
13-14: IMAC Elution fraction. Arrow indicates PSMT1 (43 kDa) position 
To produce a homogeneous solution of PSMT1 further purification was needed. Size 
exclusion and anion exchange were tested with anion exchange chromatography 
producing the purest sample. For anion exchange chromatography, the protein 
sample needed to be desalted before loading onto the anion exchange column, 
Figure 3.3. The protein sample was concentrated to 10 mL and loaded onto the 
desalting column (lane 1). The fractions with an A280 response were pooled (lane 2). 
This was then loaded onto an anion exchange column and eluted with an increasing 
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sodium chloride concentration, utilising a gradient from 10 % - 50 % ion exchange 
buffer B (lanes 3-13). Fractions containing pure PSMT1 were pooled (lanes 6-11). HRV 
3C protease eluted with a low salt concentration in lane 4. Strongly bound proteins 
were eluted with 100 % ion exchange buffer B (lane 14), this contained un-cleaved 
PSMT1 fusion construct along with some cleaved PSMT1. A typical purification is 
summarised in Figure 3.4, along with purified PSMT1 buffer exchanged into 10 mM 
Tris pH 8.0, 5 mM TCEP (lane 9) and subsequently concentrated to 15 mg mL-1 (lane 
10) for crystallisation trials. 
 
Figure 3.3: Purification of PSMT1 by desalting and Ion Exchange analysed by SDS-PAGE. Arrow indicates PSMT1 
position 1: Protein pooled from on-column cleavage containing cleaved PSMT1 (43 kDa) which was loaded onto 
the desalting column. 2: Pooled desalting fractions which were loaded onto an anion exchange column. 3-13: Ion 
exchange elution fractions obtained by increasing sodium chloride concentration. 14: Ion exchange final elution 
with 1 M sodium chloride to remove strongly bound proteins. Arrow indicates PSMT1 position 
74 
 
Figure 3.4: Analysis of PSMT1 purification by 12 % SDS-PAGE.  1: Soluble fraction loaded onto IMAC column, 2: 
IMAC flow-through containing proteins which have not bound to the column. 3: Protein washed off the column 
post on-column cleavage, band ca. 43 kDa is PSMT1. 4: Elution of bound proteins post on-column cleavage 
containing 6xHis-GST-r3CP-PSMT1 (71 kDa), 6xHis-GST (28 kDa) and 6xHis-MBP-3CP (64 kDa). 5: Purified 6xHis-
MBP-3CP utilised for on-column cleavage. 6: Protein sample loaded onto desalting column. 7: Pooled fractions 
from desalting column which was loaded onto an anion exchange column. 8: Pooled fractions from anion exchange 
chromatography containing pure PSMT1. 9: Ion exchange pool buffer exchanged into 10 mM Tris, 5 mM TECP pH 
8.0. 10: A Sample of 15 mg ml-1 PSMT1 used for crystallisation trials. Arrow indicates cleaved PSMT1 (43 kDa) 
3.3.2. Characterisation of Purified PSMT1 
3.3.2.1. Molecular Weight Determination 
15 mg mL-1 PSMT1 in 10 mM Tris, 5 mM TCEP purified by on-column cleavage and 
anion exchange chromatography was buffer exchanged into 5 mM Tris pH 8.0 using 
a centrifugal concentrator. The resulting protein solution was submitted to the 
Bioscience Technology Facility based at the University of York for molecular weight 
determination by mass-spectrometry. The predicted molecular weight of purified 
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PSMT1 is 42843.4 Da as calculated by ProtParam based on the amino acid 
composition.120 The corrected measured molecular weight by mass-spectrometry of 
PSMT1 was 42843.8 Da. This is within 1 Da of the expected molecular weight of 
PSMT1, therefore PSMT1 has been successfully purified and has not been degraded. 
3.3.2.2. Native-PAGE 
In order to determine the behaviour of PSMT1 in solution native-PAGE analysis was 
performed. PSMT1 purified by nickel affinity on-column cleavage followed by 
desalting and anion exchange in 10 mM Tris pH 8.0, 5 mM TCEP was analysed by 
native-PAGE, Figure 3.5. Native-PAGE separates proteins based on their charge and 
hydrodynamic radius, with smaller highly charged proteins migrating further than 
larger less charged proteins. The results show one major, large band of PSMT1 
indicating a folded protein in one state. A ladder effect reducing in intensity with 
reduced migration is visualised, this is most likely due to multiple charged states of 
PSMT1 in solution or could be due to multiple oligomeric states. This protein sample 
was used for crystallisation trials. 
 
Figure 3.5: Native-PAGE analysis of purified PSMT1. 30 μg of purified protein loaded 
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3.3.2.1. Size Exclusion Multi-Angle Laser Light Scattering 
In order to determine the molecular weight in solution, size exclusion-multi angle 
laser light scattering was carried out. 100 μL of a 2 mg mL-1 solution of PSMT1 in 
10 mM Tris pH 8.0, 5 mM TCEP was injected onto a Superdex 200 10/300 GL column 
(GE Healthcare) pre-equilibrated with 10 mM Tris pH 8.0, 150 mM NaCl, Figure 3.6. 
The elution UV trace shows a single monodispersed peak with a retention time of 14 
minutes and an observed mean molecular weight of 83360 Da over the peak. The 
calculated molecular weight of the purified PSMT1 gene product is 42843.4 Da. As 
the observed molecular weight is double that of the expected molecular weight it can 
be concluded that PSMT1 exists as a homodimer in solution. This is consistent with 
other characterised plant O-methyltransferases such as eugenol O-methyltransferase 
from Clarkia breweri, Medicago sativa caffeic acid O-methyltransferase and 
Thalictrum tuberosum catechol O-methyltransferase, which have all be characterised 
as homodimers.133,107,113 
 
Figure 3.6: SEC-MALLS results of PSMT1. Blue line represents normalised UV response, while the orange line 
represents the calculated molecular weight across the peak which has a mean molecular weight of 83360 Da 
3.3.2.2. Thermal Shift Assay- Thermofluor 
The melting temperature (Tm) of PSMT1 was measured as 50 ᵒC for a 1 mg mL-1 
solution of PSMT1 in 10 mM Tris pH 8.0, 5 mM TCEP, Figure 3.7. The protein solution 
was mixed 1:1 with 1xSYPRO orange dye, in the same buffer as PSMT1, with a total 
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volume of 30 μL. The PSMT1 sample showed a steady fluorescence from 25 ᵒC to 
40 ᵒC, where upon the fluorescence started to increase until 58 ᵒC. Over 58 ᵒC the 
fluorescence decays, probably due to protein aggregation. This shows that the 
protein is stable and folded in the buffer conditions used. The buffer-only sample 
shows a steady fluorescence with a slight decrease with increased temperature, 
which is expected for a non-protein sample. This shows that the response recorded 
in the PSMT1 sample is due to the protein and not an artefact of the buffer 
composition used.  
 
Figure 3.7: Thermofluor analysis of PSMT1. The graph shows a normalised fluorescence response of PSMT1 against 
time (Blue) and the calculated melting temperature (orange), buffer-only sample (grey) 
3.3.3. Enzyme Kinetics of PSMT1 
Kinetic analysis of PSMT1 purified by nickel affinity on-column cleavage was 
performed, Figure 3.8.A and B, and the Vmax and Km values were determined by 
Michaelis-Menten direct fit, Table 3.1. A Vmax of 492.6 nmol min-1 mg-1 of protein and 
a Km of 0.25 μM was calculated with scoulerine as the varying substrate concentration 
with a constant concentration of 100 μM S-adenosylmethionine (SAM). A Vmax of 
542.4 nmol min-1 mg-1 of protein and a Km of 8.76 μM was calculated with SAM as the 
varying substrate with a constant concentration of 5 μM scoulerine. The fact that the 
Vmax values for scoulerine and SAM as substrates are similar at 492.6 and 542.4 nmol 
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min-1 mg-1 of protein respectively provide confidence that the methodology used for 
this kinetic analysis is robust. 
 
Figure 3.8: Michaelis-Menten kinetics of PSMT1 with scoulerine and SAM as substrates. A. Varying the 
concentration of scoulerine with SAM at a constant 100 μM. B. Varying the concentration of SAM with a constant 
concentration of 5 μM scoulerine. SAM = S-adenosylmethionine 
Substrate  Value std error 
Scoulerine Vmax (nmol min
-1 mg-1 of protein) 492.6 28.68 
Km (μM) 0.25 0.064 
SAM Vmax (nmol min
-1 mg-1 of protein) 542.4 27.14 
Km (μM) 8.76 1.64 
Table 3.1: Michaelis-Menten enzyme kinetics of PSMT1 with scoulerine and SAM as substrates 
Kinetic data obtained for PSMT1 by Facchini et al. (2012)71 produced a Vmax of 2036 ± 
160.9 nmol min-1 mg-1 of protein and a Km of 28.5 μM for scoulerine as the substrate 
and SAM at a constant concentration of 200 μM. With SAM as the substrate and 
scoulerine at a constant concentration of 100 μM a Vmax of 1290 ± 73.18 nmol min-1 
mg-1 of protein and a Km of 19 ± 2.66 μM SAM was reported.71 These data thus report 
significantly higher Km and Vmax values than what have been obtained in this thesis, 
with the Km for scoulerine being approximately 100 fold and a Vmax that is four fold 
higher. For SAM the Km and Vmax are both approximately 2 fold higher in the Facchini 
et al. (2012)71, also reported PSMT1 performing a secondary O-methylation of 
tetrahydrocolumbamine, at the 2-hydroxyl position, to produce tetrahydropalmatine 
but did not detect direct methylation of scoulerine at this position. This activity was 
not observed for PSMT1 activity assay carried out by the author of this study. 
Compounds were separated utilising the same UPLC method as stated previously, 
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Section 3.2.2 pg. 67, but mass detection was carried out in full scan mode on an LTQ 
Orbitrap (Themo Fisher). Apart from the substrate scoulerine with a retention time 
of 2.31 minutes and a m/z of 328 and the product tetrahydrocolumbamine with a 
retention time of 2.93 minutes and a m/z of 342 no other peaks were detected on 
the total ion count chromatogram, Figure 3.9. Thus, the data obtained in the study 
could not confirm the tetrahydrocolumbamine O-methylation activity of PSMT1. It 
cannot be completely ruled out though that these differences in the PSMT1 activity 
profile are caused by minor sequence polymorphisms. The PSMT1 protein used in 
this study and that used by Facchini et al. (2012)71 very slightly differ in their amino 
acid sequence, with a percentage identity of 99.23 %, sequence alignment shown in 
Appendix 8.4. This equates to three residue polymorphisms, His14Arg, Ser16Thr and 
Val270Phe, which could be responsible for the altered substrate specificity and 
activity. 
 
Figure 3.9: UPLC-MS analysis of PSMT1 conversion of scoulerine to tetrahydrocolumbamine. A. Total Ion Count 
Chromatogram B. Mass spectrum at 2.31 min. C. Mass spectrum at 2.93 min 
Km values for other published O-methyltransferases vary from the low μM to low mM 
range but are unlikely to be their natural substrate.112,114,134–136 Secondary plant 
metabolite enzymes generally have a broad substrate specificity with higher Km 
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values than enzymes of central metabolism.90,137 PSMT1 has one of the lowest 
reported Km value compared to other enzymes of plant secondary metabolism, which 
suggests that it has evolved to methylate only scoulerine with high efficiency and 
efficacy. This is corroborated by the virus induced gene silencing experiments 
undertaken by Winzer et al. (2012)48, where scoulerine was only detectable in the 
latex when PSMT1 was silenced.48 
The data were also analysed utilising the sigmoidal Hill plot to determine if there is 
cooperativity between the subunits, Table 3.2. Positive cooperativity is when binding 
of a substrate molecule to one active site increases the affinity toward the substrate 
at a second active site; this is characterised as having a Hill coefficient greater than 
one. Negative cooperativity is when binding of a substrate molecule to one active site 
decreases the affinity toward the substrate at a second active site; this is 
characterised as having a Hill coefficient less than one. Non-cooperativity is when 
binding of a molecule to one active site has no effect on affinity towards the substrate 
at a second active site and is characterised as having a Hill coefficient of one. 
Positive cooperativity was observed for the O-methylation of scoulerine by PSMT1 
when analysing the data with varying scoulerine concentrations, with a Hill 
coefficient of 1.50. This indicates that the active sites communicate with each other 
constructively, with binding affinity increasing at the second binding site when the 
first is occupied. This has also been noted in other O-methyltransferases, such as for 
Thalictrum tuberosum O-methyltransferases with Hill coefficients varying form 
1.4-1.7 depending on the enzyme and substrate assayed, and for Sorghum bicolor 
caffeoyl-coenzyme A 3-O-methyltransferase with a reported Hill coefficient of 
2.0.113,114 The Hill coefficient value of 0.85 for SAM as the substrate indicated negative 
cooperativity, this could be due to the inhibitory effects of SAH. 
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Substrate  Value std error 
Scoulerine 
Vmax (nmol min-1 mg-1 of protein) 465.0 26.75 
Kprime (μM) 0.106 0.073 
Hill coefficient 1.50 0.39 
SAM 
Vmax (nmol min-1 mg-1 of protein) 581.6 70.52 
Kprime (μM) 7.51 1.64 
Hill coefficient 0.85 0.18 
Table 3.2: Hill plot enzyme kinetic analysis results of PSMT1 with scoulerine and SAM as substrates to probe 
cooperativity 
3.3.4. Crystallisation of PSMT1 
Commercially available crystallisation screens such as PACT premier (Molecular 
Dimensions), JCSG-plus (Molecular Dimensions), SaltRx (Hampton Research), Index 
(Hampton Research), and Structure Screen 1 and 2 HT-96 (Molecular Dimensions) 
were set-up with PSMT1 purified by nickel affinity on-column HRV-3C Protease 
cleavage followed by anion exchange chromatography in 10 mM Tris, 5 mM TCEP pH 
8.0. After optimisation apoPSMT1 crystals were produced in 0.1 M bis-tris propane 
pH 7.5, 25 % PEG3350, 0.3 M sodium citrate, Figure 3.10. The crystals were mounted 
on loops and flash frozen in liquid nitrogen. Initial X-ray diffraction images were 
collected using the in-house X-ray source at 0 ° and 90 °, Figure 3.11, and extended 
to approximately 4 Å resolution. The best crystals were sent to Diamond Light Source, 
Harwell, UK, for a full X-ray diffraction data set to be collected. The best diffracting 
crystal was that of apoPSMT1 and extended to 2.95 Å resolution. Co-crystallisation 
experiments with SAH/SAM and/or scoulerine produced crystals of poor quality 
which diffracted poorly except for that with SAH/SAM. Optimisation of 
co-crystallisation experiments of PSMT1 with SAH/SAM did not yield a data set of 
greater resolution than that obtained within earlier research carried out in the Davies 
lab prior to the start of this work. In this previous work crystals were obtained by 
Wendy A. Offen in 100 mM HEPES pH 7.0, 1 M sodium succinate, 10 % PEG 2000. 
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Figure 3.10: apoPSMT1 crystals grown in 0.1 M bis-tris propane pH 7.5, 25 % PEG3350, 0.3 M sodium citrate in a 
1:1 ratio of 15 mg mL-1 PSMT1, totalling a volume 1 µL in a 48 well sitting drop plate incubated at 20 °C 
 
Figure 3.11: In house diffraction images of apoPSMT1 at 0° and 90° 
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3.3.5. Structural Determination and Analysis of PSMT1 
The X-ray diffraction dataset for apoPSMT1 and PSMT1-SAM were indexed and 
integrated using Xia2 on the beamline to space group P 31 2 1.125 The space group 
was later determined to be P 32 2 1 with a unit cell of a=111.94, b=111.94, c=305.2, 
α=90 ᵒ, β=90 ᵒ, γ=120 ᵒ for apoPSMT1 and a=111.15, b=111.15, c=302.36, α=90 ᵒ, 
β=90 ᵒ, γ=120 ᵒ for PSMT1 co-crystallised with SAM, with an X-ray wavelength of 
0.97949 Å and 0.97626 Å, respectively. Data collection statistics are shown in Table 
3.3. The apoPSMT1 crystal extended to 2.95 Å and the PSMT1-SAM crystal extended 
to 3.25 Å. 
Both structures of PSMT1 were solved by molecular replacement using Molrep, with 
a subunit from a previously obtained 3.1 Å resolution unpublished structure of 
PSMT1 from the Davies lab by Wendy A. Offen, solved by molecular replacement, 
using residues 32-344 of caffeic acid O-methyltransferase molecule A (PDB:1KYZ) as 
a model for Phaser.138 The model was built by iterative model building in COOT and 
refinement with REFMAC to 2.95 Å resolution for apoPSMT1 and 3.25 Å for PSMT1-
SAM. The final model has an Rwork of 22 % and Rfree of 30 % for apoPSMT1, and 
Rwork of 17 % and Rfree of 25 % for PSMT1-SAM. The models contain four chains per 
asymmetric unit with electron density well defined for most amino acids.  
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 apoPSMT1 PSMT1-SAM 
Data collection   
Space group P 32 2 1 P 32 2 1 
Cell dimensions   
a, b, c (Å) 111.94, 111.94, 305.2 111.15, 111.15, 302.36 
(°) 90, 90, 120 90, 90, 120 
Resolution (Å) 96.95(2.95) 101(3.25) 
Rmerge 0.14(2.23) 0.07(0.77) 
Rpim 0.05 (0.78) 0.03(0.27) 
I/σI 9.0(1.1) 23.5(3.1) 
Completeness (%) 100.0(100.0) 100.0(100.0) 
Redundancy 9.6(9.9) 5.1(4.9) 
   
Refinement   
Resolution (Å) 96.94-2.95 100.78-3.25 
No. reflections 47543 34996 
Rwork / Rfree 0.23/0.30 0.17/0.25 
No. atoms   
Protein 20768 10613 
Ligand/ion 0 108 
Water 0 0 
B-factors (Å2)   
Protein 83.13 93.64 
Ligand/ion n/a 92.6 
Water n/a n/a 
r.m.s. deviations   
Bond lengths (Å) 0.01 0.01 
Bond angles (°) 1.7 1.8 
Table 3.3:Data collection and refinement statistics for PSMT1 structures 
3.3.5.1. apoPSMT1 
apoPSMT1 crystals contained 4 molecules per asymmetric unit and extended to 
2.95 Å. apoPSMT1 is a globular homodimer with an extensive N-terminal 
dimerisation domain comprising of residues 34-188, a putative substrate binding site 
(residues 189-222 and 334-353), and an C-terminal SAM/SAH binding domain 
(residues 229-325 and 358-390). There is a large cleft in-between the 
dimerisation/substrate domains and that of the SAM/SAH domain, indicative if an 
open conformation, Figure 3.12. 
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PSMT1 contains a SAH/SAM domain at the C-terminus containing the conserved 
Rossmann-like fold for nucleotide binding.139,140 The Rossmann-like fold is a 
conserved super-secondary nucleotide binding structure consisting of an initial beta-
alpha-beta topology with a Gly-x-Gly-x-Gly motif conserved in the loop between the 
first beta-strand and alpha helix and contains up to a seven-stranded beta-sheet 
which is usually parallel.92,139 PSMT1 has a seven-stranded beta-sheet in mostly 
parallel orientation which are ordered 3214576 with stand 7 in antiparallel 
orientation, the strand closest to the N-terminus is numbered 1. This orientation is 
consistent with other plant O-methyltransferases such as caffeic acid O-
methyltransferase and monolignol O-methyltransferase.109,112,112,141  
The putative substrate binding site is made up of three alpha helixes. There are two 
alpha-helices in the substrate binding domain which sandwich the substrate in place. 
The front face is made up of alpha helix 11 (residues 189-222) and back face is made 
from alpha helix 15 (residues 334-353) which is in-between beta-strands 5 and 6 of 
the Rossmann-like fold. The binding pocket is capped at one end by an alpha-helix, 
151-158, from the dimerisation domain and the other side is exposed to the active 
site cleft facing that of the SAM/SAH binding domain. As PSMT1 is in a classical open 
conformation without the methyl acceptor bound in the active site the catalytic 
residues are not discussed here but are extensively described in Chapter 4. 
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Figure 3.12: A. Ribbon diagrams of apoPSMT1 in an open conformation, coloured by chain. B-E Ribbon diagrams 
of apoPSMT1 with surface displayed at 20 % transparency in different orientations. B front view, C, back view, D 
top view, E bottom view, orientation based on chains A to B from right to left with the putative active site cleft on 
the upper face. Chain A - gold. Chain B - coloured by domain, green - dimerisation domain, magenta - substrate 
binding domain, cyan - SAM/SAH binding domain 
Comparing the apoPSMT1 model to that other plant type-1 O-methyltransferases 
they have the same tertiary and quaternary structure, Figure 3.12 and Figure 1.13. 
The most structurally similar models are that of: Medicago sativa caffeic acid 
A.
B.
C.
D. E.
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3-O-methyltransferase (PDB:1KYW) with a root mean squared deviation (RMSD) of 
1.22 Å over 327 equivalent residues with a 45 % sequence identity.107 Perennial 
Ryegrass Lpomt1 (PDB:3P9C) also has an RMSD of 1.22 Å but over 322 equivalent 
residues with a sequence identity of 43 %.112 Both the above structures are in an open 
conformation, caffeic acid 3-O-methyltransferase (1KYW) has both the methyl donor 
and acceptor bound, whereas Lpomt1 (3P9C) has only SAH bound in the active site. 
Calculating RMSD values for apoPSMT1 against plant O-methyltransferase models in 
a closed conformation such as Clarkia breweri monolignol O-Methyltransferase 
(PDB:3REO), monolignol 4-O-methyltransferase (PDB:5CVV) and perennial Ryegrass 
Lpomt1 (PDB:3P9K) produce RMSD values of 2.39 Å over 320 equivalent residues 
with 44 % sequence identity,2.40 Å over 318 equivalent residues with a sequence 
identity of 42 % and 2.05 Å over 320 equivalent residues with a 41 % sequence 
identity, respectively.109,112 Therefore, apoPSMT1 is in an open conformation with a 
similar overall fold compared to that of other plant O-methyltransferases. 
3.3.5.2. PSMT1-SAH 
PSMT1 was co-crystallised with SAM by Wendy A. Offen but modelled by the author 
of this thesis produced a homodimer in the same open conformation as apoPSMT1 
with an RMSD 0.41 Å over 341 residues, Figure 3.13. SAM is bound exclusively to the 
C-terminal Rossmann-like fold in an extended conformation. The nucleotide adenine 
group of SAM is surrounded by the non-polar side chains of Leu259, Met279, Phe280 
and Trp398 and forms hydrogen bonds with the carboxyl group of Asp278 with 
adenine N6 and carboxyl group of Asp258 with N3 of adenine. The ribose ring is 
“clamped” in by hydrogen bonds between the hydroxyl groups on the ribose ring and 
the carboxylic acid side chain of Asp258, along with a non-polar glycine rich segment 
Gly235-Gly236-Gly237, Figure 3.14. This glycine rich segment also forms one wall to 
the carboxypropyl moiety of methionine of SAM with Trp296 on the opposing side. 
The amine group of methionine of SAM forms hydrogen bonds to that of the 
backbone oxygen on Lys292 and Gly235. The side chain of Lys292 reaches around to 
the carboxylic acid group of methionine making a hydrogen bond via its terminal (Nζ) 
amino group. The methyl group of the sulphonium centre is positioned by Trp293 and 
88 
Asp297 which point it into the open cleft between the SAM binding domain and that 
of the putative substrate binding pocket. 
 
Figure 3.13: Ribbon diagram of PSMT1 co-crystallised with SAM in an open conformation. Chain A gold. Chain B 
coloured by domain, green dimerisation domain, magenta substrate binding domain, cyan SAM/SAH binding 
domain. SAM represented by cylinders, green carbon, red oxygen, blue nitrogen, yellow sulphur 
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Figure 3.14: 3.2 Å model of PSMT1-SAM showing SAM binding site. A. front view and B. rear view. 1. With peptide 
shown as ribbon diagram, 2. Without peptide ribbon diagram. PSMT1 represented as a ribbon diagram coloured 
by chain. SAM represented by cylinders coloured by atom type, green-carbon, yellow-sulphur, red-oxygen, blue-
nitrogen. Residues involved in SAM binding shown as cylinders with carbon atoms coloured by chain and non-
carbon atom coloured as described above 
  
90 
 Conclusion 
PSMT1 has been produced heterologously in E. coli along with an N-terminal 
purification-solubility tag, Figure 3.4. PSMT1 was purified by nickel affinity on-column 
cleavage utilising 3C protease to liberate PSMT1 from it purification-solubility tag, 
resulting in a 3 residue N-terminal extension. Subsequent desalting and anion 
exchange chromatography resulted in pure soluble homogeneous PSMT1 as analysed 
by SDS-PAGE, Figure 3.4, native-PAGE, Figure 3.5, and SEC-MALLS, Figure 3.6. The 
calculated molecular weight by mass-spectrometry was as expected and SEC-MALLS 
showed that PSMT1 is a homodimer in solution, Figure 3.6. The protein is active 
against scoulerine producing tetrahydrocolumbamine utilising the methyl donor 
SAM. Direct measurement of the product tetrahydrocolumbamine by UPLC-MS/MS 
proved to be a valid and reproducible method for determining kinetic parameters, 
Table 3.1 and Table 3.2. Michaelis-Menten kinetics of PSMT1 with scoulerine and 
SAM as substrates resulted in the convergence of Vmax of ~ 500 nmol min-1 mg-1 of 
protein with Km values of 0.25 μM and 8.76 μM, respectively. The Hill plot analysis 
showed positive cooperativity between the two active site of the homodimer, with a 
Hill coefficient of 1.5 with scoulerine as the substrate. A Hill coefficient of 0.8 is 
calculated for SAM as a substrate for PSMT1 indicating negative cooperativity. 
Positive cooperativity is an advantageous trait for an enzyme to have as it allows the 
enzyme to have a rapid response to a small increase in substrate concentration 
around that of the Kprime. In the case of PSMT1 the Kprime was calculated as 0.106 μM 
for scoulerine. The advantage of having negative cooperativity is that the enzyme will 
have a velocity which will be less responsive to changes in concentrations around the 
Kprime. The data obtained from the Hill plot analysis suggest negative cooperativity for 
PSMT1 with SAM as the substrate, but this could be due to the inhibitory effects of 
SAH. 
This would suggest that PSMT1 has evolved to have a large change of velocity to a 
relatively small change in scoulerine concentration at around 0.1 μM. PSMT1 is acting 
like a scoulerine ‘scavenger’, converting scoulerine to tetrahydrocolumbamine as its 
synthesised. On the other hand, SAM is an abundant vital co-substrate whose 
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concentration will remain relatively constant within cells. This puts less pressure on 
PSMT1 to optimise for SAM binding resulting in a higher affinity constant.  
The X-ray crystal structure of apoPSMT1 is a homodimer with a distinct SAM binding 
domain, dimerisation domain and putative substrate binding domain. The SAM 
binding site was confirmed by co-crystallisation with SAM. The inability to generate 
a protein crystal with both SAH and the methyl acceptor, scoulerine, bound in the 
same crystallisation conditions suggests that there is a conformational change upon 
binding of both substrates, such as that described for caffeic acid 
O-methyltransferase and other plant O-methyltransferases. This suggests that 
scoulerine binds to PSMT1 through an induced fit mechanism which alters the 
conformation of the binding pocket. Such an induced fit mechanism may have 
prevented crystals of PSMT1 forming with SAH and scoulerine. Further experiments 
would need to be carried out to obtain a tertiary complex structure and this will be 
discussed in Chapter 4. 
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4. PSMT1 Surface Entropy Reduction 
 Introduction 
Chapter 3 described the successful purification and crystallisation of PSMT1 in an 
open “apo” form and with SAM bound to 2.95 Å and 3.25 Å, respectively. These 
relatively low-resolution structures allowed the characterisation of the protein fold 
in an open conformation and residues involved in SAM/SAH binding but not the 
methyl acceptor binding pocket because the methyl acceptor is not bound. To fully 
understand the substrate binding pocket the substrate or product would need to be 
bound in a closed conformation where the active site is fully formed. Attempts to 
generate crystals of PSMT1 co-crystallised with SAH/SAM and scoulerine proved 
unsuccessful. In an attempt to obtain a closed crystal form of PSMT1 the surface 
entropy reduction (SER) method was used. 
Crystallisation of proteins that diffract to a high resolution, greater than 2 Å has been 
described as ‘the rate limiting step’ in structure determination by X-ray 
crystallography.121,122 It has been estimated that on average less than 30 % of soluble 
globular protein expressed in E. coli will crystallise, with only a small portion 
providing high resolution structures.142 Surface entropy reduction is a technique in 
which the high entropy residues of lysine and glutamic acid, which are generally 
located on the surface of a protein, are mutated by site directed mutagenesis to the 
low entropy residue alanine.121,123 The technique was first proposed by Derewenda 
in 2004.121  
The Eisenberg group (University of California, California, USA) generated a web based 
server to predict clusters of two or more high entropy residues to mutate to 
alanine.122 The webserver predicts the secondary structure, generates a residue 
entropy profile and generates a sequence alignment. Utilising this information, 
clusters of high entropy residues surrounded by low entropy patches are suggested 
for mutation. The generated area of low entropy will remove the ‘entropy shield’ 
allowing new crystal contacts to form. This technique has been utilised to crystallise 
a large range of proteins that otherwise would not crystallise in their wild type 
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form.122 There are several caveats to the surface entropy reduction technique. The 
SER mutations introduced could affect the protein’s function, and the mutation of 
residues containing charged side chains to the hydrophobic side chain of alanine 
could reduce the solubility and stability of the protein. These factors were 
investigated for the PSMT1 surface entropy reduction mutants generated. 
This chapter describes PSMT1 surface entropy reduction (SER) experiments along 
with the characterisation of the SER proteins. Subsequent crystallisation experiments 
resulted in high-resolution structures in a closed conformation with SAH and 
scoulerine or tetrahydrocolumbamine bound in the active sites. 
 Materials and Methods 
4.2.1. Surface Entropy Reduction 
Surface entropy reduction is achieved by using the UCLA MBI surface entropy 
reduction prediction (SERp) server.122 The SERp server carries out a series of 
processes giving a score to each residue for a given protein sequence. The secondary 
structure is predicted by PSIRED, a conformational entropy profile is generated and 
finally PSI-BLAST is utilised to predict residue conservation. Lysine and glutamic acid 
have been shown to localise predominantly on protein surfaces and interfere with 
protein-protein interfaces.123,124 A typical high scoring residue will be a glutamic acid 
or lysine on a surface exposed loop which is non-conserved. Finally, the values are 
plotted along the sequence and clusters of up to three high scoring residues 
surrounded by low scoring residues are suggested for mutation. 
4.2.2. Site-Directed Mutagenesis 
Site-directed mutagenesis of pETFPP-3-PSMT1 was carried out using the whole 
plasmid mutagenesis method. Overlapping oligonucleotides (primers) containing the 
desired mutations, flanked on either side with 15-20 complimentary nucleotides 
were generated with an annealing temperature of 78-79 ᵒC. 10 ng of purified plasmid 
DNA was mixed with forward and reverse primers to a final concentration of 0.3 μM, 
water and KOD hot start master mix to a total volume of 50 μL, Table 2.3. KOD hot 
start master mix is a 2x mixture containing KOD hot start polymerase, dinucleotides 
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and reaction buffer containing MgSO4. The whole plasmid was then amplified by PCR 
typically using the thermal-cycling conditions in Table 2.4. Extension time is based on 
KOD activity of 1 min 10 seconds per kilo base pair at 68 ᵒC, where optimal 
proofreading activity is obtained. Following the PCR, 1 μL of DpnI restriction enzyme 
(20 units μL-1) was added to the reaction mixture and incubated at 37 ᵒC for at least 
one hour to digest the methylated template DNA. E. coli XL10 Gold cells were then 
transformed by the mutated plasmid DNA and incubated on LB agar plates containing 
50 mg mL-1 kanamycin antibiotic to select for transformed cells. Typically, three 
colonies exhibiting antibiotic resistance were selected, plasmid DNA was extracted 
from overnight cultures and the DNA sequenced. Only plasmids that carried the 
desired mutation and no other mutations were transformed into E. coli BL21 (DE3) 
cells for expression. 
4.2.3. Expression and Purification 
PSMT1 SER mutants were expressed from a modified pETFPP-3-PSMT1 as a N-
terminally hexa-histidine tagged GST fusion protein with a 3C-protease cleave site 
linker (6xHis-GST-r3CP-PSMT1 SER Cx, x= 2 or 3 or 2&3) in E. coli BL21 (DE3) cells for 
in vitro characterisation (as described in Section 2.2.1, pg. 54). The predicted 
molecular weights of the full-length construct along with the cleaved components 
are shown in Table 4.1, calculated utilising ProtParam.120  
SER mutant 6xHis-GST-r3CP-PSMT1 SER Cx 6xHis-GST PSMT1-SER Cx 
Cluster 2 70356.2 Da 27645.0 Da 42729.2 Da 
Cluster 3 70355.2 Da 27645.0 Da 42728.2 Da 
Cluster 2&3 70241.0 Da 27645.0 Da 42614.0 Da 
Table 4.1: PSMT1 surface entropy reduction mutant proteins predicted molecular weights based on sequence for 
full length construct (6xHis-GST-r3CP-PSMT1-SER Cx) and its 3C protease cleaved products (6xHis-GST and PSMT1-
SER Cx) 
For each SER mutant, a single colony from a Luria-Broth (LB) agar plate containing 50 
μg mL-1 kanamycin was picked and used to inoculate 10 mL of LB medium with 50 μg 
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mL-1 kanamycin. This was incubated at 37 ᵒC overnight. 5 mL of the overnight culture 
was used to inoculate 500 mL Terrific Broth (TB) medium with 50 μg mL-1 kanamycin 
in 2.5 L baffled shaker flasks. The 500 mL culture was incubated at 37 ᵒC, 200 rpm 
until cell growth entered the exponential phase indicated by an absorbance at 600 
nm (A600nm) of 0.6 – 1.0, also known as optical density (OD). Once the desired OD was 
achieved the cultures were cooled to 16 ᵒC and expression of the gene encoding 
6xHis-GST-r3CP-PSMT1 SER Cx was induced by addition of isopropyl-β-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The culture was 
incubated at 16 ᵒC, 200 rpm overnight, for at least 18 hours, for the overexpression 
of the fusion protein. Cells were harvested by centrifugation at 5000 rpm at 4 ᵒC for 
30 minutes in a Beckman Avanti J-HC equipped with a JLA 8.1000 rotor. The 
supernatant was discarded and the cell pellet was either resuspended in 50 mM Tris 
pH 8.0, 500 mM NaCl, 10 mM β-mercaptoethanol, 20 mM imidazole with DNaseI and 
a protease inhibitor cocktail tablet (cOmplete, Roche) for purification or stored 
at -20 ᵒC. 
The cells were lysed by sonication utilising a large probe with the cells solution on ice 
to reduce protease activity. A programme of short 15 second pulses with 15 seconds 
resting time was used to reduce heat induced protein damage. The cell debris were 
removed by centrifugation at 18,000 rpm for 45 minutes at 4 ᵒC in a Sorvall SS34 
rotor, followed by filtration using a 0.22 μM syringe driven filter.  
PSMT1 SER Cx was purified using a multi-step purification protocol, utilising nickel 
affinity chromatography on-column cleavage, desalting and ion exchange. Nickel 
affinity chromatography was used to capture the 6xHis-tagged fusion protein, then 
Human rhinovirus-3C protease cleaved the fusion protein releasing PSMT1 SER Cx 
from the 6xHis-GST purification/solubility tag. Desalting removed the low molecular 
weight solutes such as NaCl and imidazole from the protein solution. Finally, anion 
exchange chromatography was used to remove any remaining contaminating 
proteins.  
The clarified cell lysate was loaded onto a 5 mL HisTrap nickel affinity column (GE 
healthcare) which was pre-equilibrated with nickel affinity buffer A (50 mM Tris pH 
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8.0, 500 mM NaCl, 10 mM β-mercaptoethanol, 20 mM Imidazole). 6xHis-GST-r3CP-
PSMT1 SER Cx would bind to the Ni2+ via the 6xHis-tag while host proteins will not 
bind and were removed by flowing nickel affinity buffer A across the column until the 
A280 response returned to baseline. The column was then treated with 1 column 
volume (CV) of 0.25 mg mL-1 Human rhinovirus-3C protease (3CP) (6xHis-Maltose 
Binding Protein-3CP, 64 kDa) and incubated overnight at 4 ᵒC. The 3CP would cleave 
6xHis-GST-r3CP-PSMT1 SER Cx into two at the 3CP recognition site (r3CP): the 
purification/solubility tag (6xHis-GST) and the now free protein of interest, PSMT1 
SER Cx with a 3 residue N-terminus overhang. The cleaved PSMT1 SER Cx was washed 
off the column with nickel affinity buffer A. The purification/solubility tag and 3CP 
remain bound to the column which were subsequently eluted with a nickel affinity 
buffer B (50 mM Tris pH 8.0, 500 mM NaCl, 10 mM β-mercaptoethanol, 0.5 M 
Imidazole). Fractions with a high A280 response were analysed by SDS-PAGE and 
fractions containing bands corresponding to PSMT1 SER Cx ca. 43 kDa were pooled. 
The fractions containing PSMT1 SER Cx were pooled then desalted using a HiPrep 
26/60 Desalting column (GE Healthcare) pre-equilibrated with ion exchange buffer A 
(50 mM Tris pH 8.0, 10 mM β-mercaptoethanol). 
Desalted PSMT1 SER Cx solution was then loaded onto a HiScreen Q HP 4.7 ml (GE 
Healthcare) anion exchange column pre-equilibrated with ion exchange buffer A (50 
mM Tris pH 8.0, 10 mM β-mercaptoethanol). The column was washed with 10 % ion 
exchange buffer B (50 mM Tris pH 8.0, 10 mM β-mercaptoethanol, 1 M NaCl) to 
remove weakly bound proteins. Bound PSMT1 SER Cx was eluted with a 10-50 % 
buffer B gradient over 10 CVs and a 100 % buffer B step was utilised to elute strongly 
bound proteins and regenerate the column. 
The fractions containing PSMT1 SER Cx, determined by SDS-PAGE analysis, were 
pooled and buffer exchanged into 10 mM Tris, 5 mM TCEP pH 8.0 utilising repeated 
concentration and dilution of the protein solution using a 30 kDa centrifugal 
concentrating unit. Finally, the protein was concentrated to 15 mg mL-1 for 
crystallisation trials or stored at -80 ᵒC for future experiments. The concentrations of 
PSMT1 SER Cx was determined using their calculated extinction coefficients, 
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calculated with the ProtParam tool (ExPASy), shown in Table 4.2.120 All steps were 
analysed by SDS-PAGE for purity. 
SER mutant PSMT1-SER Cx extinction coefficients 
Cluster 2 0.700 M-1 cm-1 
Cluster 3 0.700 M-1 cm-1 
Cluster 2&3 0.702 M-1 cm-1 
Table 4.2: PSMT1 surface entropy reduction mutants calculated extinction coefficients based on sequence 
4.2.4. Size exclusion multi angle laser light scattering 
Size exclusion multi angle laser light scattering (SEC-MALLS) was carried out in the 
Bioscience Technology Facility (TF) at the University of York using a Shimadzu LC-
20AD liquid chromatography machine linked to a Shimadzu SIL-20A auto-sampler. 
100 μL of purified protein samples of 2 mg mL-1 in 10 mM Tris pH 8.0 were injected 
onto a Superdex 200 10/300 GL column (GE Healthcare) pre-equilibrated with 10 mM 
Tris pH 8.0, 150 mM NaCl. Measurements were taken using a Shimadzu SPD-20A UV 
detector, a Wyatt Optilab rEX refractive index monitor, a Wyatt DAWN HELEOS light 
scattering detector and analysed using Wyatt ASTRA software package. BSA was ran 
as a control. 
4.2.5. Thermal Shift Assay- Thermofluor 
1 mg mL-1 PSMT1 SER mutants in 10 mM Tris pH 8.0, 5 mM TCEP which were purified 
by nickel affinity on-column cleavage followed by desalting and anion exchange were 
mixed with 5x SYPRO orange dye at a 1:1 ratio, totalling 30 μL in a 96 well plate. 5x 
SYPRO orange dye was prepared by diluting 5000x SYPRO orange dye in DMSO to 5x 
in 10 mM Tris pH 8.0, 5 mM TCEP. Protein samples were analysed alongside that of a 
buffer only sample as a control. The samples were heated at 2 ᵒC minute-1 and 
fluorescence recorded every 30 seconds, excitation 492 nm, emission 610 nm. The 
fluorescence intensity was normalised and plotted against temperature. The melting 
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point of the protein was determined at the midpoint of the unfolding event 
characterised by an increase in intensity. 
4.2.6. Molecular Weight Determination 
The molecular weight of PSMT1 SER mutants were determined by the Molecular 
Interactions Laboratory at the Bioscience Technology Facility based at the University 
of York as a service by ESI-MS. The protein samples were buffer exchanged in to 2 mM 
Tris pH 8.0 using centrifugal concentrator units and submitted at a concentration of 
5-10 mg ml-1. The calculated molecular weights were corrected in reference to the 
external standard myoglobin. 
4.2.7. Activity Assay 
The activity of PSMT1 was investigated using scoulerine as the substrate, Figure 3.1, 
by UPLC-MS/MS. Enzymatic assays were conducted using scoulerine obtained from 
Prof. Peter J. Schammells (Monash University, Australia) and SAM (Santa Cruz 
Biotechnology). Each reaction was carried out in a total volume of 11.5 mL of 100 mM 
glycine-NaOH pH 9.0, 25 mM sodium ascorbate, 1 mM β-mercaptoethanol, 100 μM 
SAM while varying scoulerine from 0.05 μM to 10. The reactions were incubated at 
37 ᵒC in a water bath and the reactions were initiated by the addition of 0.5 mL of 1 
μg mL-1 of purified PSMT1 from on-column cleavage in nickel affinity buffer A. Protein 
concentration of a ca. 1 mg mL-1 was prepared by monitoring A280 and diluted to ca. 
1 μg mL-1. The actual concentration of the ca. 1 mg ml-1 solution was determined 
using the Bradford protein assay as described in (Section 1.2.4.2), this value was used 
to calculate the reaction rate. 1 mL time points were taken over a maximum of 5 
minutes and quenched with an equal volume of methanol. The quenched samples 
were subsequently dried using a SpeedVac centrifugal evaporator (Genevac) and 
then resuspended in 100 μL of 10 % acetic acid to give a 10-fold increase in 
concentration for quantification by UPLC-MS/MS. 
The enzymatic assay samples were analysed alongside standards of scoulerine and 
tetrahydrocolumbamine (Santa Cruz Biotechnology) utilising a modified method by 
Winzer et al. (2012).48 A Waters Acquity UPLC system (Waters Ltd.) equipped with a 
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Acquity UPLC BEH C18 1.7 μm 2.1 x 100 mm column (Waters Ltd.) incubated at 60 ᵒC 
was utilised to separate the alkaloids by reverse phase chromatography. The mobile 
phases consisted of A: 10 mM ammonium bicarbonate pH 10.2 and B: Methanol with 
a flow rate of 0.5 mL minute-1. 2 μL of the sample was injected onto the column and 
the alkaloids eluted with a gradient of solvent B over 5 minutes as shown in Figure 
2.3 and Table 2.6. Scoulerine and tetrahydrocolumbamine were quantified using a 
Thermo TSQ Endura triple quadrupole Mass Spectrometer (MS) in ESI positive mode 
using selective reaction monitoring (SRM), to give greater sensitivity over the 
Orbitrap utilised in the published method. SRM is a highly sensitive and selective 
method of detection with a high signal to noise ratio. This is achieved by the first 
quadrupole selecting for the mass to charge for either scoulerine (328 m/z) or 
tetrahydrocolumbamine (342 m/z). The second quadrupole fragments the precursor 
ion by collision induced dissociation before the third, and final quadrupole is set to 
select the fragmentation product which results in the highest intensity signal. In both 
cases the fragment product which gave the highest signal intensity had a m/z of 178. 
Compound optimisation was carried out for both scoulerine (Appendix 8.2) and 
tetrahydrocolumbamine (Appendix 8.3), separately, by directly injecting them into 
the MS using a syringe driver. Scoulerine and tetrahydrocolumbamine were detected 
over a time window of 0.7 minutes, 1.85 - 2.55 minute and 2.55 - 3.25 minute, 
respectively. The time windows were selected so only one fragmentation product 
was detected at a time, to give the greatest response possible.  
The concentration of tetrahydrocolumbamine was calculated for each sample based 
on a calibration cure of known concentrations vs response. Concentration against 
time was plotted and an initial rate calculated for each reaction. The specific rate of 
reaction in nmol min-1 mg-1 of protein was plotted against the concentration of 
substrate being varied. Each point represents the mean specific rate of reaction at 
each substrate concentration over three independent replicates with standard error 
of the mean shows as vertical error bars. Km and Vmax were calculated by direct fit of 
the Michaelis-Menten equation in GraphPad software (Prism). 
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4.2.8. Crystallisation  
PSMT1 SER mutant crystallisation trays were setup using a 1:1 ratio of 15 mg mL-1 
protein in 10 mM Tris, 5 mM TCEP pH 8.0, utilising the vapour diffusion method in 
MRC 96 well dual sitting drop crystallisation plates, and incubated at 20 °C in a Rigaku 
Minstrel HT UV crystal imager (Rigaku). Drops containing 150 nL of protein solution 
and 150 nL of crystallisation screen condition were dispensed by a mosquito liquid 
handling robot (TTP Labtech). The reservoir contained 46 μL of commercially bought 
crystallisation screen as an initial screen such as PACT premier HT-96 (Molecular 
Dimensions), JCSG-plus (Molecular Dimensions), SaltRx (Hampton Research), Index 
(Hampton Research), and Structure Screen 1 and 2 HT-96 (Molecular Dimensions). 
Co-crystallisation experiments were carried out with 0.7 mM SAH and 2 mM 
Scoulerine. Conditions generating crystals were optimised in 48 well sitting drop 
plates. Optimisation consisted of varying the components within the hit reservoir, 
such as pH and the percipient concentrations, to obtain better crystals for X-ray 
diffraction studies. 48 well sitting drop trays were set-up manually using electronic 
pipettes, the same ratio of reservoir solution to protein solution were used with a 
total volume of 1 μL, against 100 μL of reservoir solution and stored at the same 
temperature. Crystals were tested in house using a Rigaku MicroMax-007 HF X-ray 
Generator and Rigaku R-Axis IV++ image plate detector. 0 ᵒ and 90 ᵒ X-ray diffraction 
images are taken with an oscillation of 0.5 ᵒ, 5 minute exposures to 2.5 Å resolution. 
Crystals which diffracted well were sent to Diamond Light Source for collection of a 
full data set. 
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 Results and Discussion 
4.3.1. Design and Generation of Surface Entropy Reduction Mutants 
The SERp server proposed three clusters of high entropy residues surrounded by low 
entropy regions that are non-conserved for mutation, along with a SERp score, Table 
4.3. The SERp score is a numerical score based on prediction confidence. The three 
suggested clusters were compared to that of the previously described apoPSMT1 
structure, Figure 4.1. Cluster one (Glu174, Glu175 and Lys176) is involved in the dimer 
interface between the two polypeptide chains, for this reason cluster one was not 
generated. Cluster two (Lys114 and Lys115) and cluster three (Glu128 and Lys239) 
are on a loop which is missing from the structural model, most likely due to its 
flexibility. Clusters two and three were generated independently of each other along 
with a dual cluster mutant containing all four residue mutations (Lys114Ala, 
Lys115Ala, Glu128Ala and Lys129Ala. 
 
Cluster Mutations SERp Score 
#1 
Glu174Ala 
Glu175Ala 
Lys176Ala 
6.88 
#2 
Lys114Ala 
Lys115Ala 
5.05 
#3 
Glu128Ala 
Lys129Ala 
4.38 
Table 4.3: Proposed surface entropy reduction mutations for PSMT1 
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Figure 4.1: Predicted surface entropy reduction clusters mapped onto the apoPSMT1 dimeric structure. ApoPSMT1 
represented as a ribbon diagram, coloured by chain. Cluster 1 residues are represented as gold cylinders and as 
transparent surface. Cluster 2 and 3 are on a missing loop between residues Thr113 and Lys132 which are 
represented as ice blue cylinders and as transparent surface. SAM binding sites are indicated by blue circles and 
the predicted scoulerine binding sites are indicated by orange circles 
Cluster three was generated using a one-step site directed mutagenesis experiment 
utilising one set of oligonucleotide primers consisting of three nucleotide mutations 
a383c, a385g, a386c, Table 4.4, the resulting plasmid was named pETFPP-3-PSMT1 
SER C3. 
Cluster 2 proved more problematic to generate and required a two-step site-directed 
mutagenesis experiment, utilising two sets of primers sequentially, Table 4.4. PSMT1 
Lys114Ala was initially generated by two nucleotide mutations, a340g and a341c. The 
second step was the introduction of Lys115Ala into pETFPP-3-PSMT1 Lys114Ala with 
a further two nucleotide mutations, a343g and a344c generating the plasmid pETFPP-
3-PSMT1 SER C2. The double cluster mutant was generated by introducing cluster 3 
mutations into pETFPP-3-PSMT1 SER C2 generating pETFPP-3-PSMT1 SER C2&3. All 
plasmids generated were confirmed by sanger sequencing utilising PSMT1 
sequencing primer 1, Table 4.4. 
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SER Cluster 3 
Glu128Ala, Lys129Ala A383C A385G A386C 
Forward 5'-gaggagatgatgtagtagtacatgcggcgctttatgggttaacaaattcgtc-3' 
Reverse 5'-gacgaatttgttaacccataaagcgccgcatgtactactacatcatctcctc-3' 
SER Cluster 2 
Lys114Ala A340G A341C 
Forward 5'-gttctattctttctgtttctactacagcaaaatcaatcaacagaggaggagatg-3' 
Reverse 5'-catctcctcctctgttgattgattttgctgtagtagaaacagaaagaatagaac-3' 
Lys115Ala A343G A344C 
Forward 5'-ttctttctgtttctactacagcagcatcaatcaacagaggaggagatg-3' 
Reverse 5'-catctcctcctctgttgattgatgctgctgtagtagaaacagaaagaa-3' 
PSMT1 Sequencing Primer 1 
 5’-TCGGAACTGACGCAAAAGT-3’ 
Table 4.4: Oligonucleotide primers for the generation of PSMT1 surface entropy reduction mutants and sequencing 
primer 1. Mutations are shown in bold 
4.3.2. Expression and Purification 
E. coli BL21(DE3) cells were transformed individually by the SER mutant plasmids and 
the genes expressed. Gene expression and purification was carried out in the same 
manner as the WT enzyme. PSMT1 SER 2, 3, 2&3 proteins were purified and analysed 
by SDS-PAGE, Figure 4.2. All three SER proteins behaved similar to that of WT PSMT1, 
resulting in pure protein at 15 mg mL-1 in 10 mM Tris pH 8.0, 5 mM TCEP. 
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Figure 4.2: SDS-PAGE analysis of PSMT1 surface entropy reduction cluster mutant proteins. 7.5 μg of purified 
protein loaded per well alongside molecular weight markers 
4.3.3. Characterisation of Surface Entropy Reduction Mutants 
4.3.3.1. Molecular Weight Determination 
15 mg mL-1 of each PSMT1 SER mutant in 10 mM Tris, 5 mM TCEP purified by on-
column cleavage and anion exchange chromatography was buffer exchanged into 
5 mM Tris pH 8.0 using centrifugal concentrators. The resulting protein solutions 
were submitted to the Bioscience Technology Facility based at the University of York 
for molecular weight determination by ESI-mass-spectrometry. The expected 
molecular weight of the purified PSMT1 SER mutants as calculated by ProtParam120 
based on the amino acid composition are shown in Table 4.5, along with the 
corrected measured molecular weights determined by mass-spectrometry. They are 
all within 1 Da of the expected molecular weights, which is consistent with the PSMT1 
SER mutants all having been successfully purified without degradation taking place. 
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PSMT1 SER Mutants Predicted Molecular weight Measured Molecular weight 
Cluster 2 42729.2 42729.6 
Cluster 3 42728.2 42727.7 
Cluster 2&3 42614.0 42614.6 
Table 4.5: Molecular weight determination of PSMT1 surface entropy reduction mutants by ESI-MS 
4.3.3.2. Size Exclusion-Multi-Angle Laser Light Scattering 
In order to determine if the surface entropy mutations had interfered with the 
dimerisation of PSMT1 size exclusion-multi angle laser light scattering (SEC-MALLS) 
was carried out for PSMT1 SER C2 and PSMT1 SER C2&3. PSMT1 SER C3 was not 
analysed due to limited availability of the protein. 100 μL of a 2 mg ml-1 solution of 
the PSMT1 SER mutants in 10 mM Tris pH 8.0, 5 mM TCEP was injected onto a 
Superdex 200 10/300 GL column (GE Healthcare) pre-equilibrated with 10 mM Tris 
pH 8.0, 150 mM NaCl, Figure 4.3. The elution UV traces show one major 
monodispersed peak with retention times of 14 minutes and an observed mean 
molecular weight of 85140 Da for PSMT1 SER C2 and 85700 Da for PSMT1 SER C2&3 
over their respective peaks. The calculated molecular weights of the purified PSMT1 
SER mutants’ gene products are 42843.4 Da and 42614.0 Da, respectively. The 
observed molecular weights in solution are double that of the expected molecular 
weights based on their sequence. This shows that the mutations introduced to 
PSMT1 to generate PSMT1 SER C2 and PSMT1 SER C2&3 have not effected the 
dimerisation state in solution. 
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Figure 4.3: SEC-MALLS results for PSMT1 surface entropy reduction mutants. A. PSMT1 SER C2 with a mean 
molecular weight of 85140 Da and B. PSMT1 SER C2&3 with a mean molecular weight of 85700 Da. Blue line 
represents normalised UV response, while the orange line represents calculated molecular weight across the peak 
4.3.3.3. Thermal Shift Assay-Thermofluor 
Melting temperature (Tm) of PSMT1 SER C2 and PSMT1 SER C2&3 were measured by 
the thermofluor thermal shift assay. 1 mg ml-1 of protein in 10 mM Tris pH 8.0, 5 mM 
TCEP that had been stored at -80 ᵒC was mixed 1:1 with 5xSYPRO orange dye with a 
total volume of 30 μL, Figure 4.4. PSMT1 SER C2 and PSMT1 SER C2&3 both denature 
in one single denaturing event with melting temperatures of 49ᵒC and 50 ᵒC, 
respectively. PSMT1 WT has a melting temperature of 50 ᵒC, Figure 3.7, therefore the 
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mutations incorporated to generate the surface entropy reduction mutants have 
little to no effect on the stability of the enzyme.  
 
Figure 4.4: Thermal denaturation assay of PSMT1 surface entropy reduction mutants utilising the Thermofluor 
method. A. PSMT1 SER C2 and B. PSMT1 SER C2&3. Graph shows normalised fluorescence response against time 
(Blue) and the calculated melting temperature (orange) 
4.3.3.4. Initial Crystallisation Trials of SER Mutants 
Initial crystallisation trials for the PSMT1 SER mutants were carried out in MRC 96 
well dual sitting drop crystallisation plates using the commercially available 
crystallisation screens PACT premier HT-96 (Molecular Dimensions) and JCSG-PLUS™ 
(Molecular Dimension). Each drop contained 150 μL of the buffer solution plus 150 μL 
of protein at 15 mg mL-1 in 10 mM Tris pH 8.0, 5 mM TCEP. Two conditions were 
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explored per buffer solution in a single plate. The first sitting drop contained protein 
only and the second drop containing protein with 0.7 mM SAH and 2 mM Scoulerine 
in a co-crystallisation experiment. The plates were stored at 20 ᵒC in a Rigaku Minstrel 
HT UV (Rigaku) and imaged periodically. 
Initial crystal hits from the commercial screens were obtained in the conditions listed 
in Table 4.6 and visualised in Figure 4.5. The crystals were fished utilising protein 
crystal mounting loops (Hampton CrystalCap™ Spine HT) and flash frozen in liquid 
nitrogen. Initial X-ray diffraction studies were carried out utilising the in-house X-ray 
source collecting two images 90 ᵒ apart with a 0.5 ᵒ oscillation over a 5-minute 
exposure to 2.5 Å. The crystals which diffracted well were sent to Diamond light 
source for X-ray diffraction data collection, these were crystals E, F, G and I, Table 
4.6. Interestingly all the crystals which diffracted well in-house were co-crystallised 
with scoulerine and SAH, whilst all the “apo” crystals diffracted poorly or not at all. 
Crystals E, F, G and I diffracted to a resolution of 1.5 Å, 2.0 Å, 3.1 Å and 2.2 Å, 
respectively.  
Crystal E (PSMT1 SER C2 co-crystallised with SAH and scoulerine) X-ray diffraction 
data were eventually solved by molecular replacement utilising residues 221(Val)-
390(Lys) of the apoPSMT1 WT model representing the SAM binding domain. This data 
set was solved first because it contained the highest resolution data of all the crystals 
tested. Initially molecular replacement was carried out utilising MOLREP with the full 
apoPSMT1 WT model along with two truncated models; one corresponding to the 
dimerisation domain, residues 34-292, and one corresponding to the SAM binding 
domain, residues 221-390. This approach was taken due to the large conformational 
change reported in the literature upon substrate binding. After molecular 
replacement and 10 rounds of refinement by REFMAC129 the SAM domain search 
model (residues 221-390) gave the best results with Rwork of 0.47 and Rfree of 0.49, 
while the dimerisation domain (residues 34-292) gave an Rwork of 0.52 and Rfree of 
0.52, and the full model (residues 34-390) gave an Rwork of 0.47 and Rfree of 0.51. 
Following molecular replacement, the auto-building program BUCCANEER127 was 
utilised to carry out 10 rounds of iterative model building (2 cycles) and refinement 
(20 cycles) with 3 initial build cycles to build the model, utilising the SAM binding 
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domain model generated during molecular replacement as a base for chain 
extension. BUCCANEER127 build 695 residues of which 678 were assigned to the 
sequence over 6 fragments. It predicted there to be two chains, 3 fragments per 
chain, of which 87 % of the residues were built of which 98 % assigned to a chain. 
Chain A consisted of fragment 1 residues 34-112, fragment 2 residues 129-234 and 
fragment 3 residues 237-392. Chain B consisted of fragment 1 residues 32-119, 
fragment 2 residues 129-234 and fragment 3 residues 237-392. The resulting model 
decreased the Rwork to 0.28 and the Rfree to 0.30, Figure 4.6. 
Form the BUCCANEER127 auto-built model manual model building was implemented 
utilising COOT130,131. Fragments two and three for chain A and chain B were joined 
together to generate a larger C-terminal fragment consisting of residues 129-392 for 
both chains. Chain B was translated to symmetry position 1,0,0 (X,Y,Z) in order to 
correctly build the dimer. The first fragment of each chain was assigned incorrectly 
due to the large unassigned region of PSMT1, this was promptly corrected by 
renaming the fragments. After iterative rounds of manual model building and 
refinement including the incorporation of water molecules the unmodeled co-
crystallised ligands are clearly visible within the weighted map from refinement (2Fo-
Fc) and the weighted difference map (Fo-Fc), Figure 4.7. SAH and scoulerine were 
modelled into the 2Fo-Fc electron density map, further refinement produced the 
model in Figure 4.8 with statistics listed in Table 4.7. 
X-ray diffraction data from crystals F (PSMT1 SER C3) and I (PSMT1 SER C2&3) were 
solved by molecular replacement utilising the model of PSMT1 SER C2 1.5 Å (crystal 
E). PSMT1 SER C2&3 crystal G has not been solved. 
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PSMT1 SER C2 
Condition Screen Well Buffer Crystal Resolution 
Apo 
PACT 
premier 
F11 0.2 M sodium citrate, 0.1 M bis-tris propane pH 6.5, 20 % w/v PEG3350 A 
No 
diffraction 
G1 0.2 M sodium fluoride 0.1 M bis-tris propane pH 7.5 20 % w/v PEG3350 B 
No 
diffraction 
G12 0.2 M sodium fluoride 0.1 M bis-tris propane pH 7.5 20 % w/v PEG3350 C 
No 
diffraction 
JCSG+ G8 0.15 M DL-malic acid pH 7.0, 20 % PEG 3350 D 
poor 
diffraction 
SAH and 
Scoulerine JCSG+ A3 
0.2 M di-ammonium citrate pH 5.0, 
20 % PEG 3350 E 1.5 Å 
PSMT1 SER C3 
Condition Screen Well Buffer  Resolution 
SAH and 
Scoulerine 
PACT 
premier B1 
0.1 M MIB buffer pH 4.0, 25 % w/v 
PEG 1500 F 2.0 Å 
PSMT1 SER C2&3 
Condition Screen Well Buffer  Resolution 
SAH and 
Scoulerine 
PACT 
premier 
B3 0.1 M MIB buffer pH 6.0, 25 % w/v PEG 1500 G 3.1 Å 
D3 0.1 M MMT buffer pH 6.0, 25 % w/v PEG 1500 H 
Poor 
diffraction 
JCSG+ 
A3 0.2 M di-ammonium citrate pH 5.0, 20 % PEG 3350 I 2.2 Å 
C3 0.2 M ammonium nitrate pH 6.3, 20 % PEG 3350 J 
No 
diffraction 
Table 4.6: Table containing crystal hits from the initial commercial screen of PSMT1 SER mutants. Images of 
crystals are shown in Figure 4.5 
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Figure 4.5: Crystals obtained for PSMT1 SER mutants. Crystallisation conditions are described in Table 4.6 
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PSMT1 SER Cluster 2 Cluster 3 Cluster 2&3 Cluster 2&3 
Co-crystallised 
with 
Scoulerine and 
SAH 
Scoulerine and 
SAH 
Scoulerine and 
SAH 
Scoulerine and 
SAH 
Crystal E F G I 
Data 
collection 
 
Space group P 21 P 21 P 21 21 21 P 21 
Cell 
dimensions  
a, b, c (Å) 68.04, 75.87, 76.19 
65.71, 78.83, 
68.11 
83.01, 105.55, 
168.18 
68.15, 75.81, 
76.35 
(°) 90.00, 101.65, 90.00 
90.00, 95.30, 
90.00 
90.00, 90.00, 
90.00 
90.00, 101.59, 
90.00 
Resolution (Å) 75.9-1.49 78.83-2.02 74.44-3.13 50.1-2.24 
Rmerge 0.06(0.82) 0.11(0.88) 0.25(1.32) 0.17(1.04) 
Rpim 0.04(0.53) 0.07(0.57) 0.13(0.55) 0.12(0.80) 
I / σI 11.1(1.4) 6.4(1.3) 8.0(1.2) 8.4(1.3) 
Completeness 
(%) 99.5(99.0) 100.0(99.9) 90.4(100.0) 96.9(76.0) 
Redundancy 4.1(4.1) 4.1(4.0) 3.9(3.9) 4.0(3.7) 
Xia2 run 3dii dials 3d 3d 
 
Refinement  
Resolution (Å) 75.9-1.49 67.91-2.02  50.10-2.24 
No. reflections 123056 45410  35608 
Rwork / Rfree 0.11/0.18 0.21/0.26  0.19/0.25 
No. atoms  
Protein 10719 10384  10702 
Ligand/ion 174 174  174 
Water 500 80  466 
B-factors (Å2)  
Protein 21.9 28.1  31.3 
Ligand/ion 14.9 20.1  26.3 
Water 31.6 20.1  34.0 
r.m.s. 
deviations  
Bond lengths 
(Å) 0.03 0.01  0.01 
Bond angles (°) 2.4 1.8  1.7 
Table 4.7: Data collection and refinement statistics for PSMT1 SER mutants 
  
113 
 
Figure 4.6: BUCCANEER results output for PSMT1 SER C2 co-crystallised with SAH and scoulerine (Crystal E) 
showing, A. completeness by residue in blue, RFREE in yellow and RWORK in light blue over the 10 cycles. B. and C. are 
ribbon diagrams of the generated model, with C rotated 90 ᵒ forward in relation to B 
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Figure 4.7: Electron density for the unmodeled ligands bound to PSMT1 SER C2 (crystal E). Blue mesh 2Fo-Fc, green 
and red Fo-Fc both at 2 sigma, screenshot from COOT 
 
Figure 4.8: Ribbon diagram of PSMTS SER C2 with SAH and scoulerine bound in a closed conformation, Protein 
shown as a ribbon diagram coloured by chain, with ligands shown as green cylinders 
As PSMT1 SER C2 generated the highest resolution model this mutant was taken 
forward for further characterisation to determine if the Lys114Ala and Lys115Ala 
mutations have affected the catalytic properties.  
115 
4.3.3.5. Activity Assay of PSMT1 SER C2 
Kinetic analysis of PSMT1 SER C2 purified by on-column cleavage was performed, 
Figure 4.9, and the Vmax and Km were determined by Michaelis-Menten direct fit, 
Table 4.8. A Vmax of 446.7 nmol min-1 mg-1 of protein and a Km of 0.22 μM was 
calculated with scoulerine as the varying substrate concentration with a constant 
concentration of 100 μM SAM. The calculated Vmax and Km values for PSMT1 SER C2 
correspond nicely to that of the activity and affinity obtained for PSMT1 WT enzyme 
of 492.6 ± 28.68 nmol min-1 mg-1 of protein and 0.25 ± 0.064 μM, respectively, Section 
3.3.3 pg. 77. Therefore, the surface entropy reduction mutations incorporated into 
PSMT1 WT have not effected activity or affinity to the substrate, scoulerine. 
 
Figure 4.9: Michaelis-Menten kinetics of PSMT1 SER C2 with scoulerine as substrate 
Substrate  Value std error 
Scoulerine 
Vmax (nmol min-1 mg-1 of protein) 446.7 23.99 
Km (μM) 0.22 0.054 
Table 4.8: Michaelis-Menten enzyme kinetics of PSMT1 SER C2 with scoulerine as the substrate 
4.3.3.6. NATIVE-PAGE 
Purified PSMT1 SER C2 by nickel affinity on-column cleavage followed by desalting 
and anion exchange in 10 mM Tris pH 8.0, 5 mM TCEP was analysed by native-PAGE 
alongside PSMT1 WT and BSA, Figure 4.10. Native-PAGE separates protein based on 
their charge and hydrodynamic radius, with smaller highly charged proteins migrating 
further than larger less charged proteins. The results show one large band of PSMT1 
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SER C2 along with a ladder effect reducing in intensity with reduced migration. PSMT1 
WT produced the same laddering effect but with reduced migration. Whereas, the 
BSA major band has migrated further. This is explained by the molecular weight and 
isoelectric point of the different proteins. The difference in migration of PSMT1 WT 
and PSMT1 SER C2 cannot be explained by the small difference in molecular weight 
of 114 Da but can be by their isoelectric points of 5.46 and 5.28, respectively. The 
lower pI of PSMT1 SER C2 would result in a greater migration towards the anode of 
the native-PAGE apparatus, which is located at the bottom of the gel tank. BSA has a 
molecular weight of 66 kDa and a pI of 4.70 and was ran alongside of the PSMT1 
samples as a control. BSA possesses a lower pI than that of both PSMT1 samples and 
having a lower molecular weight has a two-fold effect on migration, resulting in the 
furthest migration of all the samples analysed. 
 
Figure 4.10: Native-PAGE analysis of PSMT1 SER C2 alongside PSMT1 WT and BSA as a control. 30 μg of protein 
loaded per lane. Calculated pI for PSMT1 WT 5.46, PSMT1 SER C2 5.28, BSA 4.70 
4.3.4. PSMT1 SER Cluster 2 Crystal Structures 
All SER models from the initial screen, Table 4.7 are in a closed conformation with 
SAH and scoulerine bound in their active sites. 15 mg mL-1 PSMT1 SER C2 co-
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crystallised with 0.7 mM SAH and 2 mM scoulerine in a 1:1 ratio with 0.2 M 
di-ammonium citrate pH 5.0, 20 % PEG 3350 crystallisation buffer in a 300 nL total 
volume sitting drop produced the highest diffracting crystal to 1.5 Å. As the 
transferred methyl group is not present in this structure co-crystallisation 
experiments were carried out with SAM and scoulerine (the substrates) in an effort 
to obtain a substrate or product (SAH and tetrahydrocolumbamine) complex. This 
would provide a better representation of the catalytic active site. Co-crystallisation 
with SAH and tetrahydrocolumbamine was not attempted as the latter was not 
available. 
Co-crystallisation of PSMT1 SER C2 with SAM and scoulerine combined with 
optimisation in 48 well plates around the initial crystallisation buffer condition 
resulted in a crystal which diffracted to 1.3 Å at Diamond Light Source, Figure 4.11. 
This was produced with 15 mg mL-1 PSMT1 SER C2, 1 mM SAM, 2 mM scoulerine in a 
1:1 ratio with 0.2 M di-ammonium citrate pH 4.8, 20 % PEG 3350 with a total volume 
of 1 μL.  
 
Figure 4.11: Crystals of PSMT1 SER C2 co-crystallised with SAM and scoulerine. A. colour image, B. UV image 
PSMT1 SER C2 co-crystallised with 1 mM SAM and 2 mM scoulerine crystallised in the 
same space group (P 21) as the previous PSMT1 SER C2 structure. X-ray diffraction 
data was collected at Diamond Light Source and solved by molecular replacement 
with the previously described 1.5 Å PSMT1 SER C2 co-crystallised with SAH and 
scoulerine, Table 4.9. The resulting model is a homodimer with the products, SAH 
and tetrahydrocolumbamine bound within the active sites, Figure 4.12.  
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PSMT1 has either bound the substrates, SAM and scoulerine, and turned over in 
crystal resulting in the products bound in the active site, or the substrates have been 
converted to the products and subsequently rebound during crystallisation. In reality 
both methods are likely to have contributed due to the time taken for crystal growth. 
This product bound structure is essentially identical to that of PSMT1 co-crystallised 
with SAH and scoulerine with an RMSD of 0.1 Å over 686 residues. Chain A consists 
of two fragments consisting of residues 34-112 and 128-390 while chain B also 
consists of two fragments of residues 34-114 and 128-390. This is most likely due to 
the inherent flexibility of the missing loop. 
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PSMT1 SER Cluster 2 
Co-crystallised with Scoulerine and SAM 
  
Data collection  
Space group P 21 
Cell dimensions  
a, b, c (Å) 68.21, 75.93, 76.56 
(°) 90.00, 101.61, 90.00 
Resolution (Å) 75.93-1.29 
Rmerge 0.05(0.81) 
Rpim 0.03(0.52) 
I / σI 11.80(1.29) 
Completeness (%) 95.3(92.4) 
Redundancy 4.2(4.3) 
Xia2 run 3dii 
 
Refinement  
Resolution (Å) 75.11-1.29 
No. reflections 182560 
Rwork / Rfree 0.13/0.17 
No. atoms  
Protein 10694 
Ligand/ion 182 
Water 448 
B-factors (Å2)  
Protein 19.6 
Ligand/ion 14.6 
Water 28.2 
r.m.s. deviations  
Bond lengths (Å) 0.03 
Bond angles (°) 2.2 
Table 4.9: Data collection and refinement statistics for PSMT1 SER C2 co-crystallised with scoulerine and SAM 
120 
 
Figure 4.12: PSMT1 SER C2 X-ray structure co-crystallised with SAM and scoulerine but with SAH and 
tetrahydrocolumbamine bound. A. ribbon diagram coloured with chain A coloured gold and chain B coloured by 
domain. Chain B dimerisation domain green, substrate binding domain magenta, SAM/SAH binding domain cyan. 
Ligands shown as green cylinders B. PSMT1 SER C2 active site highlighting hydrogen bonding residues. Electron 
density (2Fo-Fc) shown as blue mesh clipped to SAH and tetrahydrocolumbamine contoured to 1.5 σ (0.56e Å-3) 
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4.3.5. S-Adenosylhomocysteine Binding 
SAH binding in the PSMT1 SER C2 structure with SAH and scoulerine bound compared 
to with SAH and tetrahydrocolumbamine bound are nearly identical. All the 
interactions are maintained as described for the PSMT1 WT structure co-crystallised 
with SAM in Section 3.3.5.2, pg. 87, along with several new ones. Also, due to the 
marked increase in resolution water molecules can easily be visualised in the model 
giving greater detail into secondary coordination. PSMT1 with SAH and 
tetrahydrocolumbamine bound is shown in Figure 4.13. The conserved features of 
SAM/SAH binding in plant O-methyltransferases as discussed in Section 1.7.3 pg. 41 
and outlined in Figure 1.14 are also present in PSMT1. 
The adenine moiety of SAH makes several hydrogen bonds with PSMT1. The 
carboxylic acid group of Asp278 hydrogen bonds to N6 of adenine, and Met279 
backbone amine hydrogen bonds with N1 of adenine. N6 and N7 of adenine hydrogen 
bond to a water molecule which through an extended solvent network interacts with 
Glu191 Oε, Arg203 terminal amine, Gly277 backbone oxygen, Asp278 Oδ and Glu281 
Oε. Several aromatic interactions are also involved in adenine recognition including 
Met279 Sδ-π and Leu259 CγH-π bonding to opposite faces of the adenine aromatic 
ring, and adenine C8 makes a CH-π interaction with Phe190. Residues Phe280, 
Trp298, Phe190, Asp285 and Leu259 also make up the binding pocket. 
The ribose ring of SAH is recognised mainly by Asp258 which forms hydrogen bonds 
with the ribose hydroxyl groups. The hydroxyl groups also interact with water 
molecules. Ribose 3-OH hydrogen bonds to Asn204 Oδ via a water molecule and to 
the Asn204 backbone carbonyl group and to the carboxylic acid on the methionine 
moiety of SAH by an extended solvent network. A similar interaction is made by 
ribose 2-OH to His261 Nε via a water molecule and through a solvent network 
interacts with Asn200 Oδ and its backbone oxygen, and Asn204 Oδ. Trp298 Nε and 
Asp297 Oδ hydrogen bond with the 4-O of ribose via a water molecule. Residues 
Phe190, Gly235, Gly237 and Leu259 also interact with the ribose ring of SAH. 
The homocysteine moiety of SAH is recognised by Lys292, making hydrogen bonds 
with the homocysteine amine group via its backbone carbonyl and to the 
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homocysteine carboxylic acid group via its terminal amino group. The homocysteine 
moieties carboxylic acid group hydrogen bonds to Ser211 Cγ-OH and to Ile238 
backbone amine group. Asn204 backbone carbonyl, Arg203 Cδ, Trp240 backbone 
amine, Gly236 backbone carbonyl, Ser240 Cβ-OH and its backbone nitrogen, Thr240 
backbone amine, Ser211 Cβ-OH, the 3-OH of the ribose ring and the methionine 
amino group of SAH also interact with the methionine carboxylic acid group via an 
extended solvent network. The Gly235 backbone carbonyl hydrogen bonds to the 
methionine amino group, along with the previous mentioned solvent network. 
Gly235 and Gly236 form a hydrophobic wall between the carboxylpropyl moiety of 
methionine and the ribose ring. Met207, Trp293, Asp297, Lys293, Trp293, Phe203 
and Phe190 are responsible for the correct positioning of the methyl sulphonium 
functional group by forming a channel in which the methyl group extends into. 
PSMT1 SER C2 with SAH and scoulerine bound is in a slightly more closed 
conformation than that with SAH and tetrahydrocolumbamine. This is due to the 
absence of the methyl group eliminating steric clashes and allowing hydrogen 
bonding between the SAH thioether group and the 9-hydroxyl group of scoulerine. 
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Figure 4.13: PSMT1 SER C2 co-crystallised with SAM and scoulerine binding site. Residues and solvent within 4 Å 
of tetrahydrocolumbamine and SAH represented as cylinders. Tetrahydrocolumbamine and SAH are coloured 
green, residues involved in SAH binding shown in gold, residues from chain A involved in tetrahydrocolumbamine 
binding shown in ice blue with T39 from chain B coloured blue. Those residues involved in binding 
tetrahydrocolumbamine and SAH are coloured coral. Dashed lines indicate hydrogen bonds, water molecules are 
represented by red dots 
4.3.6. Substrate Binding 
Scoulerine and tetrahydrocolumbamine bind in the active site of PSMT1 in a similar 
manner interacting with the same residues. Scoulerine/tetrahydrocolumbamine sits 
in a deep hydrophobic pocket within the enzyme, with hydrogen bonds at either end. 
The hydrophobic pocket is made up of residues Glu153, Phe,156, Thr157, Phe190, 
Phe203, Met207, Phe210, Trp293, Phe325, Asn339, Ile342, Pro343, Leu346, Leu347, 
Leu350 mainly from alpha helices six, twelve, sixteen and Thr39 from alpha helix one 
from the opposing chain. Due to the aromatic nature of the substrate and the binding 
pocket there is a large network of aromatic interactions.  
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The A-ring of scoulerine is sandwiched between a Phe210 by a CεH-π hydrogen bond 
and on the opposing face interacts with Ile342, Leu346 and Pro343. Thr157 Cγ makes 
a hydrophobic interaction with C1 and a van der Waal interaction with 2-OH of the A 
ring and it also makes a hydrogen bond with C3-O of scoulerine via a water molecule.  
The carboxylic acid group Glu153 hydrogen bonds directly to the 2-hydroxyl of 
scoulerine and to C3-O via a water molecule. The O3 of scoulerine also hydrogen 
bonds to the backbone carbonyl of Thr39 of the opposing side chain via the same 
water molecule as Glu153. The 3-O-methyl group makes hydrophobic interactions 
with Thr39 from the opposing side chain and Asn339 Cα. It also makes van der Walls 
interactions with Asn339s backbone carbonyl group along with its Cγ-OH group.  
The B-ring of scoulerine makes hydrophobic interactions with Trp293, Pro343, 
Phe325 and His296. His296 also forms van der Wall interactions with scoulerine N7 
via its CεH. The C-ring makes hydrophobic interactions with Trp293 Cβ, His296 Cε and 
Leu346 Cδ. There is also a van der Walls interaction between His296 Nε and C8a of 
scoulerine.  
Most plant O-methyltransferases methylate a hydroxyl group on a phenolic ring, the 
corresponding ring of scoulerine is the D-ring, and binds in a similar manner to the 
consensus proposed in Figure 1.16. The D-ring is held in position by Leu347 CδH-π 
bonding, with Met207 interacting on the opposing face. Along with, hydrophobic 
interactions with Leu350, Phe156 and Phe203. The 10-O-methyl position of 
scoulerine interacts hydrophobically with Phe190 and Phe203 and the carboxylic acid 
group of Asp297 via a hydrogen bond to its ether group. The 9-hydroxyl position of 
scoulerine is the hydroxyl group which is methylated by PSMT1. As expected this is 
highly co-ordinated making hydrogen bonds with the catalytic dyad of His296 and 
Asp279, as well as the backbone carbonyl of Trp293.  
4.3.7. Catalytic Mechanism 
The catalytic mechanism PSMT1 employs can be deduced from structures presented 
here. A product complex has been crystallised by co-crystallisation with the 
substrates, SAM and scoulerine resulting in turnover either in crystal or in solution 
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then rebinding the products. From this structure, a substrate bound state can be 
inferred, Figure 4.14.A. His296 acts as a catalytic base abstracting a proton from the 
9-hydroxyl position of scoulerine generating a phenoxide intermediate. Subsequently 
the sulphonium methyl group of SAM under goes SN2 nucleophilic attack by the lone 
pair of electrons on the reactive 9-phenoxide intermediate, Figure 4.14.B. Aspartic 
acid 297 may also be involved directly in catalysis or indirectly by ensuring the correct 
geometry for catalysis. His296 (Nδ) also hydrogen bonds to Glu356 terminal 
carboxylic acid group, this interaction is not only important for the correct positioning 
of His296 but also in promoting its alkalinity, making it a stronger base.  
 
Figure 4.14: Proposed catalytic reaction mechanism of scoulerine 9-hydroxyl methylation by PSMT1. A. Inferred 
orientation of the substrate complex based on PSMT1 SER C2 with SAH and tetrahydrocolumbamine bound and 
the product complex. B. Reaction schematic 
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4.3.8. Surface Entropy Reduction Mutations 
The surface entropy reduction mutations of Lys114Ala and Lys115Ala have allowed 
access to a new crystal form which diffracts to a very high resolution. To analyse how 
this new crystal form arose the crystal structure was studied. The previous apoPSMT1 
WT structure diffracted to 2.9 Å, with a missing loop between residues 112-129 in all 
four chains in the asymmetric unit. Both PSMT1 SER C2 structures presented in this 
chapter also lack part of this loop but the loop extends to residue 118 in PSMT1 SER 
C2 co-crystallised with SAH and scoulerine and the SER mutations can be visualised, 
Figure 4.15. Ala114 forms part of the crystal contact interface with a symmetry dimer, 
if the Lys114Ala mutation was not present this crystal form would be impossible due 
to steric clashes. Lys115Ala mutation points out towards a bulk solvent channel 
within the crystal. It could be possible that only the Lys114Ala mutation is necessary 
to obtain this crystal form. 
 
Figure 4.15: Surface entropy reduction mutation Lys114Ala and Lys115Ala present in PSMT1 SER C2 co-crystallised 
with SAH and scoulerine. A and B are different orientations. Model shown in purple along with a symmetry model 
shown in light green, weighted electron density (2Fo-Fc) is shown as a red mesh contoured to 1.5 σ (0.55 e Å-3), 
water molecules are represented as red crosses 
4.3.9. Open and Closed Differences 
Comparison on the open and closed structures of PSMT1 will provide a deeper 
understanding of how the conformational change occurs. apoPSMT1 WT, PSMT1 WT 
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with SAM bound presented in Chapter 3 are in an open conformation and were 
superimposed with each other and with PSMT1 SER C2 with SAH and scoulerine 
bound, and PSMT1 SER C2 with SAH and tetrahydrocolumbamine bound, which are 
in a closed conformation, Figure 4.16. As the structure is closed with SAH and 
scoulerine or tetrahydrocolumbamine bound it suggests that upon binding of both 
substrates PSMT1 undergoes a conformational change where the SAM binding 
domain rotates inwards towards the dimerisation/substrate binding domain, 
resulting in about an 8 Å closure to the active site opening. The closure of PSMT1 
leads to the formation of the functional active site binding pocket. 
 
Figure 4.16: Superposition of PSMT1 structures. apoPSMT1 WT-Open (ice blue), PSMT1 WT with SAM bound-Open 
(gold), PSMT1 SER C2 with SAH and scoulerine bound-Closed (coral) and PSMT1 SER C2 with SAH and 
tetrahydrocolumbamine bound-Closed (grey). Structures are superimposed by the dimerisation domain, peptide 
represented as ribbons and ligands represented as cylinders. Red arrows indicate the rotation of the SAM binding 
domain in relation to the dimerisation domain upon active site closure. 
PSMT1 WT with SAM bound (gold) will be compared to PSMT1 SER C2 with SAH and 
tetrahydrocolumbamine bound (grey), Figure 4.17-A&B. Figure 4.17.A shows the 
superposition of the two structural models by the dimerisation/substrate binding 
domains. Upon closure of the active site the labile methyl group of SAM, the 9-OH 
position on scoulerine and the catalytic dyad are brought into close proximity. This 
allows catalysis to occur where the SAM traps scoulerine in the active site which 
prevents the release of the phenoxide intermediate. Without the large 
conformational change catalysis could not occur. Upon closure, Phe210, Met207, 
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Phe203, Phe190 and Trp293 change conformation generating the upper face of the 
substrate binding pocket.  
Figure 4.17.B shows the superposition of the two structural models by the SAM/SAH 
binding domains. SAM/SAH ligand-protein interactions are maintained with new 
contacts bring made by Ser211, Met207, Phe203, Phe190 and Asp297 (dark grey) on 
the previously solvent exposed face of SAM. The newly positioned Met207, Phe203, 
Phe190 and Asp297, along with Trp293 form a channel in which the transferred 
methyl group extends into, ensuring the correct position for catalysis.  
Figure 4.17.C shows a summary of the differences between the open and closed 
conformations mapped onto PSMT1 SER C2 with SAH and tetrahydrocolumbamine 
bound. All the SAM/SAH binding site interactions are maintained during active site 
closure (gold). Tetrahydrocolumbamine is bound in a deep pocket at the bottom of 
the binding pocket. The majority of the residues responsible for substrate binding are 
already in the correct position for binding (ice blue), these are mostly on the bottom 
face of the molecule. The residues which take on new positions are shown in coral. 
The majority of these residue interactions are responsible for the correct positioning 
of the sulphonium methyl group of SAM and the 9-hydroxyl position of scoulerine for 
catalysis. The catalytic dyad of His296 and Asp297 is also brought into the correct 
position for proton abstraction at the 9-hydroxyl position of scoulerine. The large 
conformational change affords several advantages: In the open conformation, the 
catalytic dyad is distal to the sulphonium methyl group of SAM which will stop 
undesirable methylation of small molecules and the uncontrolled consumption of 
valuable SAM. It will also allow for high substrate specificity due to the buried 
substrate binding site and the retention of the highly reactive activated phenoxide 
intermediate. 
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Figure 4.17:Comparison of PSMT1 in open and closed conformations A. and B. show PSMT1 WT with SAH bound 
model (gold) and PSMT1 SER C2 with SAH and tetrahydrocolumbamine (THC) bound (grey) superimposed by the 
dimerisation/substrate binding domain and SAM binding domain, respectively. C. is a simplified representation of 
domain movement mapped onto PSMT1 SER C2 with SAH and tetrahydrocolumbamine bound. Gold residues 
represent residues which are conserved in SAM/SAH binding in both open and closed models. Ice blue residues are 
residues which have little conformational change upon substrate binding. Coral indicates the residues which have 
undergone significant conformational change 
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 Conclusion 
Surface entropy reduction (SER) has allowed access to crystal forms of PSMT1 which 
would not be possible otherwise. Three SER constructs were generated based on 
sequence analysis by the surface entropy reduction prediction server, Table 4.3. All 
three constructs expressed and purified in the same manner as the WT enzyme, 
producing pure soluble homogeneous protein shown by SDS-PAGE analysis, Figure 
4.2. Out of the three SER constructs PSMT1 SER cluster 2 produced the highest 
resolution diffracting crystals, extending to 1.5 Å, from the initial crystallisation 
screen trials, Table 4.6. Subsequent characterisation of PSMT1 SER C2 showed it to 
behave similar to that of WT protein in solution by SEC-MALLS (Figure 4.3), 
thermofluor (Figure 4.4) and as expected by native-PAGE (Figure 4.10) analysis. 
Activity assay data also show that the mutation introduced did not have an effect on 
catalytic activity, Figure 4.9 and Table 4.8. 
Co-crystallisation of PSMT1 SER C2 with SAH and scoulerine produced a crystal with 
SAH and scoulerine bound in the active site. In comparison of this model with the 
apoWT and the WT plus SAM models it is evident that a large conformational change 
has taken place, Figure 4.16. The conformational change is caused by a rotation of 
the SAM binding domain inwards towards the dimerisation/substrate binding 
domain, resulting in a closure of about 8 Å of the active site opening. Co-
crystallisation of PSMT1 SER C2 with the substrates SAM and scoulerine produced a 
crystal with the products, SAH and tetrahydrocolumbamine, bound in the active site. 
Not only does this provide validation of an active protein it also allowed the 
prediction of substrate binding and to infer the catalytic reaction mechanism, Figure 
4.14.  
The open and closed PSMT1 structures presented here have allowed a detailed 
description of how PSMT1 confers substrate specificity. It appears that both the 
methyl acceptor and methyl donor in either pre- or post-reaction states are need to 
be present for enzyme closure and active site formation. In the open form the 
majority of residues responsible for binding of the substrates are already in the 
correct conformation for binding. Upon closure and formation of the active site the 
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9-hydroxyl face of scoulerine and the sulphonium methyl face of SAM are brought 
together forming new protein interactions. This not only forms a channel into which 
the transferred methyl group protrudes, it also forms the catalytic dyad, with His296 
and Asp297 manoeuvred into close proximity to the 9-hydroxyl position of 
scoulerine. 
This work adds to the small number of published closed plant O-methyltransferases 
structures allowing a greater understanding of substrate and catalytic mechanism. 
Comparing PSMT1 in a closed conformation with the closed plant 
O-methyltransferase structures analysed in Section 1.7.4 pg. 42, Figure 1.14 and 
Figure 1.15 several conserved features were defined. The mode of SAM/SAH binding 
by the SAM binding domain is highly conserved, along with residues involved in 
binding of the phenolic ring to be methylated. Further analysis has shown new 
unreported conserved features, Figure 4.18. Glu356 in PSMT1 is a highly-conserved 
residue of the crystallised plant O-methyltransferases, Figure 4.18, therefore the 
feature which promotes the basicity of the catalytic histidine must also be highly 
conserved. The residues, Phe109, Met207, Phe203, Trp293 and the catalytic Asp297 
which are responsible for the formation of the sulphonium methyl transfer channel 
are highly conserved. Although the hydrophobic pocket in which the substrate binds 
is highly variable, the substrates generally have a hydroxyl group distal to the 
hydroxyl group to be methylated. This distal hydroxyl group generally makes a 
hydrogen bond with an acidic residue or the terminal carbonyl of asparagine, 
although hydrogen bonding to glutamine is not observed in this set of enzymes it 
cannot be ruled out. This distal hydroxyl group hydrogen bond feature could aid in 
the prediction of possible substrates of plant O-methyltransferases with unknown 
substrates. 
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Figure 4.18: Multiple sequence alignment of conventional plant O-methyltransferases, with a catalytic dyad of 
His/Asp, for which a tertiary complex in a closed conformation is available in the Protein Database along, with 
PSMT1. Residues highlighted in Blue are the conserved residue involved in SAM binding as outlined in Figure 1.14 
Red residues is the catalytic dyad, yellow residues are conserved in phenolic substrate binding as outlined in Figure 
1.16. Pink residues are newly described conserved features 
  
PSMT1 MATNGEIFNTYGHNHQSATVTKITASNE-SSNGVCYLSETANLGKLICIPMALRAAMELN 59
COMT ----------MGSTAA--------DMAASADEDACMF--ALQLASSSVLPMTLKNAIELG 40
MOMT ----------MGSTGNAE--IQI-IPTHSSDEEANLF--AMQLASAAVLPMALKAAIELD 45
N6OMT ---------------MEM------INKENLSSQAKLW----NFIYGFADSLVLKSAVQLD 35
COMT ----------MGNSYITKEDNQISATSEQTEDSACLS--AMVLTTNLVYPAVLNAAIDLN 48
IOMT ----------MASSINGR------KPSEIFKAQALLY----KHIYAFIDSMSLKWAVEMN 40
.                     *. *:::.
PSMT1 VFQLISKFGT-DAKVSASEIASKMPNAKNNPEAAMYLDRILRLLGASSILSVSTTKKSIN 118
COMT LLEILVAAG--GKSLTPTEVAAKLPSAA-NPEAPDMVDRILRLLASYNVVTCLVE--EGK 95
MOMT VLEIMAKSVPPSGYISPAEIAAQLPT-T-NPEAPVMLDRVLRLLASYSVVTYTLR--ELP 101
N6OMT LANIIHNHGSP---MTLSELSLHLPSQP---VNQDALYRVLRYLVHMKLFTKSSIDGE-- 87
ChOMT LFEIIAKATPPGAFMSPSEIASKLPASTQHSDLPNRLDRMLRLLASYSVLTSTTR--TIE 106
IOMT IPNIIQNHGKP---ISLSNLVSILQVPS---SKIGNVRRLMRYLAHNGFFEIIT-KEE-- 91
: :::         :   ::   :            : *::* *     .          
PSMT1 RGGDDVVVHEKLYGLTNSSCCLVPRQEDGVSLVEELLFTSDKVVVDSFFKLKCVVEEKDS 178
COMT DGR-----LSRSYGAAP-VCKFLTPNEDGVSMAALALMNQDKVLMESWYYLKDAVLDGGI 149
MOMT SGK-----VERLYGLAP-VCKFLTKNEDGVSLAPFLLTATDKVLLEPWFYLKDAILEGGI 155
N6OMT ----------LRYGLAP-PAKFLVKGWDK-CMLGAILTITDKDFMAPWHYLKEGILNDGS 135
ChOMT DGG-----AERVYGLSM-VGKYLVPDESRGYLASFTTFLCYPALLQVWMNFKEAVVDEDI 160
IOMT ----------ESYALTV-ASELLVRGSDL-CLAPMVECVLDPTLSGSYHELKKWIYEE-- 137
*  :      :                    .   :  :.  :     
PSMT1 VP------FE-VAHGAKIFEYAATEPRMNQVFNDGMAVFSIVVFEAV-FRVYDGFLDMKE 230
COMT P-------FN-KAYGMSAFEYHGTDPRFNRVFNEGMKNHSIIITKKL-LELYHGFEGLGT 200
MOMT P-------FN-KAYGMNEFDYHGTDHRFNKVFNKGMSSNSTITMKKI-LEMYNGFEGLTT 206
N6OMT TS----TAFE-KALGTNIWDYMAEHPEKNQLFNEGMANDTRLIMSALVKECSSMFDGITT 190
COMT DL------FK-NVHGVTKYEFMGKDKKMNQIFNKSMVDVCATEMKRM-LEIYTGFEGIST 212
IhOMT DL----TLFG-VTLGSGFWDFLDKNPEYNTSFNDAMASDSKLINL-ALRDCDFVFDGLES 191
*     *   ::    . . .  *...*                  * .:  
PSMT1 LLDVGGGIGTSVSKIVAKYPLIRGVNFDLPHVISVAP-QYPGVEHVAGDMFE-EVPKGQN 288
COMT LVDVGGGVGATVAAIAAHYPTIKGVNFDLPHVISEAP-QFPGVTHVGGDMFK-EVPSGDT 258
MOMT IVDVGGGTGAVASMIVAKYPSINAINFDLPHVIQDAP-AFSGVEHLGGDMFD-GVPKGDA 264
N6OMT IVDVGGGTGTAVRNIAKAFPHIKCTVYDLPHVIADSP-GYTEINSIQGDMFK-YIPNADA 248
COMT LVDVGGGSGRNLELIISKYPLIKGINFDLPQVIENAP-PLSGIEHVGGDMFA-SVPQGDA 270
IhOMT IVDVGGGTGTTAKIICETFPKLKCIVFDRPQVVENLS-GSNNLTYVGGDMFT-SIPNADA 249
::***** *     *   :* :.   :* *:*:         :    *:**   :* .: 
PSMT1 MLLKWVLHDWGDERCVKLLKNCWNSLPVG---GKVLIIEFVLPNELGNN-AESFNALIPD 344
COMT ILMKWILHDWSDQHCATLLKNCYDALPAH---GKVVLVQCILPVNPEAN-PSSQGVFHVD 314
MOMT IFIKWICHDWSDEHCLKLLKNCYAALPDH---GKVIVAEYILPPSPDPS-IATKVVIHTD 320
N6OMT IMMKCILHDWDDKECIEILKRCKDAVPRDG--GKVIIIDIILDVKSE-H-PYTKMRLTLD 304
ChOMT MILKAVCHNWSDEKCIEFLSNCHKALSPN---GKVIIVEFILPEEPNTS-EESKLVSTLD 326
IOMT VLLKYILHNWTDKDCLRILKKCKEAVTNDGKRGKVTIIDMVIDKKKDEN-QVTQIKLLMD 308
:::* :  :* *:    :*..*  ::      **: : : ::  .              *
PSMT1 LLLMALNPGGKERTISEYDDLGKAAGFIKTIPI-PISNGLHVIEFHK-- 390
COMT MIMLAHNPGGRERYEREFQALARGAGFTGVKSTYIYANAW-AIEFTK-- 360
MOMT ALMLAYNPGGKERTEKEFQALAMASGFRGFKVASCAFNTY-VMEFLKTA 368
N6OMT LDMML-NTGGKERTEEEWKKLIHDAGYKGYKIT-HISAVQSVIEAYPY- 350
ChOMT NLMFI-TVGGRERTEKQYEKLSKLSGFSKFQVACRAFNSLGVMEFYK-- 372
IOMT VNM-A-CLNGKERNEEEWKKLFIEAGFQHYKIS-PLTGFLSLIEIYP-- 352
:      *  *   ::  *   :*:               :*     
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5. Investigating the Catalytic Mechanism of PSMT1 
 Introduction 
Chapter 3 described the successful purification and crystallisation of apoPSMT1 and 
PSMT1 with SAM bound, both in the closed conformation. In Chapter 4, surface 
entropy reduction experiments allowed the crystallisation of PSMT1 SER C2 in a 
closed conformation with SAH and scoulerine or tetrahydrocolumbamine bound. 
These high resolution closed conformation structures allowed detailed analysis of the 
scoulerine/tetrahydrocolumbamine binding site, along with the catalytic machinery, 
Figure 5.1. The conserved plant O-methyltransferase catalytic dyad of histidine and 
aspartic acid were observed to be in a favourable orientation is relation to the 9-O 
position of scoulerine/tetrahydrocolumbamine for catalysis. To determine the 
importance of each of these residues site-directed mutagenesis experiments were 
carried out on His296 and Asp297.  
 
Figure 5.1: Active site of PSMT1 SER C2 co-crystallised with SAM and tetrahydrocolumbamine with SAH and 
tetrahydrocolumbamine bound. Ligands shown as green cylinders, PSMT1 SER C2 active site residues shown as 
cylinders coloured by chain, blue and gold. Waters are represented as red spheres 
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Analysis of the scoulerine/tetrahydrocolumbamine binding site in the PSMT1 SER C2 
structures revealed an intriguing feature: Thr39 of the opposing subunit directly 
participates in substrate binding at the opposing end to that of the catalytic dyad, 
Figure 4.13. Kinetic analysis of PSMT1 showed positive cooperativity with a Hill 
coefficient of 1.50 ± 0.39 towards scoulerine, Table 3.2. As such, an obvious target 
for modification of subunit communication is Thr39. In this chapter the Thr39 of 
PSMT1 SER C2 was mutated to alanine and characterised by X-ray crystallography. 
 Materials and Methods 
5.2.1. Generation of Active Site Mutants 
Site-directed mutagenesis of pETFPP-3-PSMT1 SER C2 was carried out to generate 
the active site mutants, utilising the whole plasmid mutagenesis method as 
previously described in Section 4.2.2, pg. 93. The primers utilised are listed in Table 
5.1. PSMT1 SER C2 Thr39Ala site-directed mutagenesis experiments were sequenced 
using PSMT1 sequencing primer 2, Table 5.1, due to PSMT1 sequencing primer 1 
being downstream of the mutation. 
5.2.1. Expression and Purification 
Expression of PSMT1 SER C2 active site mutants were carried out in the same manner 
to that of PSMT1 SER C2, as described in Section 4.2.3, pg. 94.  
Purification of the PSMT1 SER C2 active site mutants was carried out as described in 
Section 2.2.1.1-3, pg. 54. The purification of PSMT1 SER C2 His296Ala involved size 
exclusion chromatography, as described in Section 2.2.1.6 pg. 56, in the place of 
anion exchange chromatography. 
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Asp287Ala 
 A890C, T891C 
Forward 5'-aaaatgggtactgcacgcttggggtgatgaacgat-3'  
Reverse 5'-atcgttcatcaccccaagcgtgcagtacccatttt-3' 
His296Ala 
 C886G, A887C 
Forward 5'-gttgctaaaatgggtactggccgattggggtgatgaacga-3' 
Reverse 5'-tcgttcatcaccccaatcggccagtacccattttagcaac-3'  
His296Phe 
 C886T A887T 
Forward 5'-gttgctaaaatgggtactgttcgattggggtgatgaacga-3' 
Reverse 5'-tcgttcatcaccccaatcgaacagtacccattttagcaac-3' 
His296Asn 
 C166A 
Forward 5'-ttgctaaaatgggtactgaacgattggggtgatgaac-3' 
Reverse 5'-gttcatcaccccaatcgttcagtacccattttagcaa-3' 
Thr39Ala 
 A835G, G837A 
Forward 5'-caatggtgtctgttatctttcagaagcagctaacttggggaagttaata-3' 
Reverse 5'-tattaacttccccaagttagctgcttctgaaagataacagacaccattg-3' 
PSMT1 Sequencing Primer 2 
 5'-GTGAGCGGATAACAATTCC-3' 
Table 5.1: Oligonucleotide primers for the generation of PSMT1 mutants to probe catalytic mechanism (D287A, 
H296A, H296F, H296N) and cooperativity (T39A), along with PSMT1 sequencing primer 2. Nucleotide mutations 
are shown in bold 
5.2.2. Activity Assay 
The activity of PSMT1 SER C2 Asp296Ala was measured utilising a modified method 
of that described in Section 4.2.7, pg. 98. Only one concentration of substrates was 
monitored consisting of 5 μM scoulerine and 100 μM SAM, this was taken to 
represent Vmax based on activity assays of PSMT1 SER C2, Figure 4.9 and Table 4.8. 1 
mL time points were taken at 0 min, 1 min and 10 min and quenched with equal 
volumes of methanol. The samples were prepared and analysed as described in 
Section 4.2.7, pg. 98. 
136 
5.2.3. Crystallisation 
PSMT1 SER C2 active site mutant crystallisation trays were setup using a 1:1 ratio of 
14-15 mg mL-1 protein in 10 mM Tris, 5 mM TCEP pH 8.0, utilising the vapour diffusion 
method in 48 well sitting drop plates, and incubated at 20 °C in a Rigaku Minstrel HT 
UV crystal imager (Rigaku). Vapour diffusion crystallisation drops were manually 
dispensed, with a total volume of 1 μL, against 100 μL of reservoir solution. The plates 
reservoir solutions were designed to explore the crystallisation space around that of 
the initial PSMT1 SER C2 hit (crystal E) of 0.2 M di-ammonium citrate pH 5.0, 20 % 
PEG 3350 by altering the pH of di-ammonium citrate between 4.2 and 5.6 along with 
varying concentration pf PEG 3350 between 10 – 35 %. 
Crystals were tested in house using a Rigaku MicroMax-007 HF X-ray Generator and 
Rigaku R-Axis IV++ image plate detector. 0 ᵒ and 90 ᵒ X-ray diffraction images are 
taken with an oscillation of 0.5 ᵒ, 5-minute exposures to 2.5 Å resolution. Crystals 
which diffracted well were sent to Diamond Light Source (Harwell) for collection of a 
full data set. 
 Results and Discussion 
5.3.1. Probing the Active Site Catalytic Dyad 
To probe the catalytic dyad of PSMT1, mutations of residues His296 and Asp297 were 
generated by site-directed mutagenesis of pETFPP-3-PSMT1 PSMT1 SER C2 to 
remove their respective functional groups. This allowed further characterisation of 
the catalytic mechanism. 
5.3.1.1. PSMT1 Surface Entropy Reduction Cluster 2 Asp297Ala 
Mutation 
5.3.1.1.1. Expression and Purification 
Asp297 of PSMT1 SER C2 was mutated by site-directed mutagenesis experiments 
utilising the primers outlined in Table 5.1, generating pETFPP-3-PSMT1 SER C2 
Asp297Ala. Gene expression was carried out utilising the same methods as those 
utilised for PSMT1 SER C2. The purification differed to that of PSMT1 SER C2 as only 
nickel affinity on-column cleavage was implemented before being buffer exchanged 
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into 10 mM tris pH 8.0, 5 mM TCEP and concentrated to 14 mg mL-1 for crystallisation 
trials. This method produced a protein solution containing one major band at ca. 
43 kDa, representing cleaved PSMT1 SER C2 Asp297Ala protein, as analysed by 
SDS-PAGE, Figure 5.2. There are also two higher molecular weight contaminants of 
ca. 70 kDa and ca. 64 kDa, these are assumed to be uncleaved 6xHis-GST-r3CP-PSMT1 
SER C2 Asp297Ala and HRV 3C protease. 
 
Figure 5.2: SDS-PAGE analysis of PSMT1 SER C2 Asp297Ala mutant purification steps. Lane 1- cells extract, lane 2 
- immobilised metal affinity chromatography (IMAC) flow through, lane 3 – pooled on-column cleavage fractions. 
Arrow indicates expected position of PSMT1 SER C2 Asp297Ala 
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5.3.1.1.2. Activity Assay 
To determine if the Asp297Ala mutation has effected the activity of PSMT1, the rate 
was measured at concentrations of 5 μM scoulerine and 100 μM SAM, which are 
approaching the concentrations required for Vmax as determined for PSMT1 SER C2, 
Figure 4.9. 1 mL samples were taken at 0 min, 1 min and 10 min and quenched with 
1 mL of methanol. Samples were prepared and analysed utilising the same method 
as described for PSMT1 wild type and PSMT1 SER C2 activity assays. The rate over 10 
minutes was calculated to be 2.90 nmol min-1 mg-1 of protein for the PSMT1 SER C2 
Asp297Ala mutation, Figure 5.3. The Asp297Ala mutation has resulted in a substantial 
reduction in activity to 0.6 % of that of the Vmax calculated by Michaelis-Menten 
analysis of PSMT1 SER C2, Table 5.2. As the mutation did not result in a complete loss 
of activity it suggests that Asp297 is important for catalysis but not essential. 
 
Figure 5.3: Activity assay of PSMT1 SER C2 Asp297Ala, measuring the production of tetrahydrocolumbamine over 
time (blue dots), along with linear regression analysis (blue line) 
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 PSMT1 SER C2 
Vmax 
PSMT1 SER C2 
Asp297Ala  
Rate of product formation 
(nmol min-1 mg-1 of protein) 
492.6±28.68 2.90±0.09 
Relative rate (to Vmax) 100 % 0.6 % 
Table 5.2: Activity Assay PSMT1 SER C2 Asp297Ala mutant with 5 μM scoulerine and 100 μM SAM measuring 
tetrahydrocolumbamine production, compared to PSMT1 SER C2 Vmax 
5.3.1.1.3. PSMT1 SER C2 Asp297Ala Structures 
Crystallisation of PSMT1 SER C2 Asp297Ala was carried out utilising 48 well sitting 
drop plates utilising the vapour diffusion method. 0.5 μL of crystallisation buffer was 
mixed with 0.5 μL 14 mg mL-1 protein solution co-crystallised with either 1 mM SAM 
and 2 mM scoulerine or 0.7 mM SAH and 2 mM scoulerine in 48 well trays, against 
100 μL of crystallisation buffer. The crystallisation space around the original hit for 
PSMT1 SER C2 in JCSG-plus™ screen (Molecular Dimensions), drop A3 (0.2 mM 
di-ammonium citrate pH 5.0, 20 % PEG3350) was explored. Co-crystallisation 
experiments with SAH and scoulerine produced crystals in 0.2 M di-ammonium 
citrate pH 4.4, 20 % PEG3350 which extended to 1.20 Å and co-crystallisation 
experiments with SAM and scoulerine produced crystals in 0.2 M di-ammonium 
citrate pH4.6, 20 % PEG3350 which extended to 1.24 Å. Data was auto-processed 
utilising Xia2 on the beamline at Diamond Light Source (Harwell), statistics shown in 
Table 5.3. The PSMT1 SER C2 (closed conformation) co-crystallised with SAH and 
scoulerine structure was used, with the ligands and waters removed, as an initial 
model for refinement utilising REFMAC for both data sets. After several rounds of 
refinements, both data sets produced models of PSMT1 SER C2 Asp297Ala with SAH 
and scoulerine bound, Figure 5.4, refinement statistics are shown in Table 5.3. The 
Asp297Ala mutation in PSMT1 SER C2 has also resulted in the stabilisation of the 
missing loop (residues 112 to 130) in one of the subunits. The loop contains a small 
alpha helix (residues 117-121) and an antiparallel beta-sheet (residues 112-114 and 
130-132), Figure 5.4.A. 
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Figure 5.4: PSMT1 SER C2 Asp297Ala mutant structures co-crystallised with SAH and scoulerine (coral) or SAM and 
scoulerine (sea green). A. Ribbon diagram of both structures superimposed with ligands represented as cylinders. 
B. Active site residues of PSMT1 SER C2 co-crystallised with SAH and scoulerine, C. Active site of PSMT1 SER C2 co-
crystallised with SAM and scoulerine. Ligands and the Asp297Ala mutation are represented as green cylinders. 
Blue mesh represents 2Fo-Fc map contoured to 1.5 σ (B. 0.73 e Å-3 and C. 0.64 e Å-3)  
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The PSMT1 SER C2 Asp297Ala mutation structures shown in Figure 5.4 both clearly 
possess electron density at position 297 which is consistent with the alanine 
substitution. Both structures have been modelled with SAH and scoulerine bound in 
the active sites showing that SAM has lost its methyl group. There is an indication 
that the co-crystallisation trails with SAM and scoulerine have 
tetrahydrocolumbamine bound at a very low occupancy due to the presence of 
partial positive electron density in the difference (Fo-Fc) map but the transferred 
methyl group is not visible in the 2Fo-Fc map so was not modelled.  
In both models, the carboxyl group of aspartic acid has been replaced with a highly 
coordinated water molecule. This water molecule perturbs the positioning of 
scoulerine in such a way that might explain the marked reduction in catalysis 
observed in Figure 5.3. The angle observed between His296-Nε, 9-O of 
tetrahydrocolumbamine and the sulphur of SAH is 130.4 ᵒ in PSMT1 SER C2 co-
crystallised with SAM and scoulerine, whereas an angle of 82.2 ᵒ was observed in 
PSMT1 SER C2 Asp296Ala co-crystallised with SAH and scoulerine. This, along with 
the reduction in activity suggests that Asp297 alone is not critical for the initial 
deprotonation step on the 9-hydroxyl of scoulerine but is most likely crucial for the 
correct positioning of the substrates for the SN2 nucleophilic attack by the 
9-phenoxide intermediate on the sulphonium methyl group of SAM.  
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PSMT1 SER C2 Asp297Ala Asp297Ala 
Co-crystallised 
with 
Scoulerine and 
SAH 
Scoulerine and 
SAM 
Data 
collection 
 
 
Space group P 21 P 21 
Cell 
dimensions 
  
a, b, c (Å) 68.87, 76.62, 
77.16 
68.25, 75.93, 
76.56 
(°) 90.00, 101.55, 
90.00 
90.00, 101.48, 
90.00 
Resolution (Å) 76.62-1.20 50.19-1.24 
Rmerge 0.04(0.71) 0.05(0.44) 
Rpim 0.04(0.66) 0.04(0.46) 
I / σI 12.2(1.3) 15.0(2.3) 
Completeness 
(%) 
97.5(89.0) 74.6(18.7) 
Redundancy 3.6(2.4) 3.9(2.5) 
Xia2 run 3dii 3dii 
  
Refinement   
Resolution (Å) 75.710-1.20 50.189-1.24 
No. reflections 238131 160995 
Rwork / Rfree 0.13/0.16 0.12/0.15 
No. atoms   
Protein 10757 10736 
Ligand/ion 174 174 
Water 662 458 
B-factors (Å2)   
Protein 13.3 16.0 
Ligand/ion 7.2 10.5 
Water 26.7 24.1 
r.m.s. 
deviations 
  
Bond lengths 
(Å) 
0.03 0.03 
Bond angles (°) 2.6 2.4 
Table 5.3: Data collection and refinement statistics for PSMT1 SER C2 Asp297Ala mutant 
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5.3.1.2. PSMT1 Surface Entropy Reduction Cluster 2 Histidine 296 
Mutations 
5.3.1.2.1. Expression and Purification 
His296 of PSMT1 SER C2 was mutated by site-directed mutagenesis experiments 
utilising the primers outlined in Table 5.1, generating pETFPP-3-PSMT1 SER C2 
His296Ala. Gene expression was carried out utilising the same methods as those 
utilised for PSMT1 SER C2. Purification of PSMT1 SER C2 His296Ala was carried out by 
3C protease on-column cleavage followed by gel filtration. The first purification step 
of 3C protease on-column cleavage resulted in a poor yield of cleaved PSMT1 which 
had been liberated from its solubility/purification tag (6xHis-GST), Figure 5.4.A. The 
bands in the on-column cleavage fractions contain a small amount of cleaved PSMT1 
(43 kDa) compared to that of contaminating proteins, such as un-cleaved 6xHis-GST-
r3CP-PSMT1 (70 kDa) and 3C protease (64 kDa). A large band at 43 kDa corresponding 
to the molecular weight of cleaved PSMT1 was present in the first elution peak of 
increasing imidazole concentration. This was not observed in previously PSMT1 
purification experiments. This would indicate that there has been a structural change 
which has allowed it to bind to the IMAC column.  
To separate the cleaved PSMT1 from the co-eluting proteins in elution peak 1, Figure 
5.4.A, gel filtration was implemented and analysed by SDS-PAGE Figure 5.4.B. This 
showed that cleaved PSMT1 mainly eluted in the void volume (lane 4) by the 
presence of a band at ca. 43 kDa. Cleaved PSMT1 was also present in many of the 
subsequent fractions. This is indicative of a misfolded, unfolded or aggregated 
protein. Gel filtration also known as size exclusion chromatography separates 
proteins based on their hydrodynamic radius, therefore a protein of the same 
molecular weight can elute at differing retention times due to differences in folding 
states. As PSMT1 is co-eluting with proteins of a higher molecular weight, as analysed 
by SDS-PAGE, it suggests that the mutation has destabilised the enzyme causing it to 
misfold and form aggregates resulting in earlier elution from the gel filtration column. 
Purification of PSMT1 SER C2 His296Phe also resulted in no soluble protein. 
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Figure 5.5: PSMT1 SER C2 His296Ala mutant purification. A. Nickel affinity on-column cleavage, lane 1 – molecular 
weight markers, lane 2 - cells extract, lane 3 - immobilised metal affinity chromatography (IMAC) flow through, 
lanes 4-13 – on-column cleavage fractions, lanes 14-15 – IMAC elution peaks. B. Gel Filtration, lane 1 – molecular 
weight markers, lane 2 – concentrated IMAC elution peak 1 which was injected onto the gel filtration column, 
lanes 3-14 – gel filtration elution fractions 
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Both His296Ala/Phe mutations have resulted in insufficient soluble protein for 
characterisation. Zhou et al. also reported near complete loss of protein expression 
when the corresponding histidine was mutated in Triticum aestivum L. 
O-methyltransferase to Arg, Leu and Phe.117 To try to understand why the histidine 
mutations are causing the reduction in expression the previously obtained crystal 
structures were analysed. It was found that histidine 296 of PSMT1 forms a hydrogen 
bond with glutamic acid 356 Oε via its Nδ in all the open and closed structures of 
PSMT1 presented in this thesis. This bond tethers the SAM binding domain to that of 
the substrate binding/ dimerisation domain and is involved in an extended hydrogen 
bonding network, Figure 5.6. It is possible that its mutation would destabilise the 
quaternary structure of the enzyme.  
To maintain the hydrogen bond between histidine 296 and glutamic acid 356, His296 
was mutated to asparagine. The Oδ of asparagine could, in theory, hydrogen bond to 
the Oε of glutamic acid 356, Figure 5.7, to hopefully maintaining the hydrogen bond 
network shown in Figure 5.6. This proved unsuccessful, again resulting in poor 
protein expression. Histidine is one of the most complex of all amino acids, with it 
being both polar and hydrophobic, as well as having both positive and negative 
charges, and possessing aromatic properties. His296 makes a variety of interactions 
within PSMT1 and it might not be possible to express a stable His296 mutant with the 
21 common amino acids. It might be possible to utilise unnatural amino acids such as 
substituting the imidazole ring with a pyrrole ring generating 2-amino-3-(1H-pyrrol-
2-yl) propanoic acid. This might maintain the His296 to Glu356 hydrogen bond as well 
as maintain its aromaticity but would be unable to deprotonate the 9-hydroxyl group 
of scoulerine. 
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Figure 5.6: Analysis of the environment of His296 in PSMT1 SER C2 co-crystallised with SAM and scoulerine but 
with SAH and tetrahydrocolumbamine bound in the active site. A. Ribbon diagram coloured by chain, chain A in 
ice blue and chain B in gold with chain A’s SAM binding domain in coral. B. Hydrogen binding network of His296 
represented as cylinders, coloured as an A. Waters shown as red spheres and hydrogen bonds represented as 
broken black lines 
A.
B.
SAH
Tetrahydrocolumbamine
F325
E324
Y362
R357K355
H296
E356
H296
E356
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Figure 5.7: Hydrogen binding between A. His 296 and Asp 356 based on crystal structures, B. proposed hydrogen 
bonding between His 296 and the Asn 356 mutant. Hydrogen bonds represented as broken black lines 
5.3.2. Probing the Cooperativity of PSMT1 
5.3.2.1.1. Expression and Purification 
In Section 3.3.3, pg. 77 PSMT1 has been shown to possess positive cooperativity in 
respect to scoulerine with a Hill co-efficient of 1.5, Table 3.2. To probe the subunit 
cooperativity of the PSMT1 homodimer the X-ray crystal structures presented in this 
thesis were analysed. The binding site of scoulerine/tetrahydrocolumbamine in 
PSMT1 SER C2 co-crystallised with SAM and scoulerine but with SAH and 
tetrahydrocolumbamine bound is show in Figure 5.8 and coloured by peptide chain. 
Thr39 from the opposing chain interacts directly with tetrahydrocolumbamine by 
hydrophobic interactions between the 3-O-methyl group of tetrahydrocolumbamine 
and the Cβ of Thr39. Thr39 also interacts with the 3O of tetrahydrocolumbamine 
indirectly through a hydrogen bond water bridge via its backbone carbonyl group. 
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Figure 5.8: Binding pocket of tetrahydrocolumbamine bound to PSMT1 SER C2. Residues coloured by chain (chain 
A blue, chain B gold), ligands coloured in green, and Tetrahydrocolumbamine and threonine 39 are represented 
as a transparent surface model. The catalytic dyad of Asp 297 and His 296 are also indicated 
To probe if Thr39 is a crucial residue contributing to signalling between the two active 
sites it was mutated to alanine by site-directed mutagenesis experiments utilising the 
primers in Table 5.1 to generate the plasmid pETFPP-3-PSMT1 PSMT1 SER C2 
Thr39Ala. 
Gene expression and protein purification were carried out utilising the same methods 
as those utilised for PSMT1 SER C2 and analysed by SDS-PAGE, Figure 5.9. After 
purification by nickel affinity on-column cleavage with 3C protease followed by 
desalting and anion exchange chromatography, a solution of pure PSMT1 SER C2 
Thr39Ala was obtained, Figure 5.9. This was buffer exchanged into 10 mM Tris pH 
8.0, 5 mM TCEP and concentrated to a concentration of 15 mg mL-1 of PSMT1 SER C2 
Thr39Ala. PSMT1 SER C2 Thr39Ala behaved the same as PSMT1 SER C2 during 
expression and purification, resulting in a pure protein sample analysed by SDS-PAGE, 
Figure 5.9 
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Figure 5.9: PSMT1 SER C2 Thr39Ala purification. lanes 1 and 9 – molecular weight markers, lane 2 - cells extract, 
lane 3 - immobilised metal affinity chromatography (IMAC) flow through, lane 4 – IMAC wash step, lane 5- on-
column cleavage pool, lane 6 – IMAC elution peak, lane 7 – desalted pool fractions, lane 8 – ion exchanged pooled 
fractions. Arrow indicates position of PSMT1 SER C2 Thr39Ala 
5.3.2.1.2. PSMT1 SER C2 Thr39Ala Structures 
Crystallisation of PSMT1 SER C2 Thr39Ala was carried out utilising 48 well sitting drop 
plates utilising the vapour diffusion method. 0.5 μL of crystallisation buffer was mixed 
with 0.5 μL 15 mg mL-1 protein solution containing either 0.7 mM SAH and 2 mM 
scoulerine or 0.7 mM SAH and 2 mM tetrahydrocolumbamine. The crystallisation 
space around the original hit for PSMT1 SER C2 in JCSG-plus™ screen (Molecular 
Dimensions), drop A3 (0.2 mM di-ammonium citrate pH 5.0, 20 % PEG3350) was 
explored. PSMT1 SER C2 Thr39Ala co-crystallised with SAH and scoulerine crystallised 
in 0.2 mM di-ammonium citrate pH 5.0, 20 % PEG3350 in the space group P 21 21 21. 
Whereas, PSMT1 SER C2 Thr39Ala co-crystallised with SAH and 
tetrahydrocolumbamine crystallised 0.2 mM di-ammonium citrate pH 5.0, 25 % 
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PEG3350 in the space group P 21. Refinement statistics for both crystals are shown in 
Table 5.4. 
PSMT1 SER C2 Thr39Ala co-crystallised with SAH and tetrahydrocolumbamine 
crystallised in the same space group as the previous PSMT1 SER C2 structures, 
therefore the previous described PSMT1 SER C2 model with SAH and 
tetrahydrocolumbamine bound, with the ligands and waters removed, was utilised 
as the initial model for refinement with REFMAC. After several rounds of model 
building and refinement a final model was produced, Figure 5.10.A. and Table 5.4. 
The data set for PSMT1 SER C2 Thr39Ala co-crystallised with SAH and scoulerine 
proved challenging to solve by molecular replacement utilising Molrep. Several 
search models were explored, these were a single, full length polypeptide chain from 
PSMT1 in open and closed conformations, along with truncated models consisting of 
only the dimerisation domain and only the SAM binding domain. In the end, the data 
set was solved by utilising the peptide homodimer from the PSMT1 SER C2 model co-
crystallised with SAM and scoulerine. This method resulted in an initial model with a 
Rwork of 0.38 and Rfree of 0.42, consisting of two dimes per asymmetric unit. 
Analysis of the initial model in COOT showed that for each of the dimers one chain 
fitted the 2Fo-Fc density very well, whereas, for the second chain only the 
dimerisation domain had good density. After several iterative rounds of manual 
model building and refinement utilising COOT and REFMAC a final model was 
produced, Figure 5.10.B. and Table 5.4. 
PSMT1 SER C2 Thr39Ala co-crystallised with SAH and tetrahydrocolumbamine 
crystallised with two molecules per asymmetric unit, consisting of one homodimer. 
Both active sites are in the closed conformation with SAH and 
tetrahydrocolumbamine bound in the active sites, Figure 5.10.A. This closed 
conformation is consistent with all previous PSMT1 SER C2 structures co-crystallised 
with SAH or SAM and scoulerine or tetrahydrocolumbamine. Whereas, PSMT1 SER 
C2 Thr39Ala co-crystallised with SAH and scoulerine generated a model with four 
molecules per asymmetric unit, consisting of two homodimers. Each of the 
homodimers have one subunit in a closed conformation with SAH and scoulerine 
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bound, while the other is in an open conformation with only SAH bound, Figure 
5.10.B. 
 
 
Figure 5.10: PSMT1 SER C2 Thr39Ala structures represented as ribbon diagrams shaded by domain with ligands 
represented as cylinders A. PSMT1 SER C2 Thr39Ala co-crystallised with SAH and tetrahydrocolumbamine in a 
closed conformation with SAH and tetrahydrocolumbamine bound in the active sites, coloured blue, B. PSMT1 SER 
C2 Thr39Ala co-crystallised with SAH and scoulerine with one active site closed with SAH and scoulerine while the 
opposing active site is open with only SAH bound, coloured in green. C. Superimposition of A. and B. by the 
dimerisation domains  
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The Thr39Ala mutation has resulted in PSMT1 SER C2 crystallising in a different space 
group (P 21 21 21) when co-crystallised with SAH and scoulerine. Whereas, when co-
crystallised with the products (tetrahydrocolumbamine and SAH) PSMT1 SER C2 
Thr39Ala crystallised in the same conformation and space group (P 21) as the non-
mutant. This leads to the proposal that PSMT1 has a mechanism to recognise the 
presence the methyl group on tetrahydrocolumbamine. Upon analysis of the two 
PSMT1 SER C2 Thr39Ala structures, one striking feature stands out. Phe190 which is 
positioned at the opening of the active site on the dimerisation domain can occupy 
two conformational states. In all previously presented structures Phe190 is pointing 
into the active site, occluding the scoulerine/tetrahydrocolumbamine binding 
pocket. The trend is continued with PSMT1 SER C2 Thr39Ala co-crystallised with 
tetrahydrocolumbamine and SAH but not with scoulerine and SAH. In the latter 
structure Phe190 is in a different conformation for the open active site which has 
only SAH bound, Figure 5.11.A. This new conformation opens-up the scoulerine 
binding site, Figure 5.11.B&C, possibly acting like a gate. This feature suggests that 
Thr39 is an important residue in substrate recognition and subunit communication.  
Comparison of PSMT1 SER C2 Thr39Ala co-crystallised with SAH and scoulerine (with 
one open and one closed subunit) to that of the closed structure of PSMT1 SER C2 
Asp297Ala, which allowed the building of the flexible loop consisting of residues 110-
130, exposed a second feature. Upon comparison of the loops there is a marked 
conformational change, with that of PSMT1 SER C2 Asp297Ala making little contact 
with the opposing subunit, Figure 5.12.A. Whereas, in PSMT1 SER C2 Thr39Ala co-
crystallised with scoulerine and SAH, the loop from the closed subunit interacts 
substantially with the opposing, closed subunit, which could possibly be stabilising it 
in the open conformation, Figure 5.12.B. 
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Figure 5.11: Analysis of Phe190 in PSMT1 SER C2 Thr39Ala mutant structures. A. Ribbon diagram of PSMT1 SER 
C2 Thr39Ala co-crystallised with SAH and tetrahydrocolumbamine (blue) and co-crystallised with SAH and 
scoulerine (green). Ligands and Phe190 is represented as cylinders along with a transparent surface representation 
of Phe190, coloured by model. B. PSMT1 SER C2 Thr39Ala co-crystallised with SAH and tetrahydrocolumbamine 
(blue) in a closed conformation. Protein is represented as a solid surface with Phe190 being translucent. Ligands 
and Phe190 are represented as cylinders. C. PSMT1 SER C2 Thr39Ala co-crystallised with SAH and 
tetrahydrocolumbamine with the open conformation subunit shown in dark green and the closed subunit in light 
green. Protein is represented as a solid surface with Phe190 being translucent. Ligands and Phe190 are 
represented as cylinders. Tetrahydrocolumbamine (blue cylinders) is superimposed from B. to show the substrate 
binding pocket  
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Figure 5.12: Comparison of the loop consisting of residues 110-130 of PSMT1 SER C2 Asp297Ala co-crystallised 
with SAH and scoulerine in a closed conformation (A) to that of PSMT1 SER C2 Thr39Ala co-crystallised with SAH 
and scoulerine with one open and one closed active site (B). Protein is represented as ribbons shaded by chain, 
ligands are represented as cylinders and residues 110-130 are highlighted as transparent surfaces 
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PSMT1 SER C2 Thr39Ala Thr39Ala 
Co-crystallised 
with 
Scoulerine and 
SAH 
Tetrahydrocolumbamine 
and SAH 
Data collection  
 
Space group P 21 21 21 P 21 
Cell dimensions   
a, b, c (Å) 82.61, 102.96, 
174.26 
68.15, 75.78, 76.16 
(°) 90.00, 90.00, 
90.00 
90.00, 101.84, 90.00 
Resolution (Å) 88.67-1.98 75.78-1.61 
Rmerge 0.10(1.37) 0.12(1.08) 
Rpim 0.04(0.54) 0.07(0.62) 
I / σI 10.0(1.5) 5.9(1.6) 
Completeness 
(%) 
99.80(95.71) 99.79(97.87) 
Redundancy 7.7(8.0) 2.1(2.1) 
Xia2 run DIALS DIALS 
   
Refinement   
Resolution (Å) 88.64-1.99 74.66-1.61 
No. reflections 98126  
Rwork / Rfree 0.25/0.30 0.15/0.20 
No. atoms   
Protein 20939 10468 
Ligand/ion 262 182 
Water 47 441 
B-factors (Å2)   
Protein 38.2 14.9 
Ligand/ion 30.4 11.4 
Water 28.3 22.8 
r.m.s. 
deviations 
  
Bond lengths 
(Å) 
0.02 0.03 
Bond angles (°) 1.9 1.3 
Table 5.4: Data collection and refinement Statistics for PSMT1 SER C2 Thr39Ala Mutant 
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 Conclusion 
Site-directed mutagenesis studies of key residues in PSMT1 SER C2 have proven a 
powerful technique to probe catalytic mechanism and subunit cooperativity. Plant 
O-methyltransferases have been described as having a catalytic dyad of histidine and 
aspartic acid which correspond to His296 and Asp297 in PSMT1. The proposed 
catalytic mechanism based on crystal structures is that His296 deprotonates the 
9-hydroxyl group of scoulerine, followed by nucleophilic attack on the sulphonium 
methyl group of S-adenosylmethionine (SAM) by the 9-phenoxide intermediate, 
generating S-adenosylhomocysteine (SAH) and tetrahydrocolumbamine, Figure 4.14. 
Mutations of His296 have so far been unsuccessful, resulting in poor protein 
expression, Figure 5.5. This is most likely due to His296 not only being a crucial 
catalytic residue but also being involved in structural stability. The mutation of 
Asp297 in PSMT1 SER C2 has proven successful with Asp297Ala expressing and 
purifying in the same manner to the wild-type protein. Activity assays of PSMT1 SER 
C2 Asp297Ala showed a reduction in activity to 0.6% to that of PSMT1 SER C2. This, 
along with analysis of the crystal structures lead to the proposition that Asp297 is not 
responsible for the deprotonation step but is crucial for the correct position of the 
9-hydroxyl group on scoulerine and the sulphonium-methyl group on SAM for 
catalysis. 
Analysing subunit cooperativity by mutating Thr39 in PSMT1 SER C2 to alanine has 
introduced more questions than answers. Thr39 interacts directly with 
scoulerine/tetrahydrocolumbamine in the active site of the opposing subunit, Figure 
5.8. Co-crystallisation experiments of PSMT1 SER C2 Thr39Ala with SAH and 
tetrahydrocolumbamine resulted in the crystallisation of a closed conformation 
structure with SAH and tetrahydrocolumbamine bound in the active sites, in the same 
space group to that without the mutation present. In contrast, co-crystallisation 
experiments with SAH and scoulerine resulted in a new crystal form, under similar 
crystallisation conditions. The absence of the methyl group at the 9-O position of 
scoulerine, compared to that of tetrahydrocolumbamine, resulted in a structure with 
one closed active site and one open active site per homodimer. The closed active site 
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had both SAH and scoulerine bound, whereas the open active site only had SAH 
bound. PSMT1 appears to possess the ability to detect the presence or absence of 
the transferred methyl group on tetrahydrocolumbamine and scoulerine. The 
Thr39Ala mutation has led to a change in equilibrium between the open and closed 
conformations which should be further probed by kinetic analysis.  
Phe190 has been shown to be a residue of interest due it its large conformational 
difference in the open active site of PSMT1 SER C2 Thr39Ala co-crystallised with SAH 
and scoulerine compared to that of the rest of the structures presented within this 
thesis, Figure 5.11.A. Phe190 appears to be acting as a gate to the 
scoulerine/tetrahydrocolumbamine binding site, Figure 5.11.B&C., alternatively this 
could be a crystallographic artefact due to crystal contacts with a symmetry 
molecule. Residues 110-130 form a loop which appears to act as a regulatory domain, 
with the loop stabilising the open conformation of one of the subunits in the PSMT1 
SER C2 Thr39Ala structure co-crystallised with SAH and scoulerine, Figure 5.12.  
Due to the complex nature of subunit communication in PSMT1 it has proven difficult 
to elucidate the mechanism upon which the observed positive cooperativity is 
conferred. As a plethora of X-ray crystal structures of PSMT1 have now been solved, 
in a variety of different conformations, molecular dynamic simulations could be 
carried out to predict the complicated interactions between protein subunits and 
protein-ligand interactions which bring about the observed large conformational 
changes.  
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6. Conclusions and Future Perspectives 
PSMT1 with the addition of an N-terminus purification/solubility tag (6xHis-GST-
r3CP-PSMT1) was heterologously expressed in E. coli BL21 (DE3) cells and the 
resulting protein purified utilising 3C protease nickel affinity on-column cleavage. 
This method resulted in the purification and liberation of PSMT1 from it 
purification/solubility tag. Subsequent purification steps included desalting and 
anion exchange resulting in pure protein as visualised by SDS-PAGE. Purified PSMT1 
was subject to biochemical and structural analysis. Biochemical analysis showed 
PSMT1 is dimeric in structure with a melting temperature of 50 ᵒC. Enzymatic assays 
of PSMT1 utilising its natural substrate scoulerine and the co-substrate 
S-adenosylmethionine (SAM) were performed. Direct detection of the 
9-O-methylated product tetrahydrocolumbamine utilising LC-MS/MS proved to be a 
valid and reproducible method for determining kinetic parameters. Michaelis-
Menten analysis was performed with a calculated Vmax of 492.6 ± 28.7 nmol min-1 mg-
1 of protein and Km of 0.25 ±0.06 μM with scoulerine as the substrate. With SAM as 
the substrate a Vmax of 542.4 ±27.1 nmol min-1 mg-1 of protein was calculated along 
with a Km of 8.76 ±1.6 μM. The convergence of Vmax is a good indication of a robust 
and reliable assay. These values differ from that published and is most likely do to 
the differences in the direct detection method implemented here versus the indirect 
measurement of product formation utilising extensive liquid-liquid extraction. 
Further analysis of the activity assay data utilising the sigmoidal Hill plot indicated 
that there is positive cooperativity in respect to scoulerine with a Hill coefficient of 
1.5 ± 0.39.  
Crystallisation experiments of PSMT1 produced crystals in 0.1 M bis-tris Propane pH 
7.5, 25 % PEG3350, 0.3 M sodium citrate which diffracted to 2.95 Å. This apoPSMT1 
structure is a homodimer with a distinct SAM binding domain, dimerisation domain 
and putative substrate binding domain. Co-crystallisation experiments with SAM did 
not improve upon a previous data set collected before the onset of this thesis, with 
PSMT1 co-crystallised with SAM in 0.1 M HEPES pH 7.0, 1 M sodium succinate, 10 % 
PEG2000 which diffracted to 3.25 Å. This structure confirmed the SAM binding 
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domain and revealed its mode of binding. Both of these structures have been 
characterised as being in an open conformation, where the sulphonium methyl group 
on SAM is distal to the putative scoulerine binding site. Co-crystallisation experiments 
with scoulerine and SAH or SAM were unsuccessful. 
To obtain protein crystals of PSMT1 with the substrates bound, surface entropy 
reduction (SER) was implemented. High entropy side chains of lysine and glutamic 
acid were mutated to alanine in an attempt to increase crystal contacts. Surface 
entropy reduction analysis of PSMT1 resulted in three clusters being identified but 
cluster 1 was discounted due to it being involved in the dimerisation interface. The 
remaining two SER clusters were generated by site-directed mutagenesis 
experiments, along with a double cluster mutant, these were named PSMT1 SER C2, 
PSMT1 SER C3 and PSMT1 SER C2&3. All three SER enzymes were purified and 
subjected to biochemical analysis, alongside crystallisation trials. Biochemical 
analysis showed that the SER proteins were successfully expressed and purified and 
that the mutations had not effected stability or dimerisation. Initial crystallisation 
trials of the SER proteins resulted in all three producing crystals which diffracted 
between 3.2-1.5 Å, with PSMT1 SER C2 co-crystallised with SAH and scoulerine 
extended to the highest resolution.  
The PSMT1 SER C2 co-crystallised with SAH and scoulerine resulted in a closed 
conformation structure with SAH and scoulerine bound in the active sites. 
Subsequent co-crystallisation of PSMT1 SER C2 with the substrates, SAM and 
scoulerine, resulted in crystals which diffracted to 1.3 Å. The resulting structure was 
also in a closed conformation but the products SAH and tetrahydrocolumbamine 
were bound in the active sites. As the products are bound in the active site PSMT1 
SER C2 has either turned over in-crystal, trapping the products or PSMT1 SER C2 has 
methylated scoulerine and subsequently rebound SAH and tetrahydrocolumbamine 
before crystallisation. This indicated that the PSMT1 SER C2 alanine mutations of 
Lys114Ala and Lys115Ala had not effected activity. This was confirmed by Michaelis-
Menten analysis of activity assay data with a calculated Vmax of 446.7 ± 24.0 nmol 
min-1 mg-1 of protein and a Km of 0.22 ± 0.05 μM with scoulerine as the substrate. This 
160 
is similar to activity of the WT enzyme with calculated Vmax of 492.6 ± 28.7 nmol 
min-1 mg-1 of protein and Km of 0.25 ± 0.06 μM. 
Comparison of the open and closed structures revealed that PSMT1 undergoes a 
large conformational change, where upon binding of the substrates the SAM binding 
domain rotates inwards towards the substrate binding/dimerisation domains. 
SAM/SAH binds in an extended conformation to the SAM/SAH binding domain at the 
N-terminus of the protein containing the conserved Rossmann-like fold. In the open 
conformation, SAM/SAH binds to PSMT1 mainly on one face with major interactions 
between the adenine moiety N3 and N6 and the ribose hydroxyl groups with 
carboxylic acid side chains. The methionine moiety is clamped in place by a lysine 
interacting with both the carboxyl group and amino group of SAM/SAH. The 
carboxypropyl moiety of methionine interacts with the conserved Gly-x-Gly motif. 
The opposing face containing the methyl-sulphonium is exposed to bulk solvent 
pointing into the open cleft, which forms the active site. Upon closure of the active 
site, SAM/SAH makes new interaction with residues Met207, Phe203 and Phe190 
with the previously exposed face of SAM/SAH. Met207, Phe203 and Phe190, along 
with Trp293 and Asp297 form a channel in which methyl transfer can occur.  
Scoulerine/tetrahydrocolumbamine bind in a deep hydrophobic pocket within the 
active site with hydrogen bonds at opposing ends of the molecule. The majority of 
this binding pocket is constructed from the substrate binding/dimerisation domains. 
Upon closure the conserved catalytic dyad of His296 and Asp297 are brought into 
proximity to the 9-hydroxy of scoulerine, with the O9 positioned at the opposing 
entrance to the methyl transfer channel to that of the sulphonium methyl group of 
SAM. These observation lead to a model for the catalytic mechanism whereby His296 
acts as a catalytic base, abstracting a proton from the 9-hydroxyl position of 
scoulerine generating a phenoxide intermediate. The phenoxide intermediate 
initiates a SN2 nucleophilic attack on the methyl-sulphonium group of SAM through 
the methyl transfer channel. Further experiments need to be carried out to 
determine if His296 is responsible for the initial proton abstraction step in catalysis. 
This could be achieved by carrying out co-crystallisation experiments with deuterated 
scoulerine and determining the structure by neutron diffraction analysis. Neutron 
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diffraction is similar to that of X-ray diffraction but neutrons are scattered off the 
nucleus of an atom rather than by electrons. Neutron diffraction can differentiate 
between hydrogen and deuterium atoms due to their differences in scattering length 
of -3.7406 fm and 6.671 fm, respectively. The differences in scattering will allow the 
differentiation of the two hydrogen isotopes therefore the residue responsible for 
the deprotonation of deuterated scoulerine could be visualised. This would only work 
if PSMT1 binds the substrates and turns over in crystal rather than rebinding the 
formed products. 
Aspartic acid 297 appears to be a key catalytic residue since the Asp297Ala mutation 
in PSMT1 SER C2 reduced the activity to 0.6 % of PSMT1 SER C2 Vmax. Analysis of the 
X-ray structure of PSMT1 SER C2 Asp297Ala revealed Asp297 is responsible for the 
correct positioning of the 9-hydroxyl position on scoulerine for proton abstraction 
and subsequent nucleophilic attack on SAM. Glu356 terminal carboxylic acid group 
hydrogen bonds to His296 (Nδ), which is presumably important for the correct 
positioning of His296 and promoting its alkalinity. Site-directed mutagenesis studies 
of His296 proved unsuccessful due to insufficient soluble protein for characterisation. 
As His296 makes a variety of interactions within PSMT1 it might not be possible to 
express a stable His296 mutant with the 21 common amino acids, but optimisation 
of gene expression might yield enough soluble protein for biochemical 
characterisation. Furthermore, it might be possible to utilise unnatural amino acids 
such as substituting the imidazole ring with a pyrrole ring generating 2-amino-3-(1H-
pyrrol-2-yl) propanoic acid. This could maintain the His296 to Glu356 hydrogen bond 
as well as maintain its aromaticity but would be unable to deprotonate the 9-hydroxyl 
group of scoulerine. 
PSMT1 activity assays showed the propensity for positive cooperativity with a Hill 
coefficient of 1.5 ±0.39. To investigate the subunit cooperativity of the PSMT1 
homodimer, threonine 39 was mutated to alanine in PSMT1 SER C2. Thr39 was 
chosen as it interacts direct with scoulerine/tetrahydrolcumbamine in the active site 
of the opposing monomer. PSMT1 SER C2 Thr39Ala co-crystallisation experiments 
indicated to the ability of PSMT1 to detect the presence or absence of a 9-O-methyl 
group. Co-crystallisation experiments with SAH and tetrahydrocolumbamine, with 
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the 9-O-methyl group present, crystallised in the same space group as PSMT1 SER C2 
without the Thr39Ala mutation. Co-crystallisation experiments with SAH and 
scoulerine, without the 9-O-methyl group present, crystallised in an alternate space 
group in a different conformation but in similar crystallisation conditions. PSMT1 SER 
C2 Thr39Ala co-crystallised with SAH and scoulerine consisted of two homodimers 
per asymmetric unit with one closed active site with SAH and scoulerine bound and 
one open active site with only SAH bound.  
Two possible regulatory features involved in active site cooperativity were identified, 
the first being that of Phe190 and the second that of a regulatory loop consisting of 
residues 110-130. Phe190 can take one of two conformations. In all PSMT1 
structures, except for the open active site of PSMT1 SER C2 Thr39Ala structure co-
crystallised with SAH and scoulerine, Phe190 extends inwards towards the 
scoulerine/tetrahydrocolumbamine binding site, ultimately forming part of the 
methyl transfer channel. In this inward extended position Phe190 interacts with both 
the adenine and ribose moieties of SAM/SAH and the 10-O-methyl group on 
scoulerine/tetrahydrocolumbamine, as well as Asp297, which has been shown to be 
critical for the correct positioning of the substrates for catalysis. In an open 
conformation Phe190 generally occluded the scoulerine binding site. However, for 
the open active site of PSMT1 SER C2 Thr39Ala structure co-crystallised with SAH and 
scoulerine, Phe190 has rotated to extend away from the scoulerine binding site, 
opening it up allowing unhindered access. The loop consisting of residues 110-130 
has only previously been visible in the PSMT1 SER C2 Asp297Ala mutation 
presumably due to its inherent flexibility. In this structure the 110-130 residue loop 
extends across from one subunit toward the other but appears to make little contact. 
However, for PSMT1 SER C2 Thr39Ala co-crystallised with SAH and scoulerine the 
110-130 residue loop from the closed subunit is in a different position making 
significant contact with the opposing subunit. This interaction could be stabilising the 
open conformation of the opposing open subunit. To determine if the Thr39Ala 
mutation has effected subunit cooperativity activity assays should be carried out and 
analysed.  
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In this thesis PSMT1 has been studied in great detail with the elucidation of high 
resolution X-ray crystallographic structures. These structures along with several 
other plant O-methyltransferases structures already available in the PDB provide 
strong evidence for a highly-conserved reaction mechanism. Plant 
O-methyltransferases accept a wide variety of substrates of varying structures with a 
common phenolic ring which is to be O-methylated and generally a hydroxyl group 
at the opposing end. The current work supports the view that this common phenolic 
ring is highly conserved and is responsible for the correct positioning of the hydroxyl 
group for O-methylation. The hydroxyl group at the opposing end to the substrates 
phenolic ring forms hydrogen bonds with an acidic residue or the terminal carbonyl 
of asparagine, although hydrogen bonding to glutamine is not observed in the current 
set of available structures it cannot be ruled out. The binding site for the remainder 
of the substrate is highly variable.  
As a variety of plant O-methyltransferases with differing ligands bound have had their 
structures solved, future work needs to be targeted at analysing amino acid sequence 
of the plant O-methyltransferase class of enzymes to establish if it is possible to 
predict substrate specificity from primary amino acid sequence. Utilising the available 
crystal structures, sequence analysis and molecular modelling of plant 
O-methyltransferase it might be possible to define a set of rules to be able to predict 
the substrate from sequence alone based on the 3-dimensional shape of the binding 
pocket. 
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8. Appendix 
Appendix 8.1 pETFPP-3-PSMT1 nucleotide and amino acid sequence coloured by 
feature 
Feature    Location 
 
6His               5083 : 5100 
Glutathione S-transferase  5107 : 5760 
3C Protease recognition Site         5764 : 5787 
PSMT1             5782 : 6961 
 
A8.1.1 pETFPP-3-PSMT1 nucleotide sequence, 6His-GST-r3CP-PSMT1 gene in bold 
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTG 
CCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTA 
AATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTC 
ACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGT 
TCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGG 
TTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTCAGGTGGCACTTT 
TCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAATTAATTCT 
TAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCG 
TTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTC 
GTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACT 
GAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAA 
ATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGAC 
AATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATAT 
TCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATG 
CTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTAC 
CTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACA 
TTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTAGAGCAAGACGTTTCCCG 
TTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGACCAAAATCCCTTAA 
CGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGT 
AATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTC 
CGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAG 
AACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCT 
TACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCA 
GCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGA 
AAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTA 
TCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTAT 
GGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTA 
TCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAG 
CGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCA 
TATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTG 
GGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACA 
GACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGG 
TAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAG 
AAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGT 
AAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAA 
CATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGG 
TCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGAACA 
TAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAG 
GTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACC 
CCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGGGCCGCCATGCCGGCGATAATGGCCT 
GCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGTGACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGC 
GACAGGCCGATCATCGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTGTCCTAC 
GAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCGCGCCCACCGGAAGGAGCTGACTGGGT 
TGAAGGCTCTCAAGGGCATCGGTCGAGATCCCGGTGCCTAATGAGTGAGCTAACTTACATTAATTGCGTTGCGCTCACTG 
CCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTAT 
TGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGT 
TGCAGCAAGCGGTCCACGCTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGA 
GCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCATTG 
CGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGA 
AAACCGGACATGGCACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCC 
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AGCCAGACGCAGACGCGCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGAT 
GCTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAAAT 
AACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACT 
GACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCACGC 
TGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCA 
ACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGC 
TTCCACTTTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACCGG 
CATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTCTCTTCCGGGCGCTATCATGCC 
ATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCCGGGATCTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGAAGC 
AGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCC 
CCGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATC 
GGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGA 
TCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAA 
TTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCATGTCCCCTATACT 
AGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTTTTGGAATATCTTGAAGAAAAATATGAAGAGCATT 
TGTATGAGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTAT 
ATTGATGGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAACATGTTGGGTGGTTG 
TCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTGGATATTAGATACGGTGTTTCGAGAATTGCATATA 
GTAAAGACTTTGAAACTCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCGAAGATCGTTTATGT 
CATAAAACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACAT 
GGACCCAATGTGCCTGGATGCGTTCCCAAAATTAGTTTGTTTTAAAAAACGTATTGAAGCTATCCCACAAATTGATAAGT 
ACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAA 
GGCCTGGAAGTTCTGTTCCAGGGACCAGCAATGGCTACCAATGGCGAAATTTTCAATACCTATGGTCATAATCATCAATC 
AGCCACAGTCACTAAAATCACTGCTTCTAATGAAAGCAGCAATGGTGTCTGTTATCTTTCAGAAACGGCTAACTTGGGGA 
AGTTAATATGCATTCCAATGGCACTAAGAGCTGCGATGGAGCTAAATGTGTTCCAACTTATCTCAAAGTTCGGAACTGAC 
GCAAAAGTTTCGGCTTCTGAAATTGCCTCTAAAATGCCAAACGCGAAGAATAATCCTGAAGCAGCTATGTATTTGGATAG 
AATTCTTCGACTGCTCGGGGCAAGTTCTATTCTTTCTGTTTCTACTACAAAAAAATCAATCAACAGAGGAGGAGATGATG 
TAGTAGTACATGAGAAGCTTTATGGGTTAACAAATTCGTCGTGTTGTTTGGTCCCTCGACAAGAAGACGGGGTGTCATTA 
GTCGAAGAATTGCTATTCACATCTGACAAGGTTGTTGTGGATAGTTTTTTCAAACTGAAATGTGTGGTGGAAGAAAAAGA 
CAGTGTGCCATTTGAGGTTGCTCATGGTGCTAAAATCTTTGAGTATGCTGCTACAGAACCAAGAATGAATCAAGTATTTA 
ACGATGGAATGGCAGTTTTCTCTATTGTTGTTTTTGAGGCTGTTTTTAGAGTTTACGATGGATTTCTTGATATGAAAGAA 
TTGTTAGATGTTGGTGGTGGTATTGGTACTTCGGTTAGTAAGATTGTTGCTAAATACCCTTTGATTCGCGGTGTCAACTT 
CGACTTGCCTCATGTTATTTCTGTTGCCCCTCAATACCCAGGTGTAGAGCATGTTGCAGGAGATATGTTCGAGGAAGTCC 
CAAAGGGTCAAAACATGTTGCTAAAATGGGTACTGCACGATTGGGGTGATGAACGATGTGTGAAGCTGTTAAAGAATTGT 
TGGAACTCATTACCTGTGGGTGGAAAAGTTTTGATAATCGAGTTTGTTCTCCCGAATGAACTTGGTAACAATGCTGAATC 
ATTCAATGCGTTGATTCCCGATTTACTCCTGATGGCTCTGAATCCAGGCGGTAAAGAGCGAACGATTTCCGAATACGATG 
ATTTAGGCAAAGCAGCTGGATTCATAAAAACTATACCTATCCCTATCTCCAATGGTCTTCATGTCATTGAGTTTCACAAA 
TGACGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCGAGCTCCGTCG 
ACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAG 
TTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAA 
AGGAGGAACTATATCCGGAT 
 
A8.1.2: 6xHis-GST-r3CP-PSMT1 amino acid sequence in pETFFP-3-PSMT1 
 
MGSSHHHHHH SSMSPILGYW KIKGLVQPTR LLLEYLEEKY EEHLYERDEG 50 
DKWRNKKFEL GLEFPNLPYY IDGDVKLTQS MAIIRYIADK HNMLGGCPKE 100 
RAEISMLEGA VLDIRYGVSR IAYSKDFETL KVDFLSKLPE MLKMFEDRLC 150 
HKTYLNGDHV THPDFMLYDA LDVVLYMDPM CLDAFPKLVC FKKRIEAIPQ 200 
IDKYLKSSKY IAWPLQGWQA TFGGGDHPPK GLEVLFQGPA MATNGEIFNT 250 
YGHNHQSATV TKITASNESS NGVCYLSETA NLGKLICIPM ALRAAMELNV 300 
FQLISKFGTD AKVSASEIAS KMPNAKNNPE AAMYLDRILR LLGASSILSV 350 
STTKKSINRG GDDVVVHEKL YGLTNSSCCL VPRQEDGVSL VEELLFTSDK 400 
VVVDSFFKLK CVVEEKDSVP FEVAHGAKIF EYAATEPRMN QVFNDGMAVF 450 
SIVVFEAVFR VYDGFLDMKE LLDVGGGIGT SVSKIVAKYP LIRGVNFDLP 500 
HVISVAPQYP GVEHVAGDMF EEVPKGQNML LKWVLHDWGD ERCVKLLKNC 550 
WNSLPVGGKV LIIEFVLPNE LGNNAESFNA LIPDLLLMAL NPGGKERTIS 600 
EYDDLGKAAG FIKTIPIPIS NGLHVIEFHK  
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Appendix 8.2: Compound optimisation report for scoulerine 
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Appendix 8.3 Compound optimisation report for tetrahydrocolumbamine 
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Appendix 8.4: Sequence Alignment of PSMT1 and PsSOMT1 amino acid sequences by 
MUSCLE multisequence alignment tool. Mismatches are highlighted 
 
PSMT1           MATNGEIFNTYGHNHQSATVTKITASNESSNGVCYLSETANLGKLICIPMALRAAMELNV 
SOMT1           MATNGEIFNTYGHNRQTATVTKITASNESSNGVCYLSETANLGKLICIPMALRAAMELNV 
                **************.*:******************************************* 
 
PSMT1           FQLISKFGTDAKVSASEIASKMPNAKNNPEAAMYLDRILRLLGASSILSVSTTKKSINRG 
SOMT1           FQLISKFGTDAKVSASEIASKMPNAKNNPEAAMYLDRILRLLGASSILSVSTTKKSINRG 
                ************************************************************ 
 
PSMT1           GDDVVVHEKLYGLTNSSCCLVPRQEDGVSLVEELLFTSDKVVVDSFFKLKCVVEEKDSVP 
SOMT1           GDDVVVHEKLYGLTNSSCCLVPRQEDGVSLVEELLFTSDKVVVDSFFKLKCVVEEKDSVP 
                ************************************************************ 
 
PSMT1           FEVAHGAKIFEYAATEPRMNQVFNDGMAVFSIVVFEAVFRVYDGFLDMKELLDVGGGIGT 
SOMT1           FEVAHGAKIFEYAATEPRMNQVFNDGMAVFSIVVFEAVFRFYDGFLDMKELLDVGGGIGT 
                ****************************************.******************* 
 
PSMT1           SVSKIVAKYPLIRGVNFDLPHVISVAPQYPGVEHVAGDMFEEVPKGQNMLLKWVLHDWGD 
SOMT1           SVSKIVAKYPLIRGVNFDLPHVISVAPQYPGVEHVAGDMFEEVPKGQNMLLKWVLHDWGD 
                ************************************************************ 
 
PSMT1           ERCVKLLKNCWNSLPVGGKVLIIEFVLPNELGNNAESFNALIPDLLLMALNPGGKERTIS 
SOMT1           ERCVKLLKNCWNSLPVGGKVLIIEFVLPNELGNNAESFNALIPDLLLMALNPGGKERTIS 
                ************************************************************ 
 
PSMT1           EYDDLGKAAGFIKTIPIPISNGLHVIEFHK 
SOMT1           EYDDLGKAAGFIKTIPIPISNGLHVIEFHK 
                ****************************** 
